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Abstract 
 
 
Amyotrophic Lateral Sclerosis (ALS) is a fatal neurodegenerative disease 
characterised by progressive loss of upper and lower motor neurons, which 
ultimately leads to death within 2-3 years of diagnosis. While multiple mechanisms 
have been proposed to cause motor neuron death, altered signalling of the pro-
survival phosphatydyl-inositol-3-kinase (PI3K/Akt) signalling pathway has been 
shown in spinal cords of human cases and rodent models of ALS. The depletion of 
the phosphatase and tensin homologue (PTEN), an essential negative regulator of 
PI3K, promotes neuronal survival and axonal regeneration. The main aim of this 
study was to investigate the effect of PTEN silencing using viral vectors, on motor 
neuron survival and neuromuscular degeneration (NMJ) in experimental models of 
ALS. Lentiviral vectors expressing small interfering RNA (siRNA) against mouse 
PTEN achieved approximately 60% PTEN knockdown in purified motor neurons 
from transgenic SOD1G93A embryos and their non-transgenic littermates. PTEN 
silencing was associated with increased expression of phosphorylated Akt, and 
enhanced motor neuron survival. To validate the potential neuroprotective effect of 
PTEN silencing in vivo, wild-type (WT) mice were used to determine the efficiency 
of adeno-associated virus serotypes 6 (AAV6) and 9 (AAV9), to deliver PTEN 
siRNA to spinal cord motor neurons after intramuscular (i.m) administration. 
Despite effective transduction and PTEN knockdown in the injected muscles, low 
levels of spinal cord motor neuron transduction were observed for both vectors 
suggesting poor retrograde transport efficiency. Similar findings were seen in 
transgenic SOD1G93A mice treated with AAV9 vectors expressing PTEN siRNA, 
which may explain the lack of significant effect seen on spinal cord motor neuron 
survival. In addition, no significant effect was seen on neuromuscular junction 
degeneration in the muscles of the injected hind limbs.  
                                                      vi 
In conclusion, these results suggest that viral-mediated PTEN silencing may 
enhance the survival of transgenic SOD1G93A motor neurons by activating the 
PI3K/Akt pathway. However, the i.m route for AAV-mediated siRNA delivery to 
the spinal cord is insufficient for effective PTEN silencing. Alternative CNS 
delivery routes are needed for proof-of principle studies to determine the therapeutic 
efficacy of PTEN silencing ALS.  
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1.1 Amyotrophic Lateral Sclerosis  
 Amyotrophic Lateral Sclerosis (ALS), referred to as motor neuron disease 
(MND) or Lou Gehrig’s disease, is a fatal adult-onset disease, characterised 
by progressive loss of upper motor neurons located in the motor cortex and 
lower motor neurons in the brainstem and ventral horn of the spinal cord. 
ALS occurs with an incidence of approximately 1-2/100,000 per year and 
has a prevalence of 4-6/100,000 individuals (Pasinelli and Brown, 2006). 
The vast majority of cases (~90%) do not have a family history and are 
classified as sporadic ALS (SALS), whereas some (~10%) have a clear 
family history where either a first or second-degree relative is affected by 
the disease and these patients are classified as familial ALS (FALS) (Turner 
et al., 2013, Chen et al., 2013, Byrne et al., 2011).   
 
Affected patients typically present with progressive weakness, wasting, 
fasciculation and hyperreflexia. Initially, the disease starts focally and 
subsequently it spreads to contiguous body regions (Ravits and La Spada, 
2009). Although motor neuron degeneration is the predominant feature of the 
disease, non-motor symptoms and signs such as sensory loss (Kawata et al., 
1997) and extrapyramidal signs (Pradat et al., 2009) are found in a subset of 
patients indicating that ALS is a multisystem disorder. Indeed, cognitive 
impairment is seen in up to 50% of patients (Lomen-Hoerth et al., 2003) 
(Gordon et al., 2011) and approximately 15% of cases show signs of overt 
fronto-temporal dementia (FTD) (Ringholz et al., 2005). Hence, ALS and 
FTD are considered to be a spectrum of two overlapping diseases, referred to 
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as ALS/FTD (Lattante et al., 2015). Of interest, some motor neurons were 
found to be resistant to ALS degeneration such as those controlling eye 
movements and those originating from Onuf’s nucleus in the sacral spinal 
cord (controlling the pelvic muscles) (Mannen et al., 1977). Large variations 
are seen in the age and site of symptom onset as well as in the rate of disease 
progression; nonetheless, in most cases survival ranges from 3-5 years after 
diagnosis where patients ultimately die of respiratory failure due to 
denervation of the diaphragm and respiratory muscles (Cudkowicz et al., 
1997). However, survival of more than 10 years is observed in approximately 
10% of patients, where the disease runs a slowly progressive course (Turner 
et al., 2003). The heterogeneity seen in the disease presentation strongly 
suggests that environmental and genetic factors influence the clinical 
phenotype.  
 
The diagnosis of ALS remains clinical, based on the history and clinical 
examination showing progressive dysfunction of the upper and lower motor 
neurons (Gordon, 2013). Neuroimaging and electrophysiological studies 
support the diagnosis and help to exclude other neurological conditions that 
mimic the disease. The El Escorial Criteria  (EEC) was established to 
standardize the diagnosis for clinical studies (Brooks et al., 2000).   
 
To date, the exact underlying cause of ALS is unknown. Indeed, it is 
considered that a complex interplay between several pathogenic 
mechanisms lead to motor neuron degeneration (Figure 1.1). The spread of 
the disease from one anatomical site to another has led to two theories that 
                                                      4 
explain the progressive nature of ALS. The ‘dying forward’ theory stems 
from early studies that showed hyperexcitabilty of the motor cortex occurs 
at the early stages of the disease prior to the onset of symptoms. Thus, it 
was hypothesised that cortical abnormalities could lead to anterograde 
degeneration of the anterior horn cells (Eisen and Weber, 2001, Vucic et 
al., 2008, Kiernan et al., 2011). In support of this theory is the sparing of 
the extraocular muscles and Onuf’s nucleus, which are not directly 
connected to the motor cortex neurons. On the other hand, evidence of 
denervated neuromuscular junctions prior to motor neuron death led to the 
‘dying-back’ theory, which suggests that retrograde degeneration of lower 
motor neurons affects the motor neuron cell bodies, which leads to 
degeneration of corticospinal tracts and upper motor neurons of the motor 
cortex (Dadon-Nachum et al., 2011, Kiernan et al., 2011).   
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Figure 1.1. Molecular pathogenic mechanisms in ALS. ALS is a complex 
interplay between multiple pathogenic mechanisms, which ultimately lead to motor 
neuron loss. ALS, Amyotrophic Lateral Sclerosis, ER, endoplasmic reticulum, 
ROS, reactive oxidative Species. (Recreated from (Ferraiuolo et al., 2011e)). 
 
 
 
 
 
R
O
S 
BAX 
ER stress 
Mitochondrial  
Dysfunction 
Apoptosis 
Oxidative  
Stress Protein  Aggregation 
Impaired axonal 
 transport 
Microglia 
Astrocytes 
Neuroinflammation 
Distal axonopathy 
Excitotoxicity!
Altered RNA  
processing 
                                                      6 
 1.2 Molecular mechanisms of motor neuron degeneration in Amyotrophic 
Lateral Sclerosis 
 
1.2.1 Genetics 
The identification of genes associated with FALS provided important insights into 
the molecular pathways involved with the pathogenesis of the disease, which are 
also applicable to SALS. FALS is usually inherited in an autosomal dominant (AD) 
manner, although some autosomal recessive (AR) and X-linked cases were also 
identified (Table 1). The major disease causing genes underlying ALS encode for 
the proteins Cu/Zn superoxide dismutase 1 (SOD1) (Rosen et al., 1993), TAR DNA-
binding protein (TARDBP) (Sreedharan et al., 2008), Fused in sarcoma (FUS) 
(Kwiatkowski et al., 2009) (Vance et al., 2009) and Chromosome 9 open reading 
frame 72 (C9ORF72) (Renton et al., 2011).  
 
 
 
 
 
 
 
 
 
          
 
                                                      7 
  
   Table 1.1 Genes associated with Familial ALS 
 
 
 
Subtype/ 
Chromosome 
location 
Gene Protein Function Mode of 
Inheritance 
References 
ALS 1 (21q22.1) 
 
 
Superoxide dismutase 1(SOD1) 
 
Oxidative stress 
 
AD, AR, de 
novo 
mutation 
(Rosen et al., 1993) 
ALS 2 (2q33) Alsin (ALS2) 
 
Endosomal 
trafficking, cell 
signaling 
AR 
 
(Yang et al., 2001) 
ALS 3  (18q21) 
 
Unknown Unknown AD (Hand et al., 2002) 
ALS 4 (9q34) 
 
Senataxin (SETX) 
 
RNA processing 
 
AD (Chen et al., 2004) 
ALS 5 (15q21.1) Spatacsin (SPG11) Repair of 
damaged DNA 
AR (Orlacchio et al., 2010) 
ALS 6 (16p11.2) 
 
Fused in sarcoma (FUS) 
 
RNA processing 
 
AD and AR (Kwiatkowski et al., 
2009, Vance et al., 2009) 
ALS 7 (20ptel–p13) Unknown Unknown AD (Sapp et al., 2003) 
ALS 8 (20q13.3) 
 
Vesicle-associated membrane protein-
associated protein (VAPB) 
Endosomal 
trafficking and 
cell signaling 
 
AD (Nishimura et al., 2004) 
ALS 9 (14q11.2) 
 
Angiogenin (ANG) 
 
RNA processing 
 
AD (Greenway et al., 2006) 
ALS 10 (1p36.2) TAR DNA-binding protein (TARDBP) RNA processing 
 
AD (Sreedharan et al., 2008) 
ALS 11 (6q21) 
 
Polyphosphoinositide phosphatase 
(FIG4) 
 
Endosomal 
trafficking, cell 
signaling 
 
AD (Chow et al., 2009) 
ALS 12 (10p13) 
 
Optineurin (OPTN) 
 
Endosomal 
trafficking and 
cell signaling 
 
AD, AR (Maruyama et al., 2010) 
ALS 13 (12q24) 
 
Ataxin-2 (ATXN2) RNA processing Undefined (Elden et al., 2010) 
ALS 14 (9p13) Valsin-containing protein (VCP) Ubiquitin/protei
n degradation 
AD (Johnson et al., 2010) 
ALS 15 (Xp11) 
 
 
Ubiquilin 2 (UBQLN2) 
 
Ubiquitin/protei
n degradation 
 
X-linked (Deng et al., 2011c) 
ALS 16, ALS-FTD 
(9p13.3) 
 
σ Non-opioid receptor 1 (SIGMAR1) 
 
Unknown AD, AR (Luty et al., 2010, Al-
Saif et al., 2011) 
ALS 18 (17p 13.3) Profilin 1(PFN1) Cytoskeleton AD  
ALS 19 (2q33.3-
q34) 
v-erb-b2 avian erythroblastic leukemia  
viral oncogene homolog 4 (ERBB4) 
Cell signaling AD (Takahashi et al., 2013) 
ALS 21 (5q31.2) Matrin 3 RNA processing AD (Johnson et al., 2014) 
Other genes 
 
    
ALS-FTD1 
(9p21.2) 
Chromosome 9 open reading frame 72 
(C9ORF72) 
 
DENN protein 
 
AD (Hosler et al., 2000, 
Renton et al., 2011, 
DeJesus-Hernandez et 
al., 2011) 
ALS-FTD2 
(22q11.23) 
Coiled-coil-helix-coiled-coil-helix 
domain containing 10 (CHCHD 10) 
Unknown  (Bannwarth et al., 2014) 
ALS-dementia-PD 
(17q21) 
Microtubule-associated protein tau 
(MAPT) 
 
Cytoskeleton 
 
AD (Hutton et al., 1998) 
ALS (5q35) Sequestosome 1 (SQSTM1) Protein 
aggregation, 
autophagy 
AD (Teyssou et al., 2013) 
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Here, the different genetic factors involved in ALS are explored, along with their 
potential mechanism/s of action. 
 
 
1.2.1.1 SOD1 
SOD1 is a ubiquitously expressed protein that is predominantly found in the 
cytoplasm, and is abundant in neuronal and glia cells. It consists of 153 amino acids 
and its main function is to catalyse the dismutation of intracellular superoxide free 
radicals to hydrogen peroxide. In 1993, linkage analysis led to a breakthrough 
discovery of mutations in the SOD1 gene, which were associated with FALS (Rosen 
et al., 1993). This has led to the generation of transgenic murine models that have 
allowed a better understanding of the cellular mechanisms associated with motor 
neuron injury in ALS (Gurney et al., 1994). To date, more than 160 SOD1 mutations 
have been identified, the majority of which are inherited in an AD manner 
(Andersen et al., 2003, Zinman et al., 2009), nonetheless the most reliable evidence 
suggest that only a portion of these mutations are pathogenic (Andersen, 2006). 
Epidemiological studies showed that SOD1 mutations account for ˜12% of inherited 
and ˜1% of sporadic cases (Chio et al., 2008) (Andersen, 2006). Although most 
mutations are missense that produces a misfolded protein with a reduced dismutase 
activity, some mutations result in normal or only slight reduction in dismutase 
activity (Ratovitski et al., 1999). There is no correlation between the biochemical 
and physical properties of the mutant protein and disease duration, and the fact that 
SOD1 knockout mice do not develop motor neuron degeneration, suggests that 
mutant SOD1 acts through a novel toxic gain of function (Ratovitski et al., 1999, 
Reaume et al., 1996) (Andersen et al., 1997).  
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1.2.1.2 TARDBP and FUS  
Mutations in two other genes, TARDBP and FUS that encode for RNA/DNA 
binding proteins were detected in a subset of ALS patients. In 2006, TDP-43 (TAR 
DNA binding protein 43 kDa) was found to be a major component of ubiquitinated 
cytoplasmic inclusions in ALS and FTD (Arai et al., 2006, Neumann et al., 2006). 
This was soon followed by the discovery of mutations in the TARDBP gene that 
account for ~ 3-5% of FALS and <1% of SALS, (Sreedharan et al., 2008) (Gitcho et 
al., 2008) (Kabashi et al., 2008) (Yokoseki et al., 2008) and mutations in the FUS 
gene causing ~5% of FALS (Kwiatkowski et al., 2009) (Vance et al., 2009) (Van 
Langenhove et al., 2010). Most of the pathogenic mutations in both genes affect the 
C-terminal domain of the protein that results in translocation of the nuclear protein 
to the cytoplasm where they form aggregates in affected motor neurons and glia 
cells (Neumann et al., 2006, DeJesus-Hernandez et al., 2011, Arai et al., 2006, 
Kwiatkowski et al., 2009, Vance et al., 2009). Both TDP-43 and FUS play an 
essential role in RNA metabolism (Ayala et al., 2006) (Ayala et al., 2005) (Ling et 
al., 2010); however, whether their nuclear depletion or a toxic gain of function of the 
cytoplasmic aggregates is the cause of neurodegeneration remains unknown. 
Patients with TARDBP mutations usually present with upper limb onset have an 
earlier age of onset and longer disease duration compared to patients with SALS 
(Corcia et al., 2012). Similarly, patients carrying FUS mutations have an earlier 
disease onset but have a shorter survival than in SALS patients (Millecamps et al., 
2010). 
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1.2.1.3 C9ORF72 
In 2011, two groups reported the revolutionary discovery of a new gene associated 
with ALS (Renton et al., 2011) (DeJesus-Hernandez et al., 2011). A huge 
hexanucleotide repeat expansion in the first intron (non-coding region) of the 
C9ORF gene, located on chromosome 9, was found to be the most frequent cause of 
FALS, SALS and frontotemporal dementia (FTD) as well as in families inheriting 
both diseases (ALS-FTD). These findings provide strong evidence that FTD and 
ALS are a spectrum of disease rather than distinct diseases. The abnormal 
expansions were also found in patients with other ALS-causing gene mutations such 
as TARDBP, FUS and SOD1 (van Blitterswijk et al., 2012) as well as in other 
neurodegenerative diseases such as Parkinson’s disease (PD) (Lesage et al., 2013), 
Alzheimer’s disease (ALZ) (Majounie et al., 2012), Huntington disease (HD) 
phenocopies (suspected cases of HD that have negative genetic tests) (Hensman 
Moss et al., 2014) and prion diseases (Beck et al., 2013). In healthy subjects, the 
normal repeat region contains up to 30 repeats, however pathogenic repeats may 
range from 400 up to several thousands (Renton et al., 2011, DeJesus-Hernandez et 
al., 2011). Patients with abnormal gene expansions exhibit specific pathological 
features characterised by TDP-43 inclusions in the motor cortex and spinal cord but 
also ubiquitin- and p62-positive neuronal inclusions (which are TDP-43 negative) 
that are abundantly detected in the cerebellum and hippocampus (Al-Sarraj et al., 
2011, Brettschneider et al., 2012), as well as widespread RNA foci (DeJesus-
Hernandez et al., 2011). The function of the C9ORF72 protein remains unclear; 
however, recent studies suggest it may be related to the differentially expressed in 
normal and neoplastic (DENN)-like proteins, which are guanosine diphosphate 
(GDP)/ guanosine triphosphate (GTP) exchange factors that activate Rab-GTPases 
and regulate membrane trafficking (Levine et al., 2013). So far, studies have shown  
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no strong correlation between the size of expansion repeats and phenotype or disease 
severity (Cooper-Knock et al., 2014a). The exact mechanism by which C9ORF72 
expansion causes ALS is currently a matter of intense research. Potential pathogenic 
mechanisms that have been proposed suggest that epigenetic changes in the 
C9ORF72 DNA leads to reduced mRNA and protein expression and results in a 
loss-of-function mechanism (Gendron et al., 2014). Other authors suggested that 
mutant C9ORF72 transcripts form RNA foci that sequester several RNA-binding 
proteins, which prevents these proteins from carrying out their normal function 
(DeJesus-Hernandez et al., 2011) and other studies showed that these RNA foci are 
toxic to neurons (Lee et al., 2013). Finally, some studies revealed that aberrant 
translation of the repeat transcripts in the cytosol might form toxic insoluble 
dipeptide repeat aggregates causing a toxic gain of function that may contribute to 
neurodegeneration (Cooper-Knock et al., 2014b). Hence, targeted antisense therapy 
in patients harbouring the expansion repeats may prove to be a novel therapeutic 
option (Riboldi et al., 2014) (Sareen et al., 2013) (Donnelly et al., 2013). Moreover, 
identification of pathogenic repeats in the C9ORF72 gene has highlighted the 
importance of RNA processing in neurodegenerative disease and has become an 
exciting area for research to identify novel biomarkers and therapeutic strategies for 
treating ALS.  
 
1.2.1.4 Other genes 
On the other hand, loss of function of certain genes regulating endosomal trafficking 
and cell signalling have been linked to FALS and SALS as well as other 
neurodegenerative diseases. For example, mutations in FIG4 are known to cause 
autosomal recessive Charcot-Marie-Tooth neuropathy type 4J (CMT4J) (Chow et 
al., 2007) and have been identified in some families of FALS and sporadic ALS 
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(Chow et al., 2009). The FIG4 gene encodes for a phosphoinositide 5-phosphatase 
(a lipid phosphatase) also known as SAC3. It regulates the production of 
phosphatidylinositol 4, 5-biphosphate (PIP2), which plays an essential role in 
autophagy and retrograde endosomal trafficking to the Golgi network (Duex et al., 
2006). It has been proposed that in ALS, a loss of function of FIG4 causing 
defective autophagy with accumulation of cytoplasmic inclusions leads to motor 
neuron degeneration (Chow et al., 2009, Ferguson et al., 2009). Loss of function of 
the ALS2 gene has also been linked to a slowly progressive, AR juvenile-onset ALS 
(Yamanaka et al., 2003) found in families in North Africa and in the Middle East 
(Hadano et al., 2001).  
 
Alsin, the product protein of ALS2, is an 180kDa protein, which contains three small 
guanine nucleotide exchange factor (GEF) homologous domains that regulate 
GTPases. It is widely expressed in the brain and spinal cord, and regulates multiple 
cellular functions including endosomal trafficking, and promotes motor neuron 
survival and axonal growth (Kunita et al., 2004, Topp et al., 2004). Mice that are 
deficient in Alsin develop a slowly progressive neurological disorder (Hadano et al., 
2006) and Alsin deficiency exacerbates motor dysfunction in SOD1 mouse models 
(Hadano et al., 2010). The neuroprotective effects of Alsin are mediated via 
activation of Phosphoinositide 3-kinase (PI3K) and Akt3 survival pathways and 
studies have shown that it protects against SOD1 toxicity (Kanekura et al., 2004) 
(Kanekura et al., 2004) (Tudor et al., 2005).  
 
In addition, rare mutations in the OPTN gene were found in some patients with 
FALS and SALS (Maruyama et al., 2010) as well as in other diseases such as open 
angle glaucoma (Rezaie et al., 2002) and Paget’s disease of the bone (Albagha et al., 
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2010). The gene encodes for optineurin, a ubiquitous cytoplasmic protein that is 
highly expressed in the CNS and skeletal muscle (Rezaie and Sarfarazi, 2005). The 
protein has multiple intracellular functions including autophagy, vesicle trafficking 
(Sahlender et al., 2005) and inhibits the Nuclear factor kappaB (NF-κB) pathway 
(Zhu et al., 2007a). It remains unclear how mutant optineurin causes ALS; however, 
it was found to co-localise with skein-like inclusions in human cases and in other 
neurodegenerative diseases such as ALZ and HD (Deng et al., 2011a). The 
unopposed activity of NF-κB found in ALS caused by mutations in OPTN is 
believed to be a possible pathogenic mechanism for motor neuron degeneration 
(Maruyama et al., 2010) suggesting that therapeutic strategies aimed to inhibit NF-
κB could be novel treatments for ALS.  
 
Vesicle-associated membrane protein-associated protein B (VAPB) encodes for a 
type II transmembrane protein localised in the endoplasmic reticulum (ER). It plays 
a role in vesicle trafficking and regulates transport of lipids from the ER to other 
intracellular organelles (Soussan et al., 1999, Amarilio et al., 2005, Lev et al., 2008). 
VAPB mutations have been associated with ALS, of which two of them, P56S and 
T46I point mutations, result in insoluble cytoplasmic aggregation of the mutant 
protein leading to inhibition of the unfolded protein response (process by which the 
ER inhibits the accumulation of misfolded proteins) which ultimately causes 
neuronal death (Nishimura et al., 2004, Kanekura et al., 2006, Chen et al., 2010b). A 
loss-of-function of VAPB and prolonged ER stress response has been suggested to 
cause ALS associated with these mutations. Recent reports showed that a novel 
mutation in VAPB, V234I, produced a mutant protein that did not form aggregates 
but induced the accumulation of ubiquitin inclusions (Chattopadhyay and Sengupta, 
2014). 
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Several candidate genes that regulate RNA processing have been implicated in 
causing ALS. For example, rare missense mutations in the senataxin (SETX) gene 
were identified in AD FALS and in some families with SALS (Chance et al., 1998, 
Chen et al., 2004) where affected patients develop a slowly progressive young-onset 
disease. Senataxin is a DNA/RNA helicase protein that is highly expressed in 
neurons and is known to play a role in DNA repair and RNA processing (Suraweera 
et al., 2007) (Suraweera et al., 2009). In addition to ALS, SETX mutations were also 
found in some forms of cerebellar ataxia such as oculomotor apraxia type 2 (Moreira 
et al., 2004).  
 
Loss-of-function of human angiogenin due to mutations in the angiogenin gene 
(ANG) has been identified in rare cases of ALS and PD (Greenway et al., 2004, 
Greenway et al., 2006, van Es et al., 2011). Angiogenin is a ribonuclease, which is 
strongly expressed in developing and adult neurons of the brain and spinal cord. It 
induces angiogenesis, and plays an essential role in cell stress response where it 
mediates stress-induced cleavage of transfer RNA (tRNA), inhibiting protein 
synthesis and activating cell survival pathways (Fu et al., 2009, Yamasaki et al., 
2009, Emara et al., 2010, Ivanov et al., 2011). In vitro work has demonstrated that 
angiogenin promotes neurite growth and protects motor neurons in culture subjected 
to various stresses such as excitotoxicity, ER stress and hypoxia (Kieran et al., 2008, 
Thiyagarajan et al., 2012). In addition, it has been shown to enhance motor neuron 
survival in transgenic SOD1 mice and mediates its neuroprotective effects by 
activation of the Akt and extracellular-signal-regulated kinase (ERK) survival 
pathways (Kieran et al., 2008).  
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1.2.2 Protein aggregation 
The accumulation of insoluble protein aggregates is a pathological hallmark of ALS 
and is also observed in various neurodegenerative diseases such as ALZ, HD and PD 
(Carra et al., 2012). The presence of ubiquitinated protein inclusions is a 
characteristic finding in FALS and SALS. Three types of ubiquitin-positive 
inclusions exist in ALS: skein-like inclusions, which are specific to ALS and their 
abundance correlates with the severity of neuronal damage; dense bodies and Lewy 
body-like inclusions, which can be seen in other neurodegenerative diseases (Leigh 
et al., 1991). Bunina bodies are small cytoplasmic eosinophilic inclusions also 
specific to ALS, that do not contain ubiquitin and their load does not correlate with 
neuronal damage (Bendotti et al., 2012). In addition, hyaline conglomerate 
inclusions are considered to be specific to SOD1 FALS (Liu et al., 2009) (Ince et al., 
2011). 
 
Mutant SOD1 protein is found in inclusion bodies in affected motor neurons and 
neighbouring astrocytes in ALS patients, transgenic rodent models and primary 
motor neuron cultures expressing mutant SOD1 (Shibata et al., 1994). In transgenic 
mice, mutant SOD1 aggregates are detected prior to the onset of symptoms and their 
load correlate with disease progression and severity (Bruijn et al., 1998, Johnston et 
al., 2000, Wang et al., 2002). Of interest, inclusions containing misfolded wild type 
SOD1 were detected in motor neurons of some sporadic ALS patients suggesting 
that SOD1 may play a role in the pathogenesis of non-mutant SOD1 ALS (Bosco et 
al., 2010). In addition, TDP-43 was found to be the most predominant protein in 
cytoplasmic inclusions in ALS and FTD (Arai et al., 2006) (Neumann et al., 2006) 
(Mackenzie et al., 2007) (Sumi et al., 2009) and is an early feature of the disease 
(Giordana et al., 2010). The identification of disease causing mutations in TARDBP, 
the gene encoding TDP-43, provided evidence of a link between TDP-43 
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proteinopathy and neurodegeneration. The exact mechanism by which TDP-43 
contributes to neuronal toxicity remains elusive; however, it has been proposed that 
the cytoplasmic localisation of TDP-43 may have a pathogenic role. Of interest, 
TDP-43 inclusions were not found in patients with SOD1 mutations, implicating that 
motor neuron injury in these cases may result from a different pathogenic 
mechanism (Mackenzie et al., 2007). Other mutant proteins linked with FALS have 
also been detected in ubiquitinated inclusions, such as optineurin (Maruyama et al., 
2010), FUS (Mackenzie et al., 2010) and ubiquilin 2 (Deng et al., 2011a). 
 
Several hypotheses have been proposed to explain the mechanisms by which protein 
aggregation causes neurotoxicity. One hypothesis suggests that protein aggregates 
sequester essential cellular proteins, which decreases their intracellular 
bioavailability and prevents them performing their physiological functions. 
Examples of proteins detected in cytoplasmic inclusions in ALS include 
neurofilaments, ubiquitin, copper chaperone for SOD1 (CCS), B-cell lymphoma 2 
(BCL-2), glutamate transporters, glial fibrillary acidic protein and proteins involved 
in proteasome and chaperone function (Xu et al., 1993, Tu et al., 1996, Zhang et al., 
1997, Beaulieu et al., 1999, Watanabe et al., 2001, Lariviere et al., 2003). 
Upregulation of the small heat shock proteins (sHSP), alphaB-crystallin/HSPB5 and 
HSP27, molecular chaperones that mediate the clearance of misfolded proteins and 
prevent their intracellular aggregation, was found in the spinal cord of transgenic 
SOD1 mice (Vleminckx et al., 2002). Shinder and colleagues demonstrated the 
interaction of mutant SOD1 with some of the HSPs such as HSP40, HSP70, HSP27 
and alphaB-crystallin (Shinder et al., 2001). In addition, HSPB8 was found to be 
upregulated selectively in motor neurons expressing mutant SOD1, suggesting that 
increased expression of HSP in motor neurons is most likely a protective mechanism 
to prevent accumulation of protein aggregates (Crippa et al., 2010). Furthermore, 
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several studies in cellular and animal models of ALS have shown that 
overexpression of HSPs protects against SOD1 toxicity, induces autophagy and 
promotes clearance of misfolded proteins (Carra et al., 2012). Of interest, 
Arimoclomol, a derivative of hydroxylamine, enhances the expression of HSPs and 
was found to be neuroprotective in SOD1 mice (Kieran et al., 2004) (Kalmar et al., 
2008). The potential neuroprotective effect of Arimoclomol is currently being 
investigated in a clinical Phase II trial for ALS patients with SOD1 mutations 
(Kalmar et al., 2014). 
 
The accumulation of intracellular protein aggregates suggests dysfunction of the 
proteolytic pathway. In healthy eukaryotes, proteolysis is a tightly regulated and 
complex mechanism where the ubiquitin-proteasome system (UPS), autophagy and 
chaperones constitute its essential components (Kabashi and Durham, 2006). The 
UPS plays an essential role in the regulation of protein turnover and the clearance of 
misfolded proteins. It selectively targets short-lived proteins, which are tagged by 
ubiquitin and then rapidly degraded by the proteasomes to prevent intracellular 
accumulation and cell toxicity (Ciechanover and Schwartz, 1994, Ciechanover and 
Brundin, 2003). On the other hand, autophagy removes long-lived cytoplasmic 
proteins and organelles by their sequestration into autophagosomes that fuse with 
lysosomes for the degradation of the aberrant proteins (Bendotti et al., 2012). The 
presence of ubiquitinated protein inclusions in motor neurons in ALS indicates 
dysfunction of the UPS. Alterations in proteasome subunits have been found in 
cellular (Urushitani et al., 2002) (Hyun et al., 2002) and animal models of SOD1 
FALS. In addition, impairment of the UPS was demonstrated in spinal cords of 
transgenic SOD1G93A mice (Kabashi et al., 2004) (Cheroni et al., 2005) as well as in 
neuroblastoma-spinal cord hybrid cells (NSC34) expressing mutant SOD1G93A 
(Allen et al., 2003). Impairment of the proteolytic pathway has also been implicated 
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as a possible cause for the accumulation of ubiquitinated TDP-43 inclusions and 
neurotoxicity in ALS. Studies have demonstrated that pharmacological inhibition of 
UPS or the proteasome in cellular models of ALS results in the accumulation of 
TDP-43 aggregates (van Eersel et al., 2011). Further evidence for the role of 
proteolysis in ALS comes from the identification of mutations in genes encoding for 
VCP, UBQLN2 and SQSTM1 (Johnson et al., 2010) (Deng et al., 2011c) (Fecto et 
al., 2011). Valosin-containing protein (VCP) belongs to the AAA+ (ATPases  
 
Associated with diverse cellular Activities) superfamily of adenosine triphosphatase 
(ATPase) which has multiple essential roles including autophagy and protein 
homeostasis were it identifies misfolded proteins and transfers them to the 
proteasome for unfolding and degradation (Halawani and Latterich, 2006, Ju et al., 
2009). Mutations in the VCP gene are associated with accumulation of TDP-43 and 
ubiquitin positive inclusions and reduced clearance of mutant SOD1 in transgenic 
mice and cellular models (Ritson et al., 2010, Bendotti et al., 2012). Hence, in ALS, 
expression of mutant VCP may result in accumulation of ubiquitinated inclusions 
that may ultimately lead to neurodegeneration. The UBQLN2 gene encodes ubiquilin 
2, an ubiquitin-like protein that regulates the degradation of ubiquitinated proteins. 
The expression of mutant ubiquilin 2 is associated with dysfunction in the UPS and 
was found to co-localise with TDP-43, FUS, ubiquitin and p62 (Deng et al., 2011c). 
The p62 protein is an adaptor protein encoded by the SQSTM1 gene, which has 
multiple essential roles including cellular signalling and autophagy. It was identified 
in TDP-43-negative, ubiquitin-positive inclusions in ALS patients with C9ORF72 
repeats (Al-Sarraj et al., 2011) (King et al., 2011) (Troakes et al., 2012). Under 
physiological conditions, p62 binds to TDP-43; however, in FTD-TDP-43 patients, 
this direct interaction is disrupted and may be involved with the pathogenesis of 
TDP-43 proteinopathy (Tanji et al., 2012). The exact mechanism by which mutant 
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SQSTM1 leads to neurodegeneration is unclear; however, studies have shown that 
increased expression of p62 reduces TDP-43 aggregation by autophagy and 
proteasome activation (Brady et al., 2011). In addition it can identify mutant SOD1 
in an ubiquitin-independent manner and targets it for autophagy (Gal et al., 2009). 
 
The accumulation of protein aggregates in cellular organelles could impair their 
function, which in turn may lead to motor neuron injury. For example, mutant SOD1 
accumulates in the inner, outer and intermembrane space of the mitochondria, which 
is associated with mitochondrial dysfunction in the brain and spinal cord (Higgins et 
al., 2002, Liu et al., 2004, Pasinelli et al., 2004). Dysfunction of cellular organelles 
in ALS will be discussed below. 
 
1.2.3 Endoplasmic reticulum stress 
The presence of intracellular aggregates containing misfolded proteins is a 
characteristic feature of neurodegenerative diseases including ALS. Accumulation 
of misfolded or unfolded proteins in the endoplasmic reticulum (ER) causes ER 
stress, which triggers the unfolded protein response (UPR), a self-defense 
mechanism that re-establishes protein homeostasis and reduces the load of protein 
aggregates (Matus et al., 2013). Upon activation of the UPR, ER-resident 
chaperones recognize misfolded proteins and promote their folding (Kaufman, 2002) 
whereas aberrant proteins are translocated to the cytoplasm for degradation (Smith 
et al., 2011). Under physiological conditions, these adaptive mechanisms are 
cytoprotective; however prolonged activation of UPR triggers apoptotic signals and 
ultimately leads to cell death (Hitomi et al., 2004).  
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Several lines of evidence suggest that ER stress contributes to the pathogenesis of 
motor neuron injury in ALS. Morphological changes in the ER were detected in the 
SOD1 transgenic mouse model prior to the onset of symptoms, suggesting that ER 
stress is involved in the early stages of motor neuron degeneration (Lautenschlaeger 
et al., 2012, Dal Canto and Gurney, 1995). Similar findings were observed in 
affected areas in post-mortem tissue of ALS patients (Oyanagi et al., 2008) (Sasaki, 
2010) (Lautenschlaeger et al., 2012). In line with these findings, UPR-induced 
proteins including protein disulphide isomerase (PDI), an ER-resident chaperone, 
are upregulated at the presymptomatic stage in SOD1 mice (Atkin et al., 2008). 
Furthermore, activation of PDI was found in mutant SOD1 mice where it co-
localizes with the mutant SOD1 aggregates (Atkin et al., 2006). Increased 
expression of PDI was also detected in the cerebrospinal fluid (CSF) and motor 
neurons of ALS patients (Atkin et al., 2008). Recent studies have reported that 
genetic polymorphism in the gene encoding for PD1 (P4HB gene) may be associated 
with FALS and SALS (Kwok et al., 2013).  
 
In experimental models of FALS, gene expression profiling showed that vulnerable 
motor neurons are particularly susceptible to ER stress at the early stages of the 
disease, whereas the resistant motor neurons show evidence of ER stress in the later 
stages, suggesting that ER stress may influence the manifestation and progression of 
ALS (Saxena et al., 2009). In addition, motor neurons exposed to CSF from ALS 
patients develop ER fragmentation and increased expression of caspase 12 and ER 
stress markers; however, the neurotoxins responsible for inducing ER stress in the 
CSF have not yet been identified (Vijayalakshmi et al., 2011). More evidence from 
recent studies showed that translation of expanded repeats in C9ORF72 related 
ALS-FTD produce toxic neuronal inclusions that induce ER stress in tissue culture 
models (Zhang et al., 2014). Furthermore, disease-causing mutations in the VAPB 
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gene, which encodes for a type II transmembrane protein that has multiple cellular 
functions including regulation of the UPR, leads to aggregation of mutant VAPB 
and induces ER stress (Lev et al., 2008, Chen et al., 2010b).   
 
Accumulating evidence for the role of ER stress in motor neuron injury makes it an 
attractive therapeutic target. Strategies that involved manipulation of the UPR 
pathway to reduce protein aggregation or inhibit chronic UPR activation were 
investigated in experimental models of ALS. Overexpression of PDI in motor 
neuron cultures reduced ER stress and neuronal death (Atkin et al., 2006, Ilieva et 
al., 2007, Walker et al., 2010, Atkin et al., 2008). Other agents that activate UPR 
such as Salburinal were found to be protective against mutant SOD1 (Saxena et al., 
2009) and mutant TDP-43 toxicity (Vaccaro et al., 2013). Although the UPR is 
considered to be a cytoprotective mechanism, unexpectedly, deletion of X-box-
binding protein 1 (XBP1), an essential transcription factor in the UPR pathway that 
is known to inhibit motor neuron death, enhances autophagy and delays disease 
onset in transgenic SOD1 mice (Matus et al., 2009). Moreover, deletion of the 
apoptosis signal regulating kinase 1 (ASK1) gene, an ER stress-induced apoptotic 
gene, delayed disease progression in SOD1G93A mice (Nishitoh et al., 2008). Finally, 
other studies showed that increased expression of derlin-1, an ER factor, enhanced 
the degradation of mutant SOD1 leading to reduced accumulation of the mutant 
protein and inhibition of the ER stress response (Mori et al., 2011). 
 
1.2.4 Mitochondrial dysfunctio 
Mitochondria are dynamic organelles that have multiple essential roles including 
adenosine triphosphate (ATP) production, calcium homeostasis and regulation of 
apoptosis (Shi et al., 2010). A large body of evidence exists from studies in human 
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tissue and experimental models of ALS implicating mitochondrial dysfunction in the 
pathogenesis of ALS. Abnormal mitochondrial morphology was demonstrated in 
skeletal muscles (Atsumi, 1981) and spinal motor neurons of ALS patients (Sasaki 
and Iwata, 1996) (Sasaki and Iwata, 2007) and was also observed in the 
presymptomatic stage in transgenic SOD1 mice (Gurney et al., 1994) (Higgins et al., 
2002) (Wong et al., 1995) (Kong and Xu, 1998) (Dal Canto and Gurney, 1995) 
suggesting early involvement of mitochondria in the pathogenesis of disease. 
Altered mitochondrial structure was also seen in in NSC34 cells expressing mutant 
SOD1 (Menzies et al., 2002). Indeed, in transgenic mice, altered mitochondrial 
morphology including vacoulation was detected and the number of vacuoles was 
noted to increase with progression of the disease (Higgins et al., 2003).  
 
Abnormalities in mitochondrial structure are associated with impaired function; 
however, the exact mechanism by which mitochondrial dysfunction causes motor 
neuron degeneration is unknown. In spinal cords of human ALS cases (Wiedemann 
et al., 2002) and SOD1 mice (Mattiazzi et al., 2002), impairment of respiratory chain 
function causes oxidative damage to mitochondrial proteins and defects in 
intracellular energy metabolism, which may contribute to motor neuron injury 
(Mattiazzi et al., 2002). Moreover, studies in SOD1 mice showed that impaired 
calcium handling in mitochondria increases the susceptibly of motor neurons to 
glutamate excitotoxicity, a known pathogenic cause of motor neuron dysfunction 
and induces ER stress (Carri et al., 1997, Bernardi, 1999, Bergmann and Keller, 
2004, Damiano et al., 2006, Grosskreutz et al., 2010). Impaired anterograde and 
retrograde transport of mitochondria was observed in SOD1 mice and most likely 
contributes to the accumulation of abnormal mitochondria in addition to causing a 
decrease in normal mitochondria in nerve terminals, which is thought to play a role 
in dying-back neuronal degeneration (De Vos et al., 2007, De Vos et al., 2008).   
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The exact mechanism by which mutant SOD1 causes mitochondrial dysfunction is 
not fully understood. In transgenic mice, mutant SOD1 protein was found to 
aggregate selectively in the outer membrane, intermembrane space and matrix of 
spinal cord mitochondria (Liu et al., 2004, Pasinelli et al., 2004, Vande Velde et al., 
2008). The accumulation of the mutant protein in the mitochondrial membrane 
increases with age and has been speculated to cause severe mitochondrial 
malfunction by interfering with import of essential mitochondrial proteins (Liu et 
al., 2004). While the presence of mitochondrial superoxide dismutase (SOD2) 
mediates the clearance of superoxide generated by the respiratory chain, the 
presence of mutant SOD1 in the mitochondria was found to be associated with a 
reduced membrane potential and mitochondrial DNA damage (Mattiazzi et al., 
2002). 
 
Mitochondrial dysfunction plays a key role in ALS pathogenesis and is a potential 
therapeutic target. Several therapeutic compounds that enhance mitochondrial 
function have been tested and showed neuroprotection in ALS models (Muyderman 
and Chen, 2014). Dexpramixole, a putative mitochondrial modulator, was shown to 
reduce the mortality of ALS patients in phase 2 clinical trials (Cudkowicz et al., 
2011) (Rudnicki et al., 2013), however subsequent phase 3 trials showed no 
significant difference from placebo on disease progression and survival (Cudkowicz 
et al., 2013). 
 
1.2.5 Cytoskeletal elements and axonal transport 
Motor neurons have very long axons, and in order to maintain their survival they 
require active transport of newly synthesised organelles and materials from the cell 
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body to the axons and neuronal processes (anterograde transport), and transport of 
waste material and neurotrophic factors from the axons to the cell body (retrograde 
transport) (Holzbaur, 2004). The machinery for axonal transport is mainly 
comprised of the motor proteins kinesin (anterograde transport) and dynein 
(retrograde transport) as well as the cytoskeletal proteins microtubules, 
neurofilaments (NF) which consist of three components: NF-heavy chain (NF-H), 
NF-medium chain (NF-M), NF-light chain (NF-L), peripherin and α-internexin 
(Julien and Mushynski, 1998). Abnormal accumulation of NF in the proximal axons 
and cell bodies of affected motor neurons is a pathological hallmark of ALS (Hirano 
et al., 1984) suggesting that impaired axonal transport may play a role in ALS 
pathogenesis. Overexpression of NF-H or NF-L subunits, or mutant NF-L, in mice 
leads to the development of neurofilament-positive swellings, axonal degeneration 
and muscle atrophy similar to human ALS pathology (Cote et al., 1993, Lee et al., 
1994, Xu et al., 1993). On the other hand, increased expression of NF-H in 
transgenic SOD1 mice was found to be neuroprotective and prolonged their survival, 
although the mechanism of neuroprotection is unclear (Couillard-Despres et al., 
1998). Studies in primary neurons showed that glutamate-induced excitotoxicity 
causes phosphorylation of neurofilament subunits with concomitant slowing of 
neurofilament transport, linking these two potential pathogenic mechanisms 
(Ackerley et al., 2000). In line with these findings, other studies demonstrated that 
aberrant neurofilament phosphorylation resulting in slowing of anterograde axonal 
transport is mediated by activation of the p38 mitogen-activated protein kinase (p38 
MAPK) and cyclin-dependent kinase 5 (CDK5) pathways, which are both found to 
be activated in SALS and FALS (Guidato et al., 1996) (Brownlees et al., 2000) 
(Ackerley et al., 2003) (Ackerley et al., 2004). Further evidence for the role of 
axonal transport in ALS stems from genetic studies that identified variant alleles in 
genes encoding for NF-H (Al-Chalabi et al., 1999, Daoud et al., 2011) and 
peripherin (Leung et al., 2004, Gros-Louis et al., 2004).   
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In mutant SOD1 mice, impaired axonal transport occurs in the early stages of the 
disease prior to the onset of symptoms, providing more evidence for the role of 
defective axonal transport in ALS pathogenesis (De Vos et al., 2007, Williamson 
and Cleveland, 1999, Bilsland et al., 2010).  Dysfunction of    both anterograde and 
retrograde transport of several cargoes was observed in transgenic SOD1 mice, and 
the defects affect specific cargos, such that anterograde transport defects affect the 
transport of mitochondria  (Williamson and Cleveland, 1999, De Vos et al., 2007, 
Bilsland et al., 2010). 
 
The mechanisms by which mutant SOD1 leads to impaired axonal transport remains 
unclear and is most likely a result of several mechanisms. Mitochondrial dysfunction 
causes impaired mitochondrial transport, which in turn may affect the transport of 
other cargoes due to energy depletion (De Vos et al., 2007). Upregulation of tumour 
necrosis factor α (TNFα) in mutant SOD1 mice (Hensley et al., 2003, Cereda et al., 
2008) was shown to disrupt kinesin function by hyperphosphorylation of kinesin 
light chain (Kiaei et al., 2007) via activation of p38 MAPK signaling pathways, 
which have been shown to be activated in ALS models (Tortarolo et al., 2003, 
Ackerley et al., 2004). Moreover, mutations in genes encoding the cytoskeletal 
motor protein dynactin (DCTN1) were found in ALS patients (Puls et al., 2003) 
(Munch et al., 2004) (Munch et al., 2005) (Liu et al., 2014). Although the underlying 
mechanism is unknown, studies showed that dynein interacts with mutant SOD1 
suggesting altered dynein/dynactin function (Zhang et al., 2007a) (Ligon et al., 
2005).  
 
Impaired axonal transport of essential cargoes to and from the distal axon, in 
combination with defective anterograde transport and mitochondrial dysfunction, 
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most likely plays a critical role in dying back axonopathy (Ferraiuolo et al., 2011e) 
which has been demonstrated in human ALS and disease models (Fischer et al., 
2004, Pun et al., 2006). 
 
1.2.6 Excitotoxicity 
Glutamate is one of the essential excitatory neurotransmitters in the nervous system. 
It is released from the pre-synaptic terminal endings into the synaptic cleft where it 
binds to ionotropic (N-methyl-d-aspartate (NMDA), alpha (α)-amino-3-hydroxy-5-
methyl-4-isoxazolepropionate (AMPA) and Kainate) and metabotropic receptors on 
the post-synaptic membrane, resulting in depolarisation and initiation of an action 
potential. The glutamate signal is terminated by its removal from the synaptic cleft 
by glutamate re-uptake transporter proteins located on the pre-synaptic terminal 
endings and peri-synaptic astrocytes. The excitatory amino acid transporter 2 
(EAAT2; also known as SLC1A2 or GLT1) is one of the most abundant transporter 
proteins in the CNS. Excitotoxicity refers to neuronal damage occurring as result of 
excessive activation of glutamate receptors due to either excessive extracellular 
glutamate levels, sensitivity of glutamate receptors to glutamate due to neuronal 
energy depletion, or abnormal expression of glutamate receptors (Van Damme et al., 
2005).  Depolarization following abnormal activation of glutamate receptors opens 
up ion channels leading to influx of sodium, calcium and water. Increased 
intracellular calcium sets off a cascade of events leading to neuronal injury and 
death (Arundine and Tymianski, 2003). Motor neurons are densely populated with 
glutamate receptors and are particularly susceptible to excitotoxicity due to (1) their 
low expression of GluR2 subunits of AMPA receptors, which increases their 
permeability for calcium (Williams et al., 1997) and (2) the lack of calcium binding 
proteins, which protect neurons from intracellular calcium injury (Ince et al., 1993).  
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Excitotoxicity has been implicated in the pathogenesis of several neurodegenerative 
disorders (Mehta et al., 2013) and a large body of evidence implicates its role in 
ALS pathogenesis. In a subset of ALS patients, elevated levels of glutamate were 
detected in the CSF (Shaw et al., 1995). Other studies showed that CSF from 
affected individuals increases intracellular calcium levels of cultured motor neurons 
and induces neurotoxicity by activation of glutamate receptors (Sen et al., 2005) In 
addition, reduced expression and activity of EAAT2 receptors was observed in 
affected areas of the CNS in ALS cases (Rothstein et al., 1992, Rothstein et al., 
1995, Fray et al., 1998). Further evidence comes from neurophysiological studies 
that demonstrated hyperexcitability of affected motor neurons in human patients at 
the presymptomatic (Vucic et al., 2008) and early stages of the disease (Vucic and 
Kiernan, 2006). Studies in motor neurons from SALS cases demonstrated reduced 
RNA editing of GluR2 mRNA, which is speculated to contribute to the increased 
calcium permeability of AMPA receptors and motor neuron death (Kwak et al., 
2010). Recently, mutations in the D-amino acid oxidase (DAO) gene were identified 
in ALS patients (Mitchell et al., 2010). DAO is an enzyme that regulates the levels 
of D-serine (D-amino acid), a co-agonist and activator of NMDA receptors; hence, 
mutations in DAO may play a role in excitotoxic motor neuron degeneration. 
 
In mutant SOD1 models, several findings support the role of excitotoxicity in the 
pathophysiology of ALS, including the vulnerability of motor neurons to glutamate 
excitotoxicity (Meehan et al., 2010, Roy et al., 1998, Kruman et al., 1999), altered 
AMPA expression (Spalloni et al., 2004), down regulation and reduced activity of 
EAAT2 (Boston-Howes et al., 2006), excessive glutamate efflux from spinal cord 
nerve terminals (Milanese et al., 2011), loss of astrocyte regulation of GluR2 
expression (Van Damme et al., 2007) and reduced inhibitory/excitatory synapse 
ratio in motor neurons (Sunico et al., 2011). 
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Riluzole is currently the only effective and FDA-approved treatment for ALS. It 
antagonizes glutamate excitotoxicity by several mechanisms including inhibition of 
glutamate release and blocking of NMDA receptors (NMDARs) (Doble, 1996) 
(Cheah et al., 2010). However, other anti-glutamate therapeutic agents such as 
lithium, talampanel and gabapentin have been tried in ALS patients with no 
beneficial effect (Siciliano et al., 2010) suggesting that Riluzole may act by 
modulating other mechanisms in addition to inhibiting excitotoxicity (Cheah et al., 
2010).  Currently it remains controversial whether excitotoxicity is a primary or 
secondary event; indeed, Foran and colleugues have shown that it is linked with 
other pathogenic mechanisms such as mitochondrial dysfunction, oxidative stress 
and intracellular calcium homeostasis, which highlights the complexity of the 
pathogenic mechanisms in ALS (Foran and Trotti, 2009).   
 
1.2.7 Dysregulated transcription and RNA processing 
The identification of TDP-43 as a major constituent of ubiquitinated inclusions in 
ALS highlights the importance of altered transcription and RNA processing as a 
potential pathogenic mechanism in the disease. In support of this, mutations in FUS, 
SETX and ANG genes, which regulate transcription and RNA processing, were 
discovered in some ALS patients and have been implicated in disease pathogenesis 
(Chance et al., 1998, Chen et al., 2004, Greenway et al., 2004, Greenway et al., 
2006, Kwiatkowski et al., 2009, Vance et al., 2009). These genes are discussed 
above and the exact mechanism by which these mutations cause the disease is still 
under investigation.   
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Much of our current understanding comes from the recently developed mutant TDP-
43 models. The deletion of TARDBP in mice is embryonically lethal (Chiang et al., 
2010) and postnatal deletion of the gene produces a severe phenotype and rapid 
death (Sephton et al., 2010). In addition, overexpression of wild type TARDBP 
induced neurodegeneration and features resembling ALS associated with early 
lethality (Wils et al., 2010). These observations indicate that TDP-43 is essential for 
normal embryonic development and neuronal survival. To model the abnormal 
localisation of TDP-43 in human ALS, transgenic animals were generated such that 
the protein was specifically expressed in the cytoplasm of the forebrain (Igaz et al., 
2011). The mice developed features of ALS and severe neurodegeneration as well as 
profound changes in neuronal gene expression suggesting that the nuclear 
localisation of TDP-43 is important for its function, and that loss of function leads to 
dysregulation of gene expression. More than 4000 RNA-binding targets were 
identified, which include genes implicated in neurodegeneration (FUS/TLS, SETX, 
ALS2, VCP, VAPB, FIG4) and genes involved with synaptic function, CNS 
development and RNA metabolism (Polymenidou et al., 2011, Sephton et al., 2010).  
 
Studies attempting to identify TDP-43 RNA-binding targets demonstrated changes 
in RNA splicing in CNS tissue of human cases (Tollervey et al., 2011, Xiao et al., 
2011) and mouse models affected by TDP-43 proteinopathy (Polymenidou et al., 
2011). Studies showed dysregulation in alternative mRNA splicing in fibroblast 
cells lines derived from TARDBP-related ALS patients (Highley, 2010). Moreover, 
a recent study by Highley et al. showed aberrant mRNA splicing in lower motor 
neurons from ALS patients; and in support of these findings, similar findings were 
observed when TDP-43 was depleted in a motor neuron-like cell line (Highley et al., 
2014). Further evidence on the role of aberrant RNA processing in ALS comes from 
reports of transcriptional repression observed in motor neurons expressing mutant 
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SOD1 (Kirby et al., 2005, Ferraiuolo et al., 2007) and the detection of indices of 
RNA oxidation in mutant SOD1 mice and ALS patients (Chang et al., 2008). 
 
1.2.8 The role of non-neuronal cells  
Evidence for the role of non-neuronal cells in ALS first came from early studies 
which showed that selective expression of mutant SOD1 in either motor neurons or 
astrocytes did not cause an ALS phenotype (Pramatarova et al., 2001, Lino et al., 
2002). Reports from later studies contradicted these findings, showing that 
restricting expression of mutant SOD1 to motor neurons was associated with a later 
onset and a milder form of the disease (Jaarsma et al., 2008). Here the authors 
explained that in the previous studies the absence of disease was most likely related 
to the low expression of mutant SOD1, emphasizing that sufficient amounts of 
mutant SOD1 are needed to trigger motor neuron degeneration. Although restricted 
expression of mutant SOD1 in astrocytes solely does not cause motor neuron 
degeneration (Gong et al., 2000), selective inhibition of the mutant gene in 
astrocytes delayed disease progression (Yamanaka et al., 2008). Indeed, mutant 
SOD1-expressing astrocytes exert toxic effects when cultured with primary motor 
neurons and embryonic human or mouse stem cell-derived motor neurons (Hensley 
et al., 2006, Nagai et al., 2007), suggesting that motor neuron injury requires the 
contribution of non-neuronal cells. Further evidence for the role of non-neuronal 
cells comes from studies in chimeric mice, where cells express either mutant SOD1 
or wild-type SOD1. Normal motor neurons surrounded by mutant glial cells 
developed pathological features of ALS, whereas SOD1 motor neurons surrounded 
by wild-type non-neuronal cells were less affected (Clement et al., 2003). Moreover, 
targeted deletion of mutant SOD1 in microglia and astrocytes does not alter the 
onset of disease, but significantly delays the progression of disease at the later stages 
(Yamanaka et al., 2008). On the other hand, silencing the mutant allele in microglia 
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in transgenic SOD1G37R mice did not alter the onset of disease but significantly 
slowed down disease progression (Boillee et al., 2006). Thus, the onset and 
progression of disease may represent two distinct phases that could be separate 
targets for therapeutic intervention. These studies also highlight that non-neuronal 
cells could be a novel therapeutic target for delaying the progression of disease in 
ALS. In contrast to microglia and astrocytes, specific expression of mutant SOD1 in 
Schwann cells does not cause motor neuron pathology and increasing the expression 
of mutant SOD1 in Schwann cells does not aggravate the disease progression, 
suggesting that these cells are resistant to accumulation of the mutant SOD1 protein 
(Turner et al., 2010). 
 
The cellular mechanisms by which mutant astrocytes contribute to motor neuron 
injury remains unclear, it is speculated that the release of toxic factors from motor 
neurons may trigger their activation. Altered astrocyte functional properties in the 
presence of mutant SOD1 have been proposed as a mechanism by which they 
mediate their toxic effects (Ferraiuolo et al., 2011a). Haidet-Phillips and colleagues 
showed that astrocytes derived from FALS and SALS were both toxic to motor 
neurons suggesting a shared mechanism resulting in motor neuron degeneration 
through astrocyte-induced toxicity  (Haidet-Phillips et al., 2011).  Metabolic 
dysregulation, including impairment of the astrocyte lactate efflux transporter 
causing low levels of spinal cord lactate, was demonstrated in SOD1G93A mice 
(Ferraiuolo et al., 2011a). Another mechanism by which astrocytes may contribute 
to motor neuron injury is by activation of the pro-nerve growth factor–p75-signaling 
cascade (Ferraiuolo et al., 2011a).   
 
The evidence implicates a non-cell autonomous process involved with motor neuron 
degeneration in ALS. Further studies are needed to elucidate the mechanisms by 
which glial cells exert their toxic effects on motor neurons as this may provide novel 
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therapeutic strategies to prevent disease progression. On the other hand, altered 
expression of TDP-43 by either overexpression of the mutant protein TDP-43A315T or 
knock out of TDP-43 in astrocytes, does not induce motor neuron degeneration in 
wild-type motor neurons (Haidet-Phillips et al., 2013). These findings suggest that 
astrocytes do not play an essential role in the disease mechanism of TDP-43 related 
ALS and highlights the heterogeneity in ALS pathogenic mechanisms. 
 
1.2.9 Neuroinflammation 
Neuroinflammation is a prominent pathological feature common to ALS and other 
neurodegenerative diseases. In ALS, it is characterised by the activation of 
microglia, astrocytes and T-cell infiltration in affected areas in the brain and spinal 
cord (Henkel et al., 2004). Although traditionally inflammatory mechanisms were 
thought to occur as a secondary protective mechanism in response to motor neuronal 
injury, evidence now exists to support that it also contributes to disease progression 
(Papadimitriou et al., 2010). In line with this hypothesis, microglial activation is 
observed in the early stages of the disease prior to onset of symptoms and increases 
with the progression of disease (Alexianu et al., 2001) (Henkel et al., 2004) 
(Garbuzova-Davis et al., 2007). In fact, some studies have shown that in the early 
stages, microglia produce anti-inflammatory factors that promote the repair and 
regeneration of motor neurons. However, with progression of disease when the 
neurotoxic burden increases, microglia switch to produce pro-inflammatory 
cytokines, which contributes to motor neuron degeneration and progression of the 
disease (Appel et al., 2011).  
 
Increased levels of proinflammatory markers including IL-6, IL-8, IL-1ß, 
chemoattractant protein 1, TNF α, prostaglandin E2 and cyclooxygenase 2 were 
found in the CSF of ALS patients (Elliott, 2001, Almer et al., 2002, Hensley et al., 
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2003, Kuhle et al., 2009, Fiala et al., 2010, Henkel et al., 2004). In addition, 
alterations in the levels of biochemical markers of the immune system were detected 
in the blood and CSF of human cases (Mantovani et al., 2009, Tateishi et al., 2010). 
Likewise, upregulation of inflammatory cytokines was observed in the spinal cord of 
transgenic SOD1 mice (Alexianu et al., 2001) (Henkel et al., 2006). Activation of 
the complement system is observed in human ALS and transgenic SOD1 mice and 
may lead to the activation of an adaptive immune response and ultimately 
inflammation (Ferraiuolo et al., 2007, Lobsiger et al., 2007) (Sta et al., 2011). 
Furthermore, a significant reduction in CD4+CD25+ regulatory T (TREG) and 
monocyte (CD14+) cell counts occurs in the early stages of the disease, indicating 
their recruitment to the CNS and early involvement in neurodegeneration (Kipnis et 
al., 2004). TREG cells stimulate microglia to produce anti-inflammatory cytokines to 
inhibit the neuroinflammatory process. In line with this notion, SOD1 mice that 
were bred with mice lacking functional CD4+ T cells developed a rapidly 
progressive ALS phenotype that was reversed with bone marrow transplantation 
(Beers et al., 2008).  
 
Recent studies demonstrated that blocking CD40L, a T cell ligand that triggers an 
`immune response when it binds to CD40 receptors on antigen presenting cells, was 
discovered as a potential therapeutic target for the treatment of ALS. Systemic 
administration of monoclonal antibodies against CD40L (MR1) via intraperitoneal 
injections in SOD1 mice delayed the onset of disease, prolonged survival and 
reduced microglial and astrocyte activation (Lincecum et al., 2010). 
 
1.2.10 Oxidative stress 
Oxidative stress occurs as a result of an imbalance between the generation and 
clearance of reactive oxygen species (ROS), and/or due to impairment of 
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intracellular anti-oxidant mechanisms to prevent damage caused by ROS (Coyle and 
Puttfarcken, 1993, Lenaz, 1998). The mitochondria represent the major site for the 
generation of ROS, which are produced as a by-product of aerobic metabolism due 
to leakage of electrons from the respiratory chain (Milani et al., 2013). The 
accumulation of ROS in post-mitotic neurons during ageing is one of the main 
factors considered to tip the balance such that the cells are unable to cope with toxic 
insults, leading to a vicious cycle of intracellular damage and ultimately neuronal 
death (Ferraiuolo et al., 2011a). The large size and increased metabolic demands of 
motor neurons renders them particularly vulnerable to free radical damage (Barber et 
al., 2006).  
 
The discovery of mutations in the SOD1 gene, which encodes for an essential anti-
oxidant enzyme and accounts for one-fifth of FALS, pointed towards a role of 
oxidative stress in ALS (Rosen et al., 1993). Thereafter, extensive research has 
shown that it plays an essential role in SOD1-FALS pathogenesis. Markers of 
oxidation were found to be elevated in biological samples of ALS patients including 
CSF (Smith et al., 1998), sera (Henkel et al., 2004) and urine (Mitsumoto et al., 
2008). Furthermore, increased levels of oxidative damage to lipids (Shibata et al., 
2001), proteins (Shaw et al., 1995) and DNA (Fitzmaurice et al., 1996) were found 
in post-mortem tissue of FALS and SALS patients. In line with human studies, 
similar findings of oxidative damage were found in transgenic mouse models 
(Barber et al., 2006). Moreover, in mouse models evidence of mRNA oxidation was 
found in motor neurons at the presymptomatic stage (Chang et al., 2008). Studies 
showed that some mRNAs involved in essential metabolic pathways are particularly 
prone to oxidation (Chang et al., 2008). Evidence of oxidative damage is also found 
in cellular models of SOD1-related ALS (Barber et al., 2006). Interestingly, SOD1 
was found to be particularly susceptible to oxidative post-translational modification 
(Andrus et al., 1998). The recently developed cellular model of TDP-43 related 
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indicates that mutant TDP-43 provokes oxidative damage in motor neuron cell lines 
(Duan et al., 2010).  
 
The sources of oxidative stress have been extensively studied in transgenic SOD1 
models. Although aberrant SOD1-mediated chemical reactions have been proposed 
(Barber et al., 2006), enzymatically inactive copper-depleted mutant SOD1 can still 
cause motor neuron injury (Subramaniam et al., 2002). Thus, mutant SOD1 can 
induce oxidative stress by mechanisms other than its catalytic function. In microglia, 
expression of mutant SOD1 results in increased production of free radicals by the 
nicotinamide adenine dinucleotide phosphate (NADPH) oxidase (NOX) enzymes 
(Harraz et al., 2008). Increased expression of NOX2 was found in human ALS tissue 
(Wu et al., 2006a) and transgenic SOD1 mice, and knockout of NOX1 or NOX2 
prolonged the survival of transgenic SOD1G93A (Marden et al., 2007). One of the 
main regulators of the anti-oxidant response is the transcription factor nuclear 
erythroid-2-related factor 2 (Nrf2), which in the presence of oxidative stress, binds 
to and upregulates genes containing an anti-oxidant response element (ARE) in their 
promoter (Sarlette et al., 2008). In addition, dysregulation of Nrf2-ARE signaling 
has been shown in human ALS as well as transgenic SOD1 mice (Kirby et al., 2005, 
Sarlette et al., 2008). Furthermore, free radical damage also plays a role in non-
SOD1 related ALS (Carri et al., 2015) and environmental factors such as metals are 
speculated to induce the production of ROS in ALS (Carri et al., 2003, Lovejoy and 
Guillemin, 2014). 
 
A wealth of evidence shows that oxidative stress interacts with, and possibly 
enhances, other pathogenic mechanisms that contribute to motor neuron 
degeneration such as excitotoxicity (Rao and Weiss, 2004), mitochondrial 
dysfunction (Duffy et al., 2011), protein aggregation (Wood et al., 2003), ER stress 
(Kanekura et al., 2009) and altered signaling in non-neuronal cells (Blackburn et al., 
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2009, Sargsyan et al., 2005). Thus, oxidative stress is considered an attractive 
therapeutic target and meta-analysis studies have shown that among several drugs, 
anti-oxidant therapies are the most effective in prolonging survival in transgenic 
SOD1 mice (Benatar, 2007). However, so far anti-oxidant therapy has not shown 
beneficial effects in ALS patients, which is most likely due to suboptimal designs of 
clinical trials (Orrell et al., 2007, Zhu et al., 2015).   
 
1.2.11 Apoptosis 
Apoptosis is an example of programmed cell death, which is characterised by 
morphological changes to the cells and occurs secondary to the activation of 
intracellular death pathways. In ALS, apoptosis contributes to the selective death of 
motor neurons; although some argue that this process is too rapid to cause cell death 
in a chronic neurodegenerative disorder (Sathasivam et al., 2005). This is an 
oversimplification since there are multiple components to the apoptotic pathway, 
and the late stages of apoptosis which could be visualised in vivo, only last for a 
couple of hours (Sathasivam et al., 2005) which makes it difficult to detect in post-
mortem tissue of ALS patients. Hence much of our understanding of the cell death 
mechanisms in ALS comes from the generation of cellular and animal models of 
SOD1-related ALS.  
 
Structural changes to motor neurons consistent with apoptosis, such as the 
externalisation of phosphatidylserine (a phospholipids that normally resides in the 
inner side of cell membranes) to the outer layer of the plasma membrane, were 
found in NSC34 cells expressing mutant SOD1 (Cookson et al., 2002). Other 
features such as DNA fragmentation have been observed in ALS post-mortem tissue 
(Ekegren et al., 1999, Martin, 1999, Troost et al., 1995, Yoshiyama et al., 1994), 
although this has not been replicated by other investigators (He and Strong, 2000, 
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Migheli et al., 1994). Other studies demonstrated the presence of apoptotic cells in 
the spinal cord of transgenic SOD1G93A mice according to morphological criteria 
(Guegan and Przedborski, 2003). Early reports by Martin and colleagues described 
the stages of morphological changes that are reminiscent of apoptosis, affecting 
dying motor neurons in human ALS post-mortem tissue, although not all of the 
classical features of apoptosis were present (Martin, 1999). Evidence of biochemical 
markers of apoptosis was also found in ALS patients as well as in cellular and 
animal models. For example, activation of caspases, which are crucial for mediating 
the apoptotic process (Mu et al., 1996), were found in cellular (Sathasivam et al., 
2005, Ghadge et al., 1997) and mouse models of SOD1-related ALS (Wootz et al., 
2004, Guegan and Przedborski, 2003, Kang et al., 2003). In addition, increased 
activity of caspases 1 and 9 was observed in the spinal cords (Li et al., 2000) as well 
as in serum (Ilzecka, 2012) of ALS patients. Additional evidence shows that 
conditional deletion of the pro-apoptotic proteins BCL-2-associated X protein (BAX) 
and BCL-2-homologous antagonist/killer (BAK) in the CNS delayed the onset of 
symptoms and prolonged the survival of the transgenic SOD1 mouse. Moreover, 
increased expression of other pro-apoptotic proteins such as LeY antigen 
(Yoshiyama et al., 1994), fractin (Vukosavic et al., 2000) and prostate apoptosis 
response-4 protein, were found in affected motor neurons (Pedersen et al., 2000). In 
support of this notion, overexpression of the anti-apoptotic BCL-2 protein prolongs 
the survival of transgenic SOD1 mice (Kostic et al., 1997, Azzouz et al., 2000) and 
motor neuron-like cell lines (Nicholson and Thornberry, 1997) and low levels of 
BCL-2 mRNA were detected in motor neurons of the lumber spinal cords of human 
cases. Furthermore, evidence of apoptosis was seen in cultures of rat embryonic 
cortical neurons exposed to CSF from ALS patients (Gomez-Pinedo et al., 2014). In 
these studies, the cells developed nuclear fragmentation and increased expression of 
apoptotic markers including caspase 3.  
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All of the above mentioned pathogenic mechanisms lead to apoptotic cell death. 
Emerging evidence shows that mutant TDP-43 induced apoptosis in neuronal cells 
(Mutihac et al., 2015). Recent studies showed that overexpression of full length 
TDP-43 or its mutant forms induced caspase activation and apoptosis (Yamashita et 
al., 2014). In their study, Wang et al. demonstrated that TDP-43 induces p53-
mediated apoptosis (Wang et al., 2014). Likewise, cellular models of C9ORF72-
related ALS also showed features of apoptotic cell death (Stepto et al., 2014).  
 
Thus, the evidence suggests that a form of programmed cell death resembling 
apoptosis plays a role in motor neuron degeneration. Although apoptosis is likely to 
be a terminal event, anti-apoptotic treatments may prevent disease progression. It 
could be argued that prolonging the survival of diseased neurons may not be an 
effective strategy; however, anti-apoptotic treatments could be combined with other 
therapies targeting upstream mediators of motor neuron injury. Alternatively, 
activation of cell survival pathways may counteract the apoptotic process and may 
help to prevent disease progression.  
 
1.3 The PI3K/Akt survival Pathway 
The PI3K/Akt signaling pathway is an essential pathway, which regulates cell 
survival, proliferation, translation and transcription (Osaki et al., 2004). PI3K is a 
lipid kinase made up of a catalytic (P110) and a regulatory (P85) subunit (Katso et 
al., 2001). It is activated by receptor tyrosine kinases and G protein coupled 
receptors to phosphorylate the 3 position of the inositol ring of PIP2, to produce 
phosphatidylinositol 3,4,5 trisphosphate (PIP3), a lipid secondary messenger and an 
important component of the PI3K/Akt pathway (Katso et al., 2001). Generation of 
PIP3 results in the recruitment of the cytosolic protein, Akt, also known as protein 
kinase B (PKB), to the plasma membrane where it is activated and phosphorylated 
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by phosphoinositide-dependent kinase-1 (PDK1) (Scheid and Woodgett, 2003). Akt 
is a 57-kDa serine/threonine kinase, which is an essential mediator of several 
signalling pathways including cell survival, glucose metabolism and protein 
translation (Datta et al., 1999). It exists in three isoforms encoded by three distinct 
genes: Akt1 (PKBα), Akt2 (PKBβ) and Akt3 (PKBγ) (Datta et al., 1999). Neurons 
predominantly express Akt1 and Akt3 (Osaki et al., 2004). Translocation of Akt to 
the cell membrane results in a conformational change in its protein structure 
resulting in the exposure of two essential phosphorylation sites: Threonine 308 
(Thr308) and Serine 473 (Ser 473) (Cantley, 2002). Activation of Akt requires the 
phosphorylation of both Thr308 and Ser473. Activated Akt then translocates to the 
cytoplasm and nucleus where its substrates are located. Akt exerts its role as a cell 
survival and proliferation mediator by phosphorylating various downstream signals 
including: BCL-2 antagonist of cell death (BAD) (Datta et al., 1997), glycogen 
synthase kinase 3-β  (GSK3-β) (van Weeren et al., 1998), forkhead transcription 
factors (FHTF) (Kops and Burgering, 1999), caspase-9 (Cardone et al., 1998) 
(Cardone et al., 1998), IκB kinase (IKK) (Kane et al., 1999) and mammalian-target-
of rapamycin (mTOR) (Manning and Cantley, 2003). Among these targets, BAD is 
one of the most important molecules in regulating cell survival. PTEN is a crucial 
negative regulator of Akt that inhibits cell survival and proliferation, by 
dephosphorylating PIP3 to PIP2 (Datta et al., 1997) (Figure 2). 
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Figure 1.2. The PTEN/PI3K/Akt pathway. The binding of ligands to tyrosine 
kinase receptors activates PI3K which catalyses the generation of PIP3 from PIP2. 
The production of PIP3 leads to the translocation of Akt from the cytoplasm to the 
cell membrane where it becomes phosphorylated and activated at Ser473 and 
Thr308. Activated Akt phosphorylates several cytoplasmic substrates and regulates 
protein translation, glucose metabolism and inhibits apoptosis. PTEN 
dephosphorylates PIP3 and acts as a main negative regulator of the PI3K/Akt 
pathway.  
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1.3.1 PTEN 
For many years, the observation of loss of heterozygosity of chromosome 10 in 
human cancers, particularly glioblastoma, pointed to the existence of a tumour 
suppressor gene in chromosome 10. It was not until 1997 when three independent 
groups reported the first discovery of a candidate tumour suppressor gene, PTEN 
(phosphatase and tensin homologue deleted in chromosome 10) (Datta et al., 1997) 
MMAC1 (mutated in multiple advanced cancers-1) (Steck et al., 1997) or TEP1 
(TGF b regulated and epithelial cell enriched phosphatase 1) (Li and Sun, 1997), 
which was mapped to chromosome 10q23. Somatic mutations in PTEN were 
detected in a variety of human cancers including glioblastoma, advanced prostate 
and endometrial cancers, and PTEN is now considered as one of the most frequently 
mutated genes in human malignancies. Germline mutations were also detected in 
almost 80% of patients suffering from autosomal dominant Cowden disease (CD) 
(Liaw et al., 1997), Lhermitte Duclos disease (LDD) (Nelen et al., 1997) and 
Bannayan-Zonana syndrome (BZS) (Marsh et al., 1997). These syndromes share 
characteristic developmental defects, benign tumours and increased susceptibility to 
thyroid and breast malignancies. 
 
The PTEN gene consists of nine exons and encodes a 5.5 kb mRNA (Steck et al., 
1997). It encodes a protein consisting of 403 amino acids with a relative molecular 
weight of 47 kDa (Steck et al., 1997). Analysis of PTEN’s crystal structure revealed 
that it consists of three main domains (Lee et al., 1999). The amino terminal end (N-
terminal), comprising 190 amino acids, carries the signature motif HCXXGXXR that 
defines the family of protein tyrosine phosphatases (PTPs) and dual-specificity 
protein phosphatases (DSPs). Within this motif, the Cys-124 and Arg-130 are 
essential for the catalytic function of the protein (Lee et al., 1999). Most of the 
mutations are found to affect the N-terminal (Figure 1.3). Sequence analysis 
revealed that the catalytic amino terminal end bears homology to chicken tensin 
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(Steck et al., 1997), an actin binding protein found in focal adhesions, and bovine 
auxillin (Steck et al., 1997), a protein that disassembles clathirin-coated vesicles. 
The evidence suggests that the N-terminal has additional roles to that of a 
phosphatase. The C-terminal domain (carboxyl terminal) consists of a C2 domain, 
which mainly functions in the binding of PTEN to phospholipids in the plasma 
membrane (Lee et al., 1999); it also contains a PDZ-binding motif which is 
responsible for protein-protein interactions (Wu et al., 2000) and two PEST (peptide 
sequence rich in proline (P), glutamic acid (E), serine (S) and threonine (T) 
sequences (Georgescu et al., 1999). A known role for PEST sequences is to target 
proteins for proteolytic degradation; however, studies have shown that PEST 
sequences play a role in the stability of the PTEN protein (Georgescu et al., Vazquez 
et al.). Finally, the tail of PTEN consists of 50 amino acids that are also essential for 
PTEN’s stability (Lee et al., 1999). 
 
The discovery of PTEN in 1997 stimulated several research groups to identify its 
substrates. The finding by Mahaema and Dixon, that PTEN is a phosphatidylinositol 
phosphatase, was a major step towards the understanding of its function (Maehama 
and Dixon, 1998). In their in vitro studies, they demonstrated that overexpression of 
PTEN in a human cell line (HEK293) led to reduced levels of   PIP3, and 
transfection of inactive PTEN resulted in the accumulation of PIP3 levels (Maehama 
and Dixon, 1998).  Further evidence comes from the elevated levels of PIP3 
detected in cells of PTEN-deficient embryos (Stambolic et al., 1998).  Studies in 
Caenorhabditis elegans demonstrated that this pathway is highly conserved in 
worms and its inhibition prolongs its survival (Mihaylova et al., 1999).  
 
Recent progress has been made in understanding the association of PTEN with other 
signalling pathways. PTEN has been shown to inhibit cell migration by 
dephosphorylating focal adhesion kinase (FAK) (Tamura et al., 1998, Tamura et al., 
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1999). In addition, PTEN negatively regulates the MAPK pathway, another 
important pathway in cell survival and proliferation (Weng et al., 2001b, Waite and 
Eng, 2002). Moreover, PTEN is a negative regulator of the mammalian target of 
rapamycin (mTOR) pathway, which plays an essential role in regulating neuronal 
cell size and growth (Sansal and Sellers, 2004). mTOR is a large serine/threonine 
protein kinase that regulates ribosome biogenesis, protein synthesis and autophagy 
(Sarbassov et al., 2005). mTOR acts primarily by phosphorylating eukaryotic 
translation initiation factor 4E binding protein (4EBP) proteins and p70 ribosomal 
S6 protein kinase (p70S6K), which are essential regulators of protein translation 
(Sarbassov et al., 2005). In response to nutrients and growth factors, the PI3K/Akt 
pathway activates mTOR (Sarbassov et al., 2005). PTEN is an essential negative 
regulator of mTOR whereas activated mTOR signaling negatively inhibits the 
PI3K/Akt pathway (Song et al., 2012). Studies have shown that PTEN exhibits its 
regulation of cell size and proliferation through regulation of the mTOR pathway 
((Sansal and Sellers, 2004).   
 
 
            
Figure 1.3. PTEN domains. This schematic diagram illustrates the structure of 
PTEN. The N-terminal domain contains the signature motif HCXXGXXR of protein 
tyrosine and dual-specificity phosphatases. The C2 domain facilitates the binding of 
PTEN to phospholipids in the plasma membrane. The PDZ binding motif is 
responsible for protein-protein interactions. The PEST sequences and PTEN tail are 
essential for PTEN’s stability. 
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1.3.2 The role of PTEN in the CNS 
Studies in human post-mortem brain tissue showed that PTEN was mainly expressed 
in neurons and glia cells (Sano et al., 1999) (Sano et al., 1999). 
Immunohistochemistry showed that PTEN is localised to the cytoplasm and nucleus 
of neurons (Sano et al., 1999). In adult mice PTEN is widely expressed in the CNS 
with marked expression in the cortex, cerebellum and pyramidal neurons, compared 
to the very low levels in glial cells (Lachyankar et al., 2000).  
 
Initially, much of the research focused on PTEN’s role in the molecular 
pathogenesis of brain cancers; however, studies have demonstrated a link between 
PTEN and several neurological disorders, which unravelled a broader role for PTEN 
in the nervous system. A wealth of evidence showed that PTEN has crucial roles in 
the CNS and contributes to neurodegeneration in diseases such as ALS (Kirby et al., 
2011f), PD (Diaz-Ruiz et al., 2009, Domanskyi et al., 2011, Kim et al., 2005), ALZ 
(Griffin et al., 2005, Sonoda et al., 2010, Zhang et al., 2006) and multiple sclerosis 
(Harrington et al., 2010). Targeted deletion of the murine PTEN gene resulted in 
embryonic lethality, demonstrating that PTEN is essential for early embryogenesis 
(Di Cristofano et al., 1998) (Suzuki et al., 1998) (Podsypanina et al., 1999). 
Conditional PTEN knockout in CNS progenitor/stem cells of mouse embryos at 
mid-gestation, using the cre-lox technology, resulted in mice with multiple 
anomalies and early lethality (Groszer et al., 2001), while postnatal PTEN silencing 
produced mice with enlarged brains that died shortly after birth (Backman et al., 
2001, Kwon et al., 2001). These mouse models demonstrated the importance of 
PTEN in early and late neuronal development and showed that PTEN negatively 
regulates neuronal cell size and proliferation. On the other hand, PTEN depletion 
causes progressive loss and degeneration of Purkinje cells during early postnatal 
development (Marino et al., 2002). Furthermore, several studies showed that PTEN 
plays an essential role in synaptogenesis and synaptic plasticity (Williams et al., 
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2015) (Lugo et al., 2014) (Fraser et al., 2008). The developmental function of PTEN 
in the CNS is out of the scope of this review; its role in neuronal apoptosis and axon 
regeneration will be discussed below. 
 
1.3.3 PTEN and neuronal apoptosis 
The lack of apoptosis in brain tumours associated with PTEN mutations raised an 
increasing interest in a possible role for PTEN in neuronal apoptosis (Kyrylenko et 
al., 1999). In vitro models of post-mitotic neuronal cell death have shown that PTEN 
expression is altered in response to various apoptotic inducers (Kyrylenko et al., 
1999). For example, in primary cultured cerebellar granules, serum withdrawal with 
potassium deprivation reduced the expression of PTEN mRNA (Kyrylenko et al., 
1999). While okadeic acid, an apoptotic inducer, induces an initial increase in PTEN 
mRNA, this was followed by a reduction in PTEN expression (Kyrylenko et al., 
1999). Similar effects of serum withdrawal were also seen in cultured 
Neuroblastoma-2a cells (Kyrylenko et al., 1999). Thus, it seems that the reduction in 
PTEN expression is a compensatory mechanism by which post-mitotic neuronal 
cells activate the PI3K/Akt pathway to enhance their own survival. In accordance 
with this, in the motor neuron cell line (VSC4.1), exposure to interferon-gamma was 
associated with increased PTEN expression and apoptotic cell death, reduced Akt, 
increased caspase 3 activity and BAX: BCL-2 ratio (Smith et al., 2009a). In 
addition, treatment of motor neuron cells with oestrogens inhibited PTEN and 
prolonged their survival (Smith et al., 2009b). Increased expression of PTEN and 
inhibition of the Akt pathway was observed in experimental models of chronic 
exposure to alcohol during gestation (Xu et al., 2003). In this model, the mice 
showed marked cerebellar hypoplasia and cell death indicating a correlation of 
PTEN with neuronal death (Xu et al., 2003). In primary hippocampal neurons, 
overexpression of wild type PTEN decreased Akt expression and increased 
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glutamate induced cell death (Gary and Mattson, 2002). On the other hand, over 
expression of mutant PTEN increased Akt levels and significantly increased 
neuronal survival (Gary and Mattson, 2002). Furthermore, PTEN+/- mice showed 
increased resistance to death induced by glutamate excitotoxicity (Gary and 
Mattson, 2002). In vitro studies showed that peroxynitrite mediates its 
neuroprotective effects by down regulating PTEN (Delgado-Esteban et al., 2007). In 
line with these findings, it has been shown that hypothermia preserved the levels of 
phosphorylated PTEN, and attenuated the decrease in active pAkt, leading to 
neuroprotection against ischemic injury (Zhao et al., 2005). Moreover, there is 
accumulating evidence suggesting that downregulation of PTEN is neuroprotective 
in ischemic brain injury (Zhang et al., 2007b). 
 
Although these studies clearly demonstrate the involvement of PTEN with neuronal 
apoptosis, the molecular mechanisms mediating these effects still remain under 
investigation. It was observed that in rat hippocampal neurons, PTEN physically 
associates with NR1 and NR2 subunits of NMDAR; a glutamate receptor, which is 
implicated in excitotoxicity, induced neuronal death (Ning et al., 2004). In models of 
brain ischemia, PTEN downregulation leads to a diminished extra-synaptic 
expression of NMDARs in addition to activating the Akt pathway (Ning et al., 
2004). This study elegantly demonstrated the dual protective role of the protein and 
lipid phosphatase activities of PTEN (Ning et al., 2004). Furthermore, studies 
revealed that PTEN deletion preserves the expression of gamma-aminobutyric acid 
(GABA) receptors, which are suppressed in brain ischemia (Liu et al., 2010). 
Together these data provide evidence for the multiple functions of PTEN and 
emphasise its role in brain ischemia. 
 
An intriguing question is how PTEN reaches its main targets, which are localised to 
the cell membrane. Studies in primary mouse cortical neurons demonstrated that 
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Lactacystin, a proteasome inhibitor, induced apoptosis that was associated with the 
cleavage of PTEN to a truncated form (50 kDa). The truncated PTEN was found to 
accumulate in the insoluble fractions of the membranes, suggesting that during 
neuronal apoptosis, PTEN translocates to the cell membrane where it’s targets are 
localised, and mediates its inhibitory effects on cell survival (Cheung et al., 2004a, 
Choy et al., 2006a). Further studies revealed that Lactacystin-induced neuronal 
apoptosis was associated with caspase 3 activation, which induced the cleavage of 
PTEN to its truncated form (Cheung et al., 2004a). Moreover, staurosporine (STS)-
induced apoptosis in rat hippocampal cultures causes release of cytochrome c, 
activates caspase 3 and release of ROS (Zhang et al., 2006). PTEN was found to 
directly associate with the pro-apoptotic protein, BAX, in the cytoplasm and 
translocates with BAX to mitochondria during apoptosis. PTEN knockdown has 
reduced apoptosis induced by STS and release of ROS implicated in the 
pathogenesis of neurodegenerative disorders such as ALS and PD (Zhang et al., 
2006). Further studies using different models of neurotoxicity, demonstrated that 
PTEN is a common regulator for ROS in pathological conditions (Zhu et al., 2007b). 
PTEN knockdown reduced the production of ROS, independent of the antioxidant 
enzyme superoxide dismutase 2 (SOD2) (Zhu et al., 2007b). 
 
It is clearly evident that PTEN is an important mediator of mitochondrial-induced 
neuronal apoptosis. Since apoptosis and mitochondrial dysfunction are characteristic 
features in neurodegenerative disorders, down regulation of PTEN seems to be an 
attractive tool to prevent apoptotic death and delay the progression of 
neurodegenerative disorders. 
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1.3.4 PTEN and axonal regeneration 
For many years numerous efforts to identify strategies to promote axonal 
regeneration has been a major challenge and with very limited success. The 
evidence suggests that inhibition of the mTOR pathway and hence decreased protein 
synthesis is a critical barrier for CNS regeneration (Horner and Gage, 2000). 
Activation of mTOR via PTEN deletion has been shown to promote axon 
regeneration of normal and diseased neurons. Park and colleagues utilised the optic 
nerve crush model to study axonal regeneration in mutant mice with conditional 
deletion of various growth control genes (Park et al., 2008). Among a variety of 
genes that were tested, mutant mice with PTEN deletion showed a significant 
increase in the survival of axotomised retinal ganglion cells (RGCs) and a robust 
axonal regeneration of the injured optic nerves (Park et al., 2008). The mTOR 
pathway was inhibited in mature neurons and was further suppressed in axotomised 
adult neurons (Park et al., 2008). Further studies demonstrated that PTEN deletion 
promoted the compensatory sprouting of un-injured corticospinal tracts (CST) and 
led to robust regeneration of injured CST axons which extended beyond the lesion 
site (Liu et al., 2010). These findings suggest that PTEN deletion prevents dying-
back axonopathy; hence, PTEN deletion attenuated the injury-induced mTOR down 
regulation, promoting axonal regeneration, and could be utilised as a novel strategy 
to treat neurological disorders where dying back axonopathy contributes to 
neurodegeneration. 
 
PTEN modulates other factors such as GSK3-β, which also enhances axonal 
regeneration. An important observation by Jiang et al. was that inhibition of PTEN 
increased the number of growing axons in differentiating hippocampal neurons 
(Jiang et al., 2005). Activation of Akt and inhibition of GSK3-β played a critical role 
in axonal growth (Jiang et al., 2005). In agreement with these findings, the increase 
in axonal length of hippocampal neurons induced by nerve growth factor (NGF) is 
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mediated by the activation of casein kinase II (CK2) that phosphorylates and inhibits 
PTEN (Arevalo and Rodriguez-Tebar, 2006). 
 
Recent studies revealed that the concomitant deletion of PTEN and suppressor of 
cytokine signalling 3 (SOC3) enhances a sustained axonal regeneration with an 
ability of axons to extend over long distances (Sun et al., 2011). Furthermore, PTEN 
deletion combined with induced intraocular inflammation also promotes axonal 
regeneration (Leibinger M AA, 2012). Hence, PTEN acts synergistically with other 
factors to promote axonal regeneration. 
 
Our team has recently reported that PTEN protein is enriched in motor neuron 
growth cones (Ning et al., 2010). The same study revealed that PTEN depletion in 
purified spinal motor neurons of wild type mice enhances axonal growth and 
resulted in an increase in the size of growth cones (Ning et al., 2010). In line with 
previous studies, this correlated with activation of the mTOR pathway and similar 
findings were replicated in purified motor neuron cultures from transgenic mouse 
models of spinal muscular atrophy (SMA). In addition it was observed that PTEN 
deletion restored the levels of β-actin in growth cones (Ning et al., 2010).  
 
Several studies have shown that PTEN is involved with synaptic development and 
plasticity. One study demonstrated that a 34-kDa fragment of PTEN was localised to 
the mouse neuronal dendrites (Perandones et al., 2004). In the weaver mouse model, 
PTEN was absent in Purkinje dendrites where there is defective synaptogenesis 
(Perandones et al., 2004). Moreover transgenic mice with conditional deletion of 
PTEN in the brain had enlarged dendrites and axons with defective synaptic 
transmission, indicating a role for PTEN in synaptic plasticity (Fraser et al., 2008). 
Furthermore, recent studies have demonstrated that conditional deletion of PTEN 
during early postnatal development in the mouse auditory cortex enhanced the 
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outgrowth of dendrites and spines, which was associated with increased synaptic 
activity (Xiong et al., 2012). Therefore, evidence from these studies indicates that 
PTEN and its downstream effectors could be attractive therapeutic targets for the 
treatment of CNS injuries and neurodegenerative disorders. 
 
1.3.5 The role of PTEN/PI3K/Akt survival pathway in ALS 
Early genetic studies have shown altered signal transduction in response to motor 
neuron injury. For example, following crush injury to the hypoglossal nerves in rats, 
increased gene expression for extracellular signal regulated kinase 1 (ERK1), an 
essential component of the Ras signalling pathway (Kiryu et al., 1995), and PI3K 
(Ito et al., 1996) was found in the hypoglossal nuclei. Further attempts to explore the 
signalling pathways in motor neuron injury proved that Akt plays an important role 
in mTOR neuronal survival and regeneration (Namikawa et al., 2000). Cultured 
motor neurons deprived of trophic factors showed reduced PI3K activity and 
reduced levels of active Akt (Newbern et al., 2005). Moreover, transgenic mice over 
expressing BCL-2, an anti-apoptotic protein, were resistant to motor neuron injury 
(Kostic et al., 1997) (Azzouz et al., 2000).  
 
Considering the importance of the PI3K signalling pathway in motor neuron 
survival, it is not surprising that increased attention has been focused to study the 
role of this pathway in ALS. Several studies have shown that increased motor 
neuron survival in ALS in response to trophic factors such as vascular endothelial 
growth factor (VEGF) (Tolosa et al., 2009, Tolosa et al., 2008, Lunn et al., 2009) 
(Kaspar et al., 2003, Vincent et al., 2004), insulin-growth factor 1  (IGF-1) (Kaspar 
et al., 2003, Vincent et al., 2004), glial cell-derived neurotrophic factor (GDNF) 
(Manabe et al., 2002c) and Ghrelin (Lim et al., 2011) was mediated by the activation 
of the PI3K/Akt pathway. Observations from several studies in human post-
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tissue of ALS patients hint to a possible dysregulation of the PI3K/Akt pathway. For 
example, genetic studies in our lab have shown decreased expression of the PTEN 
gene in cervical motor neurons from SOD1-related ALS patients (Kirby et al., 
2011a). This was associated with a concomitant increased expression of Akt and 
protein kinase C genes. These findings are in agreement with previous studies where 
increased levels of the PI3K protein was detected in the particulate fraction of spinal 
cords of ALS patients, when compared to unaffected controls (Wagey et al., 1998). 
Although increased total Akt and p70S6K were also detected in the particulate 
fractions of the spinal cord, paradoxically this did not correlate with an increased 
activity (Wagey et al., 1998). Further studies on human ALS post-mortem tissue 
have shown a significant loss of the phosphorylated Akt (active form) protein in 
motor neurons (Dewil et al., 2007c) and low levels of Akt were found in muscle 
tissue of human cases and were found to correlate with unfavourable survival (Yin 
et al., 2012). In support of these findings, low levels of BDT10, an Akt activator, 
were observed in motor neurons of SALS and transgenic SOD1G93A mice (Nawa et 
al., 2012) and recent studies showed that overexpression of activated Akt3 is 
neuroprotective in cellular and mouse models of FALS (Peviani et al., 2014). 
Furthermore, angiogenin protects motor neurons against excitotoxicity via activation 
of the PI3K/Akt pathway; whereas the mutant form of the angiogenin protein (K40I) 
found in some ALS cases cannot activate Akt (Kieran et al., 2008). It is unclear 
whether the activation of the PI3K pathway contributes to neurodegeneration or is a 
neuroprotective response in ALS. Since studies in human post-mortem tissue of 
ALS patients demonstrate changes at the end-stage of the disease, we speculate that 
although the surviving motor neurons are capable of activating the PI3K/Akt 
pathway, this adaptive response fails to reach significant protective levels in such a 
chronic and progressive disease. This hypothesis appears to be supported by our 
studies, which demonstrated that targeted deletion of PTEN in in vitro models of 
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ALS (Kirby et al., 2011a) and SMA (Ning et al., 2010) significantly enhances the 
survival of transgenic SOD1G93A and SMA motor neurons respectively.  
 
Loss of active Akt was also observed in pre-symptomatic transgenic models of ALS, 
which remained to the end stages of the disease (Dewil et al., 2007c). Contradictory 
to the data from human studies, reduced PI3K protein levels were detected in pre-
symptomatic mouse models, which may account for the selective vulnerability of 
motor neurons (Warita et al., 2001, Nagano et al., 2002). The discrepancy in these 
findings with the human studies could be attributed to differences in pathogenesis, 
whereby the disease in mouse models is rapidly progressive. 
 
Thus the evidence suggests that the PI3K/Akt pathway plays a crucial role in motor 
neuron survival. It is reasonable that attempts to activate this pathway by inhibition 
of PTEN or over expressing its anti-apoptotic components could be explored to 
identify new treatment strategies for motor neuron disorders such as ALS. In fact 
PTEN deletion prolongs the survival of transgenic SMA mouse models (Little et al., 
2015) and is currently being investigated as a potential treatment of other 
neurodegenerative disorders such as PD (Domanskyi et al., 2011). The effects of 
PTEN inhibition in promoting neuronal survival and axonal regeneration could be a 
novel therapeutic strategy to prevent disease progression in ALS patients.  
 
1.4  RNA interference (RNAi) therapies 
RNA interference is a naturally occurring system within living cells that regulates 
gene expression (Davidson and Boudreau, 2007). Its role in regulating 
posttranscriptional gene silencing was first discovered in plants (Napoli et al., 1990) 
and worms (Fire et al., 1998).  
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The pathway begins in the nucleus with the generation of long hairpin double 
stranded RNA (dsRNA) (Gonzalez-Alegre, 2007). The dsRNA are exported to the 
cytoplasm where they are cleaved into small double stranded fragments of 20-25 
nucleotides by a ribonuclease (RNA III) called Dicer. These short fragments called 
small interfering RNA (siRNA) contain a 2-nucleotide overhang at the 3’ end. The 
sense strand of the duplex siRNA is degraded and the antisense strand, which is 
complementary to the target mRNA, incorporates with the RNA-induced silencing 
complex (RISC). This complex is targeted to the complementary messenger RNA 
(mRNA) which is then cleaved and degraded to prevent translation (Mello and 
Conte, 2004, Gonzalez-Alegre, 2007). Micro RNAs (miRNAs) are endogenously 
produced short fragments of RNA (21-22 nucleotides base pairs), which also 
regulate gene expression and are processed in a similar way to siRNA (Ralph et al., 
2005a). miRNAs have incomplete base pairing to the target mRNA, and hence they 
suppress the translation of different mRNAs with similar sequences. In contrast, 
siRNAs have full complementarities to the target mRNA, and therefore prevent the 
translation of specific genes (Ralph et al., 2005a).  
 
The discovery of RNAi has revolutionized biomedical research. It is has proved to 
be a powerful tool to investigate gene function in vitro and in vivo (Ralph et al., 
2005c). RNAi is now widely used to understand the mechanisms of 
neurodegeneration (Dreyer, 2011) (Gonzalez-Alegre, 2007) and is also used as a 
therapeutic tool for the silencing of disease-linked genes. For example, dominantly 
inherited neurodegenerative disorders such as FALS, HD and inherited ataxias are 
considered to be potential targets for RNAi- based therapy for silencing the 
dominant mutant alleles (Ralph et al., 2006).   
 
In the context of ALS, RNAi therapies have been used for the silencing of mutant 
SOD1 in experimental models of ALS, which led to a good outcome in some studies 
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(Nizzardo et al., 2012). In addition, RNAi-mediated knockdown of the Fas receptor 
in motor neurons of transgenic SOD1 mouse models improved motor function and 
survival (Locatelli et al., 2007). Other molecular pathogenic targets involved in 
neurodegenerative disorders such as PTEN have been effectively inhibited using 
RNAi strategies in SMA models with promising results (Little et al., 2015, Ning et 
al., 2010). 
 
In order to translate RNAi therapies to patients with chronic and progressive 
neurological disorders like ALS, the efficacy and safety of such a strategy needs to 
be considered and well investigated. Direct administration of siRNA into the CNS to 
target the affected areas would be ideal and the treatment could be stopped if side 
effects occur. However, this is technically difficult in human cases and the treatment 
being short-acting means multiple administrations would be required. Another 
challenge is the blood-brain barrier, which can prevent some potential therapies 
from reaching the CNS. To overcome these obstacles, the development of viral 
vectors provides a promising approach for the efficient delivery and long-term 
expression of siRNA into the nervous system.  
 
1.5 The principles of gene therapy 
Gene therapy is an exciting therapeutic approach where nucleic acids are introduced 
into human cells for the treatment of inherited and acquired diseases and is generally 
classified into two types: germline and somatic gene therapy. In germline gene 
therapy, functional genes are introduced into germline cells such as sperms or ova 
and hence the genetic modification is inherited by the individual’s offspring. This 
procedure is currently prohibited for ethical reasons (McDonough, 1997) (Kay et al., 
1997). Somatic gene therapy is the transfer of functional genes into somatic cells of 
an individual and therefore, the genetic modifications are not passed on to later 
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generations. There are two main approaches for the transfer of genes: in vivo gene 
therapy, in which the gene of interest is directly introduced into the target cells in the 
patient; and ex-vivo gene therapy, where the target cells are genetically modified 
outside the body and then re-implanted (Kay et al., 1997). 
 
Over the last two decades there have been an increasing number of clinical trials 
using gene therapy to treat various diseases; however, the major challenge that faces 
investigators is the generation of safe and efficient vehicles to transfer the genes to 
the target cells. Vectors for gene transfer are generally classified into viral and non-
viral vectors. Viral vectors currently used in clinical trials include, retroviruses, 
adenoviruses and adeno-associated viruses. The non-viral vectors include liposomes, 
polymers, nanoparticles, proteins and polypeptides (Kay et al., 1997). Vector 
delivery systems based on nanoparticles and liposomes are an exciting strategy, 
which are currently being developed for the delivery of genes to the CNS (Peluffo et 
al., 2015). Nonetheless, viral vectors have proved to be a promising tool for gene 
delivery to the CNS and are widely used for pre-clinical studies in models of 
neurodegenerative disease. 
 
1.5.1 Viral vectors in neurodegenerative disorders 
Viral vectors have been investigated as a tool to deliver genes, neuroprotective 
factors and silencing RNA to generate in vivo models of human diseases and for 
silencing pathogenic genes. The non-dividing nature of neurons and the blood brain 
barrier made it challenging for the use of gene therapy to treat neurological 
disorders. Over the years, investigators identified means of overcoming these 
obstacles and generating safe viruses with long lasting expression. The commonly 
used viruses in gene therapy are described below (Table 1.2). 
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 Table 1.2 Viral vectors used for gene therapy     
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1.5.1.1 Herpes simplex virus (HSV) 
Herpes simplex virus (HSV) is a large double-stranded DNA virus of which there 
are two types that cause human diseases, HSV-type1 and HSV-type 2. It is 
characterized by efficient retrograde transport where the viral genome enters the 
nucleus of neuronal cells and can be lytic or may persist in a latent form for life 
(Roizman and Taddeo, 2007, Epstein, 2009). These features allowed investigators to 
produce HSV vectors that are capable of transducing neurons of the CNS (Wolfe et 
al., 1992) (Pakzaban et al., 1994). Genetic engineering of the viral genome 
generated vectors which were replicative-defective, nonetheless the early designs of 
the vectors were cytotoxic and hence were used for targeting proliferating cells, and 
in the CNS were mainly used for the treatment of brain tumors (Mineta et al., 1995, 
Andreansky et al., 1997, Lou, 2003, Markert et al., 2009). Manipulation of the viral 
genome with deletion of the accessory genes produced vectors that were less toxic, 
but shut down of transgene expression occurred after approximately 1 month 
(Krisky et al., 1998). The generation of amplicon vectors, where most of the HSV 
genome is removed, provided vectors with a larger insert capacity that are capable of 
long-term expression of the transgene in host cells. Transduction with these vectors 
was shown to persist for up to 7 months in the rat brain (Zhang and DeGroot, 2000) 
(Sun et al., 2003) (Epstein, 2009). Since these vectors are replication-deficient, they 
require helper function for their production and their instability may result in loss of 
transgene expression. In addition, difficulties in producing high viral titers, and 
potential side effects secondary to the helper-virus, limited their use for pre-clinical 
studies (Segura et al., 2011). Hence, recombinant HSV vectors did not gain 
popularity for use in progressive neurodegenerative diseases due to their short 
duration of transgene expression and potential cytotoxicity. 
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1.5.1.2 Adenovirus 
Adenoviruses are double-stranded DNA, non-encapsulated viruses that do not 
integrate into the host genome but persist as a linear episome (Hillgenberg et al., 
2001). They belong to the family Adenoviridae of which there are more than 50 
known serotypes. Among the viral vectors, they proved to be the most efficient 
vectors for in vivo gene therapy because of their wide host tropism and they could be 
produced in high concentrations (Weinberg et al., 2013). Although they are 
commonly used in clinical trials, their efficacy is limited by the high 
immunogenicity they induce in recipient hosts, which limits transgene expression to 
a few weeks (McKelvey et al., 2004). Moreover, safety issues were raised after the 
report of the death of a clinical trial patient following administration of toxic doses 
of adenovirus vector. Investigators capitalized on the immunity evoked by 
adenoviruses and their short-term transgene expression for their use in cancer 
treatment and production of vaccines (Tatsis and Ertl, 2004) (Chen et al., 2010a). 
The latest generation vectors are helper-dependent, requiring helper viruses for their 
production (Parks et al., 1996). Although they are capable of transducing neuronal 
and non-neuronal cells, have sustained transgene expression and are less 
immunogenic than previous vectors, they induce significant toxicity in the CNS 
(Morral et al., 1999, Candolfi et al., 2006, Candolfi et al., 2007). Even though the 
episomal nature of the genome implies a low risk of random integration into the host 
genome, their use for the treatment of neurological disease is limited by their 
immunogenicity and absence of scalable methods for their production (Bessis et al., 
2004, Chirmule et al., 1999).   
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1.5.1.3 Retroviral and Lentiviral vectors 
Retroviruses are single-stranded RNA viruses that are categorized into simple (alpha 
retroviruses, beta retroviruses, gamma retroviruses, and epsilon retroviruses) or 
complex (delta retroviruses, lentiviruses and spumaviruses) according to the proteins 
they encode. All retroviruses harbour the gag (encodes for the major structural 
proteins), pol (encodes for all essential enzymes including those required for reverse 
transcription) and env (encodes for envelope proteins) genes that are needed for 
replication and packaging, in addition to cis-regulatory sequences such as long 
terminal repeats (LTR) that are necessary for reverse transcription, gene expression 
and integration into the host genome (Freed, 2001) (Breckpot et al., 2010) (Leis et 
al., 1988). In addition, complex retroviruses encode several small regulatory proteins 
that are involved with virus-host interactions, packaging and gene expression. 
Vectors for gene delivery have been produced from both simple and complex 
retroviruses (Escors and Breckpot, 2010) (Maier et al., 2010). The main difference 
between the two vectors is their dependence on cell division for infection. Simple 
retroviral vectors can only transduce dividing cells but are incapable of transducing 
post-mitotic neuronal cells (Lewis and Emerman, 1994). Moreover they are 
associated with a high incidence of insertional mutagenesis and instability of the 
vectors, and the difficulty in obtaining high titre viral stocks (Andreadis et al., 1997) 
(Hematti et al., 2004) (Le Doux et al., 1999) which rendered them unsuitable for use 
in clinical trials of neurodegenerative disease. On the other hand, they are capable of 
stable gene expression following integration into the host genome and exhibit low 
immunogenicity due to the absence of viral proteins; hence, they have been 
employed for ex vivo applications. For example, ex vivo transduction of fibroblasts 
for the production of nerve growth factor has been achieved with simple retroviral 
vectors; these fibroblasts were subsequently transplanted into the brains of patients 
with ALZ (Tuszynski et al., 2005). The major advantage of complex retroviruses is 
their ability to transduce non-dividing cells, and lentiviral vectors became the most 
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widely used retroviral vectors for gene delivery to the CNS (Lentz et al., 2012). 
 
Lentiviral vector systems can originate from primate viruses such as HIV-1 (human 
Immunodeficiency virus) and SIV (simian immunodeficiency virus) vectors 
(Zufferey et al., 1997). Concerns over the use of HIV-based vectors led to the 
development of vectors derived from non-primates such as the FIV (feline 
immunodeficiency virus) and EIAV (equine infectious anemia virus), which share 
similar properties to the HIV-based vectors and transduce the CNS with high 
efficiency. However, some studies have shown that HIV-based vectors are 
potentially more efficient in transducing human cells due to species-specific 
restrictions and are currently the predominant lentiviral vectors used in the field of 
CNS gene therapy. First generation HIV-derived vectors were generated to express 
all genes required for enzymes, core proteins, accessory factors and an envelope of 
another virus (Naldini et al., 1996c). To improve the biosafety and efficacy of the 
vector systems based on lentiviruses, second generation (Zufferey et al., 1997) and 
subsequently third generation vectors were produced by the removal of the majority 
of the viral genes, retaining only the cis-acting sequences required for transcription, 
reverse transcription, encapsidation and integration (Dull et al., 1998, Zufferey et al., 
1998, Azzouz et al., 2002, Kordower et al., 2000). These vectors are also 
characterized by a large cloning capacity of 8 kb, the ability to transduce both 
dividing and non-dividing cells, stable integration into the host genome (Naldini et 
al., 1996a, Blomer et al., 1996) and long-term transgene expression which they can 
maintain for up to 44 months (Kordower et al., 2000, Balaggan et al., 2006, Jarraya 
et al., 2009). 
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Lentiviral vectors do not naturally infect neuronal cells, and in order to achieve 
targeted transduction in the CNS two strategies have been used. First, it is possible 
to use promoters that drive gene expression in a specific subset of cell population 
(Jakobsson and Lundberg, 2006). For example, neuron-specific and glial-specific 
promoters are active only in neurons and glial cells respectively, allowing cell-
specific transgene expression (!!! INVALID CITATION !!! {Jakobsson, 2003 
#150;Jakobsson, 2004 #151;Dittgen, 2004 #152;Lai, 2002 #153;Greenberg, 2006 
#154;Gascon, 2008 #155;Liu, 2008 #156;Lai, 2002 #153}, Lai and Brady, 2002). 
This approach helps to achieve higher levels of gene expression in the desired cells 
and reduces the host immune responses. Although promoter-based targeted gene 
expression is highly specific, the major disadvantage is that if frequent integration 
occurs in the transduced cells this may lead to non-specific activation of the 
integrated transgene, which can result in non-specific expression in other cells 
(Jakobsson and Lundberg, 2006). Alternatively, to broaden the tropism of lentivirus 
vectors, another strategy is to pseudotype them with envelope proteins from other 
viruses. HIV-1-based vectors pseudotyped with vesicular stomatitis virus 
glycoprotein (VSV-G) provide more stable vectors that can be produced in high 
titers and have a wide host tropism including transduction of neuronal and astroglial 
cells (Burns et al., 1993, Naldini et al., 1996c, Bischof and Cornetta, 2010, Chen et 
al., 1996). Of interest, pseudotyping HIV and EAIV vectors with rabies-G envelope 
allow retrograde transport of the vector (Mazarakis et al., 2001, Azzouz et al., 
2004b, Wong et al., 2004, Mentis et al., 2006). This approach was found to be very 
efficient for the delivery of genes to distant neuronal cells when the vectors were 
injected peripherally. Several natural viral envelopes as well as genetically 
engineered ones have been used for targeted gene therapy (Waehler et al., 2007). 
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One of the major drawbacks of lentiviruses is the risk of insertional mutagenesis that 
can occur following integration into the host genome (Hematti et al., 2004) 
(Bokhoven et al., 2009). In a clinical trial for the treatment of X-linked severe 
combined immune deficiency (X-SCID), the occurrence of leukemia in 4 out of 20 
patients highlighted the potential risk of insertional mutagenesis which has hindered 
the use of lentiviral vectors (Hacein-Bey-Abina et al., 2003, Pike-Overzet et al., 
2007). To overcome this challenge, several approaches were used. One strategy is to 
direct the integration of the vector into the heterochromatin regions of the genome to 
reduce the risk of gene activation (Gijsbers et al., 2010). Another approach was to 
construct self-inactivating vectors (SIN) which carry mutations that knockout the 
activity of the LTR promoter that significantly reduced the risk of insertional gene 
activation and prevents the development of replication competent lentiviruses 
(Miyoshi et al., 1998, Zufferey et al., 1998, Ginn et al., 2003). Additionally, the 
development of non-integrating lentiviral vectors (NIL) that carry mutations in the 
LTR or mutant integrase and maintain the transgene episomally, minimised the risk 
of integration (Apolonia et al., 2007, Philippe et al., 2006, Cornu and Cathomen, 
2007, Sarkis et al., 2008). This method did not affect the transduction efficiency of 
the vector and although the duration of transduction is not well characterized some 
studies showed that it may persist for 3 months in rat brains and up to 9 months in 
other tissues (Bayer et al., 2008, Yanez-Munoz et al., 2006). Recently, further 
reduction in integration was achieved when a sequence element involved with DNA 
synthesis was removed from the NIL vectors (Kantor et al., 2011). 
 
Several studies demonstrated that lentiviral vectors are generally safe and exhibit 
low immunogenicity when used in the CNS (Naldini et al., 1996a) (Blomer et al., 
1997) (Abordo-Adesida et al., 2005). Since the vectors do not express any viral 
proteins following transduction of cells, a host immune response may develop 
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against either the viral capsid or the transgene product.  
 
Only HIV patients are expected to have circulating antibodies against the vector and 
these patients could be excluded from lentiviral gene therapy studies. Moreover, the 
HIV-1 capsid has a short half-life, which shortens the time the immune system 
recognizes the transduced cells. However, other studies showed that lentiviral 
vectors expressing shRNAs may induce an interferon response that may result in 
neuronal toxicity (Hutson et al., 2012a, Bauer et al., 2009). 
 
Third generation lentiviral vectors provide an excellent system for gene delivery in 
the CNS. Importantly, their ability to stably and efficiently transduce post-mitotic 
cells makes them an attractive tool for delivering siRNAs. Lentiviral-mediated RNA 
silencing became an invaluable tool for investigating gene function, generation of 
disease models and as a novel therapeutic strategy for several CNS diseases (Hutson 
et al., 2014). The vectors have been extensively utilized both in vitro and in vivo in 
models of neurodegenerative disorders such as ALS, PD, ALZ and HD (Jakobsson 
and Lundberg, 2006). Their use is however limited to preclinical research due to the 
potential insertional mutagenesis and immunogenicity. Further studies are required 
to characterize and determine the biosafety of lentiviral vectors before they can be 
used in the clinic.  
 
1.5.1.4  Adeno-associated-virus (AAV) 
Adeno-associated-virus is a single stranded, non-enveloped virus, which belongs to 
the family Parvoviridae in the genus Dependovirus, that requires a helper virus 
(herpes or adenovirus) to replicate (Lentz et al., 2012). The biological features of 
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AAV that make it an attractive vehicle for gene therapy include: non-pathogenicity 
in humans; low immunogenicity; ability to infect dividing and non-dividing cells 
such as neurons; and scalable production of highly purified vectors that can be used 
for clinical applications (Kaplitt et al., 1994) (Guy et al., 1999) (Bessis et al., 2004) 
(McCarty et al., 2004) (Tenenbaum et al., 2004) (Giacca and Zacchigna, 2012). 
Hundreds of naturally occurring serotypes have been isolated from different animal 
species as well as humans (Wu et al., 2006b) (Vandenberghe et al., 2009a) 
(Vandenberghe et al., 2009b). The capsid proteins (VP1, VP2, VP3) that surround 
the virus genome determine the entry of the virus into the host cell and account for 
the diversity of serotypes, which in turn determines the differences in receptor 
usage, tissue tropism and antigenicity (Summerford and Samulski, 1998, Xie et al., 
2002, Wu et al., 2006b). For example, AAV serotype 1 (AAV1) and AAV serotype 
6 (AAV6) transduce neurons more efficiently than AAV serotype 2 (AAV2) and 
AAV serotype 5 (AAV5) (Bartlett et al., 1998) (Davidson et al., 2000) (McFarland 
et al., 2009) (Hutson et al., 2012b). AAV serotype 4 (AAV4) preferentially infects 
ependymal cells and astrocytes, whereas AAV serotype 8 (AAV8) transduces 
oligodendrocytes as well as astrocytes with high efficiency (Liu et al., 2003) 
(Lawlor et al., 2009) (Hutson et al., 2012b) (Aschauer et al., 2013). In addition, the 
mode of delivery also plays an essential role in determining which tissues are 
transduced; for example, several serotypes (6, 7, 8 and 9) transduce the heart and 
liver with high efficiency after intravenous injection (Wang et al., 2010).  Moreover, 
chimeric or mosaic vectors produced from the protein capsids of various serotypes, 
or through a DNA shuffling-based approach, generated novel vectors with unique 
tropisms (Burger et al., 2004, Maheshri et al., 2006, Li and Wang, 2008). Finally, 
similar to all vectors, target-specific promoters could be used to limit the transgene 
expression to specific cells or to enhance the transduction of target cells (Shevtsova 
et al., 2005).  
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For gene delivery to the CNS, AAV6 is capable of transducing spinal cord motor 
neurons following intramuscular injections (Ning et al., 2010, Towne et al., 2011, 
San Sebastian et al., 2013, Low et al., 2013) and AAV9 (AAV serotype 9) has been 
shown to cross the blood brain barrier (Duque et al., 2009, Foust et al., 2009, Gray et 
al., 2011b). Long-term expression has been observed in murine brain persisting for 
more than 6 months (Klein et al., 1999), and also for > 6 years in primates and up to 
8 years in dogs (Niemeyer et al., 2009) (Rivera et al., 2005) (Stieger et al., 2009). 
Large-scale animal studies showed no evidence of significant side effects or an 
increased risk of tumourigenesis associated with the delivery of AAV vectors 
(Bessis et al., 2004, Bell et al., 2005).   
 
Another advantage of AAV vectors is that they do not always integrate into the host 
genome and in the absence of a helper virus they persist episomally in most types of 
cells, including neurons, providing stable transgene expression (Kaplitt et al., 1994, 
Ferrari et al., 1996). Other studies have shown that non-targeted integration is 
relatively inefficient and associated with a low risk of mutagenesis (Donsante et al., 
2007) (Li et al., 2011). However, reports of clinical trials using AAV vectors for the 
treatment of hemophilia B (an X-linked disease characterized by a bleeding 
tendency due to mutations/deletion in the gene encoding factor IX), showed that it 
was challenging to achieve the required therapeutic expression needed (Kay et al., 
2000).  
 
 Although AAV is a non-pathogenic virus, one of the concerns of its use in gene 
therapy is the immune response of the host induced against the AAV vector, which 
could lead to clearance of the vector and the transduced cells leading to 
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inflammation and damage to the targeted tissues. Lack of a significant immune 
response has been shown in animal studies (Franco et al., 2005, Woo et al., 2005, 
Cao et al., 2007, Viiala et al., 2009), nonetheless, immunogenicity was observed in 
human clinical trials using AAV2-vecor for delivering factor IX to the liver 
(Martino et al., 2009, Somanathan et al., 2010). Despite efficient transduction of the 
liver, expression of the transgene was short-lived and followed by activation of 
cytotoxic T cells and destruction of liver cells. The discrepancy seen between the 
animal and human studies could be attributed to a natural exposure to the wild type 
virus resulting in pre-existing memory CD8+ cells or due to variations in dendritic 
cell maturations between species (Mingozzi et al., 2007) (Manno et al., 2006). 
Furthermore, the presence of circulating neutralizing antibodies may also affect the 
transgene expression (Scallan et al., 2006) (Lin et al., 2008) (Vandenberghe et al., 
2009b). Pre-existing immunity is more frequently observed with AAV5, whereas it 
is occasionally associated with AAV7 and 8 since both serotypes were isolated from 
non-human primates and human exposure is rare (Vandenberghe et al., 2009b, 
Arbetman et al., 2005). 
 
Early designs of AAV vectors were produced by removing the coding regions of the 
wild type virus and replacing it with the transgene cassette (Samulski et al., 1989). 
Since the vector encoded no viral genes, this minimized the host immune response 
against the vector and transduced cells. These single-stranded DNA vectors 
(ssAAV) required the synthesis of a second strand, which is a rate-limiting step for 
the transgene expression (Ferrari et al., 1996). To overcome this issue, self-
complementary AAV vectors (scAAV) were developed such that the genome could 
self-anneal to form a double-stranded molecule and the vectors express the 
transgene earlier and at greater levels compared to the ssAAV vectors; however, this 
approach limited the coding capacity to approximately 2.2 kb (McCarty et al., 2001). 
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To increase the packaging capacity of these vectors (Hirsch et al., 2009, Hirsch et 
al., 2010), a dual vector system was designed where the transgene cassette was 
separated into two vectors and assembly of the full length of the transgene requires 
co-transfection of a single cell with subsequent recombination (Duan et al., 2001). 
Although this strategy increases the transgene capacity up to ~ 8 kb, the vectors have 
low efficiency compared to the ssAAV vectors. 
 
AAV vectors are currently the preferred vehicles for gene delivery to the CNS, 
although their use is hindered by their limited packaging capacity. AAV2 vectors are 
the predominant vectors used in in human clinical trials for the treatment of PD 
(Bartus et al., 2007) (Marks et al., 2008) (LeWitt et al., 2011) and ALZ (Bishop et 
al., 2008) (Mandel, 2010). The field of gene therapy is advancing rapidly and 
improvements in vectors design and purification methods (Wright et al., 2010) may 
hold a promising future for clinical applications and may broaden their use for the 
treatment of other neurodegenerative disorders.  AAV vectors are considered the 
vectors of choice for in vivo gene transfer whereas lentivirus vectors are mainly used 
for ex vivo gene transfer.  
 
1.5.2 Gene therapy approaches in ALS 
Despite extensive research there are currently no effective treatments for ALS 
patients, partly due to the complex pathophysiology of the disease and partly due to 
the challenges of safely and efficiently delivering of potential therapeutic molecules 
to the CNS. Gene therapy offers an exciting and novel approach to target motor 
neurons and glia cells, and both cellular and transgenic murine models provide an 
invaluable tool for investigating gene therapy strategies in ALS. 
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Viral vectors based on adenoviruses were one of the earliest vectors used for gene 
therapy in ALS. As these vectors are capable of retrograde transport following 
intramuscular injections, they have been employed to deliver anti-apoptotic genes 
(Yamashita et al., 2001) (Yamashita et al., 2002) and several neurotrophic factors 
such as cardiotrophin-1 (CT-1) (Toth et al., 2002), GDNF (Toth et al., 2002) 
(Manabe et al., 2002a) and ciliary neurotrophic factor (CNTF) (Haase et al., 1999). 
However, their use is hindered mainly due to the host immune response against the 
vector, their short-term transgene expression and suboptimal efficacy for gene 
delivery. Currently, lentiviral vectors and AAV vectors are the most widely used 
vectors in ALS research. 
 
Several routes were employed for delivering potential therapeutic genes to motor 
neurons. The peripheral administration of viral vectors via intramuscular or nerve 
injections takes advantage of retrograde axonal transport of the vectors directly to 
motor neurons of the spinal cord (Boulis et al., 1999, Boulis et al., 2002, Millecamps 
et al., 2002, Boulis et al., 2003, Kaspar et al., 2003). In particular, the intramuscular 
route is commonly used, as it is a non-invasive and relatively safe procedure. Robust 
gene expression following intramuscular injections of AAV6 with efficient 
retrograde transport was shown in non-human primates (Towne et al., 2010). 
Promising results were demonstrated with intraspinal injections of viral vectors 
(Azzouz et al., 2000, Franz et al., 2009, Lepore et al., 2007); however, as it is an 
invasive procedure, the safety of this strategy needs to be validated and well 
characterized in pre-clinical studies before it is can be used in patients. The 
feasibility of gene delivery via intramuscular, nerve or intraspinal routes in human 
cases remains questionable, since with this segmental approach multiple injections 
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will be needed to target the whole spinal cord and other affected areas. Furthermore, 
ALS is a disease with distal axonopathy and efficient gene delivery may not be 
achievable with peripheral administration. Alternatively, efficient transduction of 
motor neurons and astrocytes was achieved by systemic delivery of AAV9 via 
intravenous injections (Duque et al., 2009) (Federici et al., 2012) (Gray et al., 
2011b). This non-invasive approach has gained attraction and is currently being 
evaluated in experimental models since there is potential for its translation to be 
used in the clinic.  
 
In order to target motor neuron degeneration, gene therapy strategies were used 
either for neuroprotection or for RNAi-mediated silencing of the mutant genes. 
Proof-of-principle studies in animal models of ALS showed that neurotrophic 
factors enhanced motor neuron survival and neurotrophic-based gene therapy 
showed promising results in vivo. For example, adenoviral-based vectors were used 
in ALS models for the delivery of neurotrophic factors such as cardiotrophin-1 (CT-
1) (Bordet et al., 2001) (Mitsumoto et al., 2001) (Oppenheim et al., 2001), CNTF 
(Haase et al., 1999) and GDNF (Gimenez y Ribotta et al., 1997) (Acsadi et al., 
2002). In addition, retrograde transport of (IGF-1) following intramuscular 
injections of AAV-2 IGF-1 delayed disease progression and extended the survival of 
SOD1 mice (Kaspar et al., 2003). The trophic effects of AAV-mediated IGF-1 were 
also seen on injected muscles; however, intraspinal injections resulted in differential 
neuroprotection (Franz et al., 2009). Other routes for delivering IGF-1, such as 
stereotactic injections to the deep cerebellar nuclei, were explored in transgenic ALS 
mice and led to attenuation of disease pathology and extended the life span of the 
mutant mice (Dodge et al., 2008). Likewise, VEGF was shown to have 
neuroprotective effects in ALS models implicating that it may play a role in the 
pathogenesis of the disease (Cleveland, 2003, Lambrechts et al., 2004, Storkebaum 
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and Carmeliet, 2004, Storkebaum et al., 2005). EIAV delivery of VEGF 
significantly prolonged the survival of transgenic mice by 30% (Azzouz et al., 
2004b) and a similar effect was seen with AAV-mediated delivery (Dodge et al., 
2010). Furthermore, a delayed onset of disease was observed in transgenic mice 
following intraspinal delivery of AAV-granulocyte stimulating factor (GCSF) 
(Pitzer et al., 2008) (Henriques et al., 2011). Moreover, electrophysiological studies 
showed an improved motor performance in SOD1 mice treated with intramuscular 
injections of AAV-neurotrophin-3 (NT-3) (Petruska et al., 2010). 
 
Since apoptosis is involved with the motor neuron death in ALS, viral-mediated 
delivery of anti-apoptotic genes showed a neuroprotective effect both in vitro and in 
vivo. Intramuscular injections of adenoviral vectors expressing BCL-2 into the 
tongue enhanced motor neuron survival in mutant SOD1 mice (Yamashita et al., 
2001). On the other hand, intraspinal delivery of AAV-BCL-2 gene in transgenic 
mice delayed the disease onset but had no effect on overall survival. (Azzouz et al., 
2000) Other studies overexpressed the antioxidant protein metallothionein-III (MT-
III) in SOD1G93A mice using intramuscular injections of adenoviral vectors, which 
prevented motor neuron loss and prolonged the survival of the mutant mice 
(Hashimoto et al., 2011). 
 
Gene silencing is another potential therapeutic strategy to protect motor neurons 
from the toxic effect of mutant proteins in ALS. In familial ALS, disease-causing 
genes encode for mutant proteins that have been implicated to contribute to motor 
neuron injury by a toxic-gain of function mechanism. Specific knockdown of the 
mutant protein via gene silencing could lead to a reduction in the expressed mutant 
protein, which may protect neurons from its toxic effect. Viral delivery of short 
                                                      71 
hairpin RNA (shRNA) or small interfering RNA (siRNA) has been employed to 
target mutant SOD1 in transgenic mice.  Intramuscular and intraspinal injections of 
lentiviruses expressing siRNA to specifically knockdown mutant SOD1 improved 
motor neuron survival, delayed disease onset and extended the survival of transgenic 
SOD1 mice (Raoul et al., 2005, Ralph et al., 2005c). Other studies aimed to target 
SOD1 exclusively in muscles by pseudotyping lentiviruses with vesicular stomatitis 
virus glycoprotein (VSV-G), which lack the capacity of retrograde transport, 
showed no effect on the survival of mutant mice. However retrograde transport of 
AAV vectors expressing siRNA against SOD1 to spinal cord motor neurons resulted 
in a therapeutic effect, suggesting that exclusive inhibition of mutant SOD1 in 
muscles has no effect on survival (Miller et al., 2006). Similar studies comparing 
intramuscular and nerve injections of SOD1 siRNA showed a modest therapeutic 
effect only in mice that received nerve injections (Wu et al., 2009). Recent studies 
showed that efficient retrograde transport occurred after multiple intramuscular 
injections of AAV6 expressing SOD1 siRNA, yet despite efficient SOD1 
knockdown and enhancing the survival of transduced motor neurons as well as 
preventing muscle atrophy, this approach did not modify the disease phenotype 
(Towne et al., 2011). These studies suggest that global neuronal transduction may be 
required to obtain a therapeutic effect.  
 
In summary, several gene therapy strategies have been employed in ALS research to 
unravel disease pathogenic mechanisms and to identify novel therapeutic targets.  
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1.6 Aims of the project 
The aim of this project is to investigate the potential neuroprotective role of PTEN 
silencing as a novel therapeutic target for the treatment and prevention of 
neurodegeneration in amyotrophic lateral sclerosis. It was hypothesised that PTEN 
silencing may enhance motor neuron survival and prevent neuromuscular 
degeneration (NMJ) in SOD1G93A experimental models of ALS. For the in vitro 
studies, a lentiviral vector delivery system was utilised for the stable expression of 
PTEN siRNA in primary motor neuron cultures because of their high efficiency of 
transduction. The effect of PTEN silencing on the downstream effectors of the 
PI3K/Akt pathway and neuronal survival was studied in in vitro models of ALS. The 
adeno-associated vectors were used for the delivery of PTEN siRNA to the spinal 
cord motor neurons by intramuscular injections. The simultaneous injections of 
muscle and spinal cord allow direct analysis of the effect of PTEN silencing on 
neuromuscular degeneration and spinal cord motor neuron survival. 
The aims of the project can be summarised as follows: 
1. Study the effect of lentiviral-mediated PTEN silencing on the PI3K/Akt survival 
pathway and whether it would enhance motor neuronal survival in vitro.  
2. Investigate the effect of viral mediated PTEN knockdown on motor neuron 
survival in transgenic mouse models of ALS.   
3. Determine whether viral-mediated PTEN silencing could prevent neuromuscular 
degeneration in ALS mouse models. 
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2. MATERIALS AND METHODS 
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2.1 Materials 
 
2.1.1 Materials for molecular techniques 
Analytic grade solvents methanol, ethanol, acids and isopropanol were all purchased 
from Fisher Scientific. The western blotting system (power pack, tanks, glass plates, 
gel holder cassettes and filter paper) was purchased from Bio-Rad. Pipette tips were 
purchased from Fisher Scientific.  
 
2.1.2 Preparation of DNA 
All DNA plasmids were prepared using the Qiagen mega-prep kit (Qiagen) 
according to the manufacturer’s recommendations. For lentiviral vector production, 
transfections were performed using sterile tissue culture water (Sigma), 0.5 M CaCl2 
(Sigma) and 2x Hank’s Buffered Salt Solution (HBSS, Gibco, Fisher). Ultra-
centrifugation was performed using the Optima L-100K Ultracentrifuge (Beckman 
Coulter) for viral production, and the Harrier 15/80 Centrifuge (Sanyo) was used for 
other centrifugation steps. 
 
2.1.3 Protein extraction and analysis 
Protein was extracted from cells and from muscle tissue by cell lysis, using a whole-
cell lysis buffer (nuclear and cytoplasmic) containing 50 mM Tris-HCl pH 7.4, 150 
mM NaCl, 2 mM ethylenediaminetetraacetic acid (EDTA, Melford), 1% Igepal 
CA630 (Sigma) and 0.1% sodium dodecyl sulphate (SDS, Sigma). The lysis buffer 
was supplemented with a complete protease (Roche) and phosphatase inhibitor 
cocktail (phosSTOP, Roche) to prevent proteolysis and dephosphorylation of the 
proteins, respectively. Protein extracts were added to loading buffer (10 mL 4x stock 
contained 4 ml Glycerol (Sigma), 2.5 mL stacking gel 4x buffer, 2 mL 10% SDS, 
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0.25 mg bromophenol blue (Sigma) and 0.5 mL β-mercaptoethanol (Invitrogen). For 
the separation of proteins, polyacrylamide gels were prepared using a separating gel 
4x buffer (1.5 M Tris base, 13.87 mM SDS, pH 8.8) and a stacking gel 4x buffer 
(0.5 M Tris base, 13.87 mM SDS, pH 6.8) including 30% acrylamide (Geneflow), 
10% ammonium persulfate (APS, Sigma) and TEMED 
(tetramethylethylenediamine, Sigma). The proteins were transferred onto a 
polyvinylidene difluoride (PVDF), Millipore Immobilon P) membrane in the 
presence of a transfer buffer containing 25 mM Tris, 192 mM Glycine and 10% v/v 
methanol. The membranes were incubated in a blocking buffer (TBS-T with 5% w/v 
dried, skimmed milk) to block non-specific binding sites. TBS-T (0.137 M NaCl, 
25.92 mM Tris base, 0.1% Polyoxyethylene-Sorbitan Monolaurate (Tween 20, 
Sigma), pH 7.6) was used for all membrane washes. Stripping of the membrane 
blots was performed when necessary using a stripping buffer (62.5 mM Tris (pH 
6.7), 100 mM β-mercaptoethanol, 2% SDS). 
 
2.1.4 Spectrophotometry 
The FLUOstar Omega plate reader (BMG Labtech) was used for assays requiring a 
microplate reader for measurement of UV/Vis absorbance.  
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2.2 In vitro experimental work 
 
2.2.1 Cell lines and cell culture 
HEK293T cells (human embryonic kidney cell line immortalized by the adenoviral 
E1A/E1B protein and expressing the SV40 large T antigen) were used for 
transfection and lentiviral vector production. HeLa cells (an immortal cell line 
derived from a patient’s cervical cancer) were used for lentiviral vector tittering by 
flow cytometry and fluorescence-activated cell sorting (FACS) analysis. A full 
medium containing Dulbecco’s modified Eagle’s medium (DMEM with 4.5 g/L 
glucose, L-glutamine, without Na Pyruvate, Lonza) was used for HEK293T cells; 
and for the Hela cells a complete medium consisting of Eagle's Minimum Essential 
Medium (EMEM, Sigma) with 2 mM Glutamine (Sigma) and 1%  non-essential 
amino acids (NEAA, Sigma) was used. Both media were supplemented with 10% 
Foetal Calf Serum (FCS, Biosera), 100 µg/mL streptomycin sulphate and 100 U/mL 
penicillin (penicillin G sodium and streptomycin sulphate in 0.85% saline, 
Invitrogen). All cell lines were passaged when they were 80-90% confluent and 
were incubated in in a humidified incubator at 37°C with 5% CO2.  
 
2.2.2 Preparation of purified motor neuron cultures 
Spinal cord motor neurons were purified from transgenic SOD1G93A embryos at 
embryonic day 12.5-13 using the immunopanning protocol as previously described 
(Ramon-Cueto and Nieto-Sampedro, 1992, Wiese et al., 2010, Graber and Harris, 
2013). Motor neurons were cultured on sterile tissue culture dishes (36 x 10 mm 
with 4 inner rings, Greiner Bio-One) with sterile 10 mm coverslips for 
immunocytochemistry, without coverslips for survival assays, and on 12 well plates 
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(CellStar) for western blotting. One day prior to the culture, the coverslips and/or 
wells were initially coated with 5% Poly-DL-ornithine hydrobromide (PORN, 
Sigma) in 0.15 M Borate-buffered saline (pH 8.2) (Fluka Analytical); the tissue 
culture dishes were tightly sealed and then incubated at 4°C overnight. On the day of 
the culture, a 12-well immunopanning plate was prepared to select the motor 
neurons and was kept at room temperature until the spinal cords were dissected. 
Each well was labelled for the respective embryo and then coated with 500 µl of p75 
NGF receptor monoclonal antibody (Abcam, 1:5000 diluted in 10 mM Tris (Sigma), 
pH 9.5) against the extracellular domain of p75 (low-affinity nerve growth factor 
(NGF) receptor) on motor neurons. The excess PORN solution was removed from 
the wells and/or coverslips which were washed twice with sterile filtered HBSS 
(Sigma), coated with Laminin (Invitrogen) at a concentration of 1.5 µg/mL in HBSS 
(0.75 mg/mL of Laminin stock diluted in 50 mM Tris (pH 7.4) and then incubated at 
37°C in an incubator until the motor neurons were ready.  
 
The pregnant mice were sacrificed by cervical dislocation and the embryos were 
removed from the uterus and placed in sterile petri dishes containing dissection 
buffer (1:1000 beta-mercaptoethanol (β-ME, Invitrogen) in HBSS). Each embryo 
was removed from its sac, decapitated and the tails were cut off and stored at 4ºC for 
genotyping. The spinal cords were carefully dissected under a dissection microscope 
(Leica) in a sterile hood. The meninges and dorsal root ganglia were removed from 
the spinal cords, which were then placed into labelled tubes containing the 
dissection buffer. The spinal cords were dissociated with 0.1% Trypsin 
(Worthington, 3x crystallized dissolved in HBSS with NaOH added to adjust the pH 
and filtered through a 0.22 um sterile filter) which was deactivated 15 minutes later 
with Trypsin inhibitor (Sigma, 500 mg dissolved in 49 mL HBSS and 1 mL of 1 M 
HEPES and filtered through a 0.22 µm sterile filter). The cords were triturated with 
a 1 mL pipetteman and the cell solution was added to the pre-coated 
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immunopanning plate for 30 minutes at room temperature. Thereafter, the medium 
was discarded and the unattached cells were carefully washed off three times with 
washing medium (Neurobasal Medium, Gibco (Invitrogen) with 0.2 µM β-ME). The 
motor neurons were detached off the plates with 150 µl (per well) of depolarisation 
buffer containing 30 mM KCl (Sigma) and 0.8% NaCl (Sigma) and then 750 µl of 
full media (Neurobasal Medium with 1x Glutamax (Invitrogen), 2% horse serum 
(Invitrogen), and 1x B27 (Invitrogen) was added afterwards to re-suspend the motor 
neurons. For immunocytochemistry, 2000 cells per coverslip were plated on PORN 
and mouse Laminin pre-coated 10 mm coverslips in 4-well tissue culture dishes 
(Greiner) in the presence of a small volume of full medium. For survival assays, 
1500 cells were plated on PORN and mouse Laminin pre-coated 4-well tissue 
culture dishes (Greiner) without coverslips. For western blotting, 200 000 cells/well 
were plated on PORN and mouse Laminin pre-coated 12-well plates. The medium 
was changed 2 hours after plating the cells and thereafter the cultures were fed every 
2-3 days by removing half the medium and adding half fresh medium. The motor 
neurons were cultured for 7 days in full medium and incubated in a humidified 
incubator at 37°C with 5% CO2. Neurite growth was observed after the first night in 
culture. Genotyping of the mouse embryos was performed after the cells were 
plated, using the same protocol for adult mouse genotyping, which will be described 
in detail below. All steps of preparing purified motor neuron cultures were 
performed in a sterile hood (Envair). Training and technical support was provided 
by Dr. Ke Ning.  
 
2.2.2.1 Motor neuron cell counting  
For motor neuron survival assays the cells were plated as described above, and 6 
hours after plating, the number of attached cells was counted under a phase-contrast 
microscope (Leica). At 5 days post-transduction, the cells were fixed with 4% 
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paraformaldehyde (PFA, Sigma) in PBS and the number of surviving cells was 
determined. All cell counts were performed under 40x magnification in a blinded 
manner.  
 
2.2.3 Lentiviral vector construction 
Dr. Chiara Valori generated constructs before this PhD project was started. For the 
effective reduction of mouse PTEN expression levels, a stem-loop- stem short 
hairpin RNA (shRNA) was generated using a 19 nucleotide sequence targeting exon 
1 of mouse PTEN (si-PTEN oligonucleotide) that was subcloned into the pLVTHM 
lentiviral genome vector (pLVTHM was a gift from Didier Trono (Addgene plasmid 
#12247) (Figure 2.1) (Ning et al., 2004, Wiznerowicz and Trono, 2003). This 
lentiviral vector expresses the shRNA under the Histone H1 promoter, and also 
expresses green fluorescent protein (GFP) driven by the human elongation factor-1 
alpha (EF1α) promoter, to mark the successfully transduced cells. Similarly, a 
scrambled 19-nucleotide sequence was used to generate the control vector (ssi-
PTEN). The following sequences were used: 
 
 
                  
 
 
 
   5’-CGCGTCCCCGCCAAATTTAACTGCAGAGTTCAAGAGACTCTGCAGTTAAATTTGGCTTTTTGGAAAT-3’ 
si-PTEN oligonucleotide sequence (si-PTEN):  
  Sense   Loop Antisense 
5’-  CGCGTCCCCCGCAATATTCAATCGAGGATTCAAGAGATCCTCGATTGAATATTGCGTTTTTGGAAAT-3’ 
Scrambled si-PTEN oligonucleotide sequence (ssi-PTEN): 
 Sense   Loop    Antisense 
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Figure 2.1. Lentiviral vector (pLVTHM) backbone. The diagram shows the 
essential components of the lentiviral vector. Abbreviations: AmpR – ampicillin 
resistance, cPPT – central polypurine tract, EF1-alpha - elongation factor-1 alpha, 
GFP –green fluorescent protein, gpt - phosphoribosyl transferase, H1-Histone 1 
promotor, LoxP- locus of X-over of P, LTR – long terminal repeat, LV – lentivirus, 
psi- packaging signal, ORI- origin of replication, pA - poly-A – polyadenylation, 
RRE – Rev responsive element, SIN – self-inactivating, SV40 - simian virus 40 
promoter, tetO- tetracycline operator elements, WPRE – Woodchuck Hepatitis Virus 
(WHP) Posttranscriptional Regulatory Element. 
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2.2.4 LV vector production 
Lentiviral vectors carrying si-PTEN and ssi-PTEN were produced by a four-plasmid 
calcium phosphate co-transfection of HEK2932T cells as previously described 
(Deglon et al., 2000). One day before transfection, HEK293T cells were plated on 
10 cm petri dishes at a density of 3.6 x 106  cells per plate and were allowed to grow 
overnight at 37 ̊C and 5% CO2. For each 10 cm dish, 13 µg of LV-vector plasmid 
was mixed with 3.75 µg of plasmid encoding vesicular stomatitis virus G envelope 
(pMD.2G), 13 µg of gag/pol plasmid (pCMVDR8.92) and 3 µg of plasmid encoding 
the rev protein of HIV-1 (pRSV-Rev) in a 5 mL polystyrene tube (Biosciences) with 
0.5 M CaCl2; sterile tissue culture water (Sigma) was added to make a final volume 
of 500 µl. The DNA mixture was slowly added to 500 µl of 2x HBSS (Sigma) with 
gentle shaking and then incubated for 15 minutes at room temperature until the 
mixture became translucent. Thereafter, 1 mL of the precipitate solution was added 
gently to the cells by uniformly distributing drops to the petri-dish medium. 
Following incubation for 7 hours (at 37°C and 5% CO2), the medium was discarded 
and replaced with 10 mL of fresh complete DMEM and the cells were returned to 
the incubator. GFP expression was seen 48 hours post-transfection using a 
fluorescent microscope (Nikon). Figure 2.2 shows an example of a live image of 
HEK293T cells expressing GFP prior to harvesting the lentivirus vector. Three days 
following transfection, the supernatant was harvested, filtered through a 0.45 µm 
filter (Millipore Stericup) into a new sterile T75 flask (Falcon) to remove any cell 
debris, and then transferred into 6 Ultra-clear centrifuge tubes (Beckman, 344058) 
where each tube was placed into a Beckman 115.6 bucket. The virus-containing 
supernatant was centrifuged at 50,000 g for 90 minutes at 4ºC (19,000 rpm, 
ultracentrifuge). The supernatant was discarded and the viral pellets were then 
suspended in 200 µL of 1% bovine serum albumin (BSA, Fluka) in phosphate 
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buffered saline (PBS, Lonza) for 60 minutes at 4ºC. Viral suspensions were stored in 
50 µl aliquots in 1.7 mL low-retention tubes (Axygen Scientific) at -80ºC.  
 
 
 
Figure 2.2. A representative live image of HEK293T cells showing GFP 
expression 48 hours post-transfection with LV-si-PTEN (20x magnification, 
scale bar=100µm). Images were captured prior to harvesting the viral vectors using a 
fluorescent microscope. GFP, green fluorescent protein, LV, lentiviral 
 
 
 
 
2.2.4.1 LV tittering by FACS analysis 
To determine the titre of the LV vectors produced, Hela cells were plated in a 12-
well plate, at a density of 75,000 cells per well in 1 mL of complete EMEM medium 
(Sigma) supplemented with 2 mM Glutamine (Sigma), 1% NEAA (Sigma) and 10% 
FBS (Gibco) and incubated overnight at 37ºC at 5% CO2. The following day, the 
number of cells in one representative well (of each plate) was counted to confirm the 
total number of cells per well. The cells were transduced with serial dilutions of 
each lentivirus (diluted in complete EMEM medium) starting at a concentration of 
10-2 to 10-4, and untransduced cells were used as negative controls. The medium was 
replaced 4 hours later with fresh complete EMEM medium and the transduced cells 
were incubated at 37°C and 5% CO2 for a further 72 hours. GFP expression was 
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seen at 48-72 hours post-transduction. At three days post-transduction, the cells 
were harvested. First, the medium was discarded and the cells were gently washed 
with 1x PBS (pH 7.4, Gibco), trypsinised with 0.005% trypsin (in HBSS and 0.053 
mM EDTA, Sigma) and then resuspended in complete EMEM medium and 
centrifuged at 200 rpm for 5 minutes. The supernatant was discarded and the pellet 
from each sample was resuspended in 200 µL of 4% PFA to fix the cells for 15 
minutes at room temperature. The cells were then centrifuged at 200 rpm for 5 
minutes, the PFA was discarded and the fixed cells were resuspended in 1x PBS 
(Gibco) and stored at 4°C until they were analysed by FACS. Technical support for 
FACS analysis was kindly provided by Susan Newton (Flow Cytometry 
Technician). Dilutions that gave 1-20% GFP positive cells were used for calculating 
the titre of the lentivirus using the following formula: 
 
Vector titre (in transducing units/mL, TU/mL) = [(% positive gated cells  x number 
of cells during transduction) x dilution factor x 2] 
 
2.2.5 Western blotting 
Protein was extracted from cultured motor neurons at the appropriate time point and 
analyzed by western blotting. For motor neuron cultures, the medium was discarded, 
the cells were gently washed with 1 mL of PBS/well and then scraped off the wells 
with a 25 cm cell scarper (Sarsted) and collected in whole cell lysis buffer. The cell 
suspension was incubated at 4°C for 45 minutes and then centrifuged at 1300 g for 
10 minutes. The supernatant was collected for western blot analysis and the pellet 
was discarded. Protein samples were stored at -20°C until needed. The protein 
concentration of the cell and muscle samples was measured using the Bradford 
(Pierce) assay following the manufacturer’s recommendations. 
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To make the gels, two glass plates of an SE245 Dual gel caster were first cleaned 
thoroughly with 70% alcohol and then assembled on a casting stand. A separating 
gel of 10% sodium dodecyl sulphate polyacrylamide gel electrophoresis (SDS-
PAGE) was prepared and poured between the plates to make a 1.5 mm thick gel, 
which was allowed to polymerise for 30 minutes. Thereafter, a 1.5 cm stacking gel 
was added on top of the polymerised separating gel and a comb was placed to create 
wells for loading the samples. The stacking gel was allowed to polymerise for 5 
minutes and was then placed in a tank containing 1x running buffer (prepared from 
10x stock: 25 mM Tris-base, 250 mM glycine, and 0.1% SDS in distilled H2O, 
National Diagnostics).  
 
Meanwhile, the protein samples were thawed on ice and spun down briefly. 20 µg of 
each sample was diluted in nuclease-free H2O and denatured in the presence of a 4x 
loading buffer at 100°C for 5 minutes. The protein samples were then loaded in each 
well of the gel and 5 µl of a protein standard (Bio-Rad) was loaded in a separate 
well. Electrophoresis was performed using a 1x running buffer for 45 minutes at 50 
V to enable proper separation of the proteins, and then for 1.5-2 hours at 100 V.  
 
For immunoblotting, the proteins were transferred on to a polyvinylidene difluoride 
membrane (PVDF, Millipore Immobilon P) in a transfer buffer containing 25 mM 
Tris, 192 mM Glycine and 10% v/v methanol. Prior to transfer, the membranes were 
initially soaked in methanol for 20 seconds and then soaked in ice-cold transfer 
buffer and similarly the gels were also soaked in ice-cold transfer buffer. Proteins 
were transferred to the membrane in transfer buffer at 250 mA or 100 V for 1 hour 
at room temperature, or at 25 V overnight at 4°C. To check for the success of the 
transfer, the membranes were incubated with Ponceau S solution (0.1% (w/v) 
Ponceau S (Sigma) in 5% (v/v) acetic acid) to check that the proteins were 
transferred onto the PVDF membrane; and the membrane was then destained with 
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water and washed once with TBS-T. In order to block non-specific binding, the 
membranes were then incubated in a blocking buffer (5% milk in TBS-T) for 1 hour 
at room temperature with agitation. The membranes were subsequently incubated 
with primary antibodies diluted in 5% BSA in TBST overnight at 4ºC, washed 3 x 
15 minute washes at room temperature with agitation and then incubated with the 
appropriate secondary antibody for 1 hour at room temperate and finally washed 3 x 
15 minute washes before being developed. Table 2.1 summarises the antibodies used 
for western blot analysis.  
 
When necessary, the bound antibodies were stripped off the membranes using a 
stripping buffer (62.5 mM Tris (pH 6.7) at 50°C for 30 minutes with agitation and 
then re-washed, blocked and re-probed with the appropriate antibody. The proteins 
were visualised using the ECL Plus chemiluminescence detection kit (GE 
Healthcare) for HRP (horseradish peroxidase) according to the manufacturer’s 
instructions. The membranes were visualized by the G-BOX Image Capture System 
(G: BOX, Syngene) and densitometric analysis was performed using the GeneSys 
software (GeneSnap and GeneTools, GeneSys software, Syn). 
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Table 2.1 Primary and secondary antibodies used for western blot analysis 
 
Target Protein Species Dilution Supplier 
 
Primary antibodies/ MW 
PTEN, ~54 kDa Rabbit 1:1000 Cell Signalling, 
5106 
Akt (Akt1, Akt3), ~60 kDa Rabbit 1:1000 Cell Signalling, 
2966 
Bad, ~23 kDa  Rabbit 1:1000 Cell Signalling, 
9292 
Phospho-Akt (Ser473)   ~60 kDa  Rabbit 1:1000 Cell Signalling, 
4060 
Phospho-BAD (Ser155) ~23 kDa Rabbit 1:1000 Cell Signalling, 
5284 
Phospho-p44/42MAPK(ERK1/2) 
(Thr202/Tyr204),  ~42/44 kDa 
Rabbit 1:1000 Cell Signalling, 
9101 
Phospho-p70 S6 Kinase (Thr389),  ~70, 
85 kDa 
Rabbit 1:1000 Cell Signalling, 
9234 
GFP,   ~30 kDa Rabbit 1:3000 Clontech, 632460 
GAPDH,   ~36kDa Mouse 1:5000 Calbiochem, 
CB1001 
 
Secondary Antibodies 
Rabbit IgG – HRP Goat 1:5000 Dako, P0449 
Mouse IgG – HRP Goat 1:10,000 Biorad, 170-6516 
Abbreviations: GAPDH, glyceraldehyde-3-phosphate dehydrogenase; GFP, Green 
Fluorescent Protein; HRP, horseradish peroxidase; MW, molecular weight; PTEN, 
phosphatase and tensin homologue deleted on chromosome ten. 
 
 
 
2.2.6 Immunocytochemistry 
Immunocytochemical staining was performed on primary motor neuron cells 
following transduction with LV-ssi and si-PTEN. At seven days post-transduction, 
the medium was removed and motor neurons were washed with 1 mL of PBS and 
fixed with 1 mL of 4% PFA per 35 mm dish for 15 minutes at room temperature, 
then incubated with PBS at 4ºC until needed for immunocytochemistry. Prior to 
staining, the cells were carefully washed once with PBS for 5 minutes. For 
permeabilisation, 0.5% Triton X-100 (Polyethylene glycol tert-octylphenyl ether, 
Sigma) in PBS with 10% normal goat serum (NGS, Sigma) was added for 1.5 hours 
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at room temperature. The cells were then incubated in a blocking solution (0.25% 
Triton X-100 and 10% NGS in PBS) for 30 minutes at room temperature; then 
incubated with the primary antibody (diluted in 0.25% Triton X-100 in PBS) 
overnight at 4°C followed by the secondary antibody (diluted in 0.25% Triton X-100 
PBS) for 2 hours at room temperature. Table 2.2 shows the concentrations of the 
antibodies used according to the optimised conditions. The nucleus was visualised 
with Hoechst stain (Life Technologies) diluted in the secondary antibody solution at 
a concentration of 1:1000. Between the antibody incubations, the cells were washed 
3 x 5 minute washes with PBS. The coverslips were then mounted on glass slides 
using fluorescent mounting media (Dako), fixed to the slides with nail polish and 
were left to dry. Immunoreactivity was visualised with a fluorescence microscope 
(ZEISS). Images were captured using the OpenLab software (Improvision) at 63x 
magnification, and analysed with Image J.    
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Table 2.2 Primary and secondary antibodies used for immunocytochemistry 
and immunohistochemistry 
 
Target Protein Species Dilution Supplier 
 
Primary antibodies 
PTEN  Mouse 1:100 Santa Cruz, sc-
7974 
Phospho-Akt (Ser473)  Rabbit 1:200 Cell Signalling, 
4060 
Phospho-p44/42MAPK(ERK1/2) 
(Thr202/Tyr204) 
Rabbit 1:200 Cell Signalling, 
9101 
Phospho-p70 S6 Kinase (Thr389) Rabbit 1:200 Cell Signalling, 
9234 
GFP Rabbit 1:200 Clontech, 632460 
GFP Chicken 1:500 Life 
Technologies, 
A10262 
CGRP Rabbit 1:200 Abcam, Ab81887 
GFAP Mouse 1:200 Sigma, G3893 
 
 
Secondary Antibodies 
Alexa Fluor 594, anti-mouse IgG Goat 1:200 Invitrogen, A1105 
Alexa Flour 594, anti-rabbit IgG Goat 1:200 Life 
Technologies, A-
11037 
Alexa Flour 488, anti-chicken IgG Goat 1:2001 Life 
Technologies, A-
11039 
Fluorescein (FITC)- Affini anti-rabbit 
IgG 
Goat 1:200 Jackson, 111-095-
003 
 
Hoechst 33342 Fluorescent Stain - 1:1000 Life 
Technologies, 
H3570 
Abbreviations: CGRP, Calcitonin Related Peptide, FITC, Fluorescein 
Isothiocyanate; GFP, Green Fluorescent Protein; GFAP, Glial fibrillary acidic 
protein, IgG, Immunoglobulin G, PTEN, phosphatase and tensin homologue deleted 
on chromosome ten.  
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2.3 In vivo experimental work 
 
2.3.1 Animals 
For the in vivo studies the wild type C57BL/6 (Charles Rivers Laboratories) and 
C57BL/6J Tg (SOD1 G93A) 1Gur (G93A-SOD1) mice (Jackson Laboratories) were 
used. The transgenic mice were based on C57BL/6J and were backcrossed onto 
C57BL/6 mice for at least 10 generations to produce this congenic strain. These 
mice are hemizygous for the human SOD1G93A gene harboring a glycine to alanine 
substitution at codon 93 (driven by its endogenous human SOD1 promoter) and 
express a high transgene copy number. Mice were maintained in a controlled facility 
in a 12 h dark/12 h light photo cycle with free access to food and water; no more 
than 4 mice of the same sex and receiving the same treatment were housed in a 
single box. All animals were bred and maintained by Dr. Ellen Bennett and Ian 
Coldicott. All in vivo experimental studies were performed in accordance to the UK 
Home Office Animals (Scientific Procedures) Act 1986. 
 
2.3.2 Genotyping 
Transgenic male SOD1G93A mice were crossed with C57BL/6 females, and the 
offspring were genotyped after birth by polymerase chain reaction (PCR) to detect 
the presence of the human SOD1 transgene. Mouse ear clips were incubated in 50 
µL of DNA extraction buffer (1.0 Epicenter biotechnologies) at 65°C for 1 hour and 
then at 98°C for 5 minutes to inactivate the proteinase K in the extraction buffer. 
The DNA solution was used as a template for a PCR reaction with two pairs of 
primers: one pair that recognizes the mouse interleukin 2 (IL2), which was used as 
an internal control; and a second pair that recognizes the human SOD1 gene (Table 
2.3). 
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Table 2.3. Primers used for genotyping SOD1G93A mice 
 
Primer Primer Sequence 
Human superoxide dismutase 
1 (SOD1), Forward 
5’ CATCAGCCC TAATCCATCTGA 3’ 
 
Human superoxide dismutase 
1 (SOD1), Reverse 
 
5’ CGCGACTAACAATCAAAGTGA 3’ 
 
Mouse interleukin 2 (IL2), 
Forward 
5’ CTAGGCCACAGAATTGAAAGATCT 3’ 
 
Mouse interleukin 2 (IL2), 
Reverse 
 
5’ GTAGGTGGAAATTCTAGCATCATCC 3’ 
 
 
The PCR reaction consisted of 12.5 µL of ReddyMix (2x ReddyMix PCR 
Mastermix, Thermo Scientific), 0.2 µM of each primer, 1 µL of DNA solution 
(template) and nuclease-free H2O to make a final volume of 25 µL. The PCR was 
run using the following program: 
 
 
     95oC  5 minutes 
                                                           
 95oC        30 sec 
                                                  60oC      30 sec                                                                     35 cycles
                                                            
     72oC        45 sec 
                                                                 72oC        7 minutes      
                                                                10oC      hold 
 
The PCR products were electrophoresed on a 2% agarose gel (Melford) in Tris-
acetate-EDTA buffer (TAE, 40 mM Tris acetate, 20 mM glacial acetic acid and 1 
mM EDTA) with 0.5 µg/µL ethidium bromide (Sigma) that ran at 140 V for 30 
minutes in TAE buffer. A DNA marker (Promega) containing a set of DNA 
fragments of known sizes  (1000 base pair, (bp) was loaded alongside the samples to 
                                                      91 
determine the size of DNA in the test samples. DNA from a known transgenic 
mouse was used as a positive control and nuclease-free water was used as a negative 
control. Wild-type mice were expected to have only one band, representing mouse 
IL2 at 324 bp, whereas transgenic mice were expected to have 2 bands, one for IL2 
at 324 bp and another band for human SOD1 at 236 bp (Figure 2.3). The bands were 
visualized using the GENi imaging system (Syngene).  
 
                                       
Figure 2.3. Representative image of an agarose gel showing PCR amplification 
of DNA extracted from mouse ear clips for genotyping. Wild type mice have one 
band only at 324 bp representing Mouse interleukin 2 (IL2) and transgenic mice 
have 2 bands, one at 324 bp for IL2 and one at 236 bp representing human SOD1.  
 
2.3.3 Recruiting mice for in vivo experiments 
For the validation of transduction efficiency of AAV vectors, wild type mice 
(C57BL/6) were used (Chapter 4). The animals were recruited to five experimental 
groups (3 mice per group).  Two groups received the control vectors, AAV6-ssi-
PTEN or scAAV9-ssi-PTEN, to monitor the effect of the viral vectors; two groups 
received the therapeutic vectors, AAV6-si-PTEN or scAAV9-si-PTEN; and one 
group received PBS to monitor the effect of injections. All mice were age, sex and 
litter-matched when possible.  
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Transgenic SOD1G93A mice were used to evaluate the effect of scAAV9-mediated 
PTEN silencing on motor neuron survival (Chapter 4). In this study, the mice were 
recruited to two groups (6 mice per group); one group received the control vector 
scAAV9-ssi-PTEN, and one group received the therapeutic viral vector scAAV9-si-
PTEN. One group of age-matched untreated wild-type littermates was also included 
in the study. This cohort of mice was also used to study the effect of scAAV9-si-
PTEN on NMJ degeneration (Chapter 5). Another group of transgenic mice were 
used for a pilot study to investigate the effect of AAV6-mediated PTEN silencing on 
NMJ degeneration. Here, one group received the control vector AAV6-ssi-PTEN 
and another group received AAV6-si-PTEN. 
 
2.3.4 AAV Vectors 
The viral vectors, AAV6-ssi-PTEN, AAV6-si-PTEN, scAAV9-ssi-PTEN and 
scAAV9-si-PTEN used for the in vivo studies were outsourced and produced at the 
University of North Carolina (UNC Vector Core). The titre of the vector was 
measured by quantitative PCR (Q-PCR) and expressed as vector genomes (vg)/ml. 
Table 2.4 shows the concentrations of each vector. 
 
Table 2.4 Concentration of AAV vectors used for in vivo studies 
 
Virus vector Titre 
AAV6-ssi-PTEN 1.0 x 1011 vg / mL 
AAV6-si-PTEN 1.0 x 1011 vg / mL 
scAAV9-ssi-PTEN 1.0 x 1012 vg / mL 
scAAV9-si-PTEN 1.0 x 1012 vg / mL 
Abbreviations: AAV6, adeno-associated virus serotype 6, scAAV9, self-
complementary adeno-associated virus serotype 9, vg, vector genomes. 
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2.3.5 In vivo injections of viral vectors  
For the validation of viral vectors, AAV-6 and scAAV-9 vectors carrying PTEN 
shRNA or scrambled-PTEN shRNA (control vector) were injected unilaterally in to 
the left hind limb of wild-type C57BL/6 mice, a total of     20 µl of viral vector 
solution at 4 weeks of age ± 1 day (n=3 per group). Another group of mice were 
injected with 20 µl of PBS into the left hind limb (n=3).  
 
Transgenic SOD1G93A mice (n=6 per group) received unilateral injections of either 
AAV6-si-PTEN or AAV6-ssi-PTEN into the left foot muscles (plantaris) (10 µl 
each) at 26 days of age (P26), and were used solely for the NMJ study. Another 
group of transgenic SOD1G93A mice received unilateral intramuscular injections of 
scAAV9 expressing si-PTEN or scrambled si-PTEN into the left gastrocnemius 
(GA) and Tibialis Anterior (TA) muscles (15 µl each) at P26. In this cohort of mice, 
a group of untreated wild-type C56BL/6 littermates were included in the study (see 
Table 2.3 for virus vector titre).  
 
The viral vectors and PBS were slowly administered into the muscles of interest 
with a 10 µL 33-Gauge Hamilton syringe (ESS Lab) to avoid damage to the injected 
muscles. Every injected muscle received a single injection into multiple sites with a 
maximum of 5 µl of vector solution injected per site. All injections were performed 
under gas anesthesia (IsoFlo, 100% w/w isoflurane inhalation vapour, liquid, 
Abbott) using an anaesthesia apparatus (Burtons). After the injections, the mice 
were left for at least 10 minutes to recover before they were returned to their cage.  
Dr Ke Ning performed the in vivo procedures and he was blinded to the treatment 
groups.  
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2.3.6 Collection of spinal cords and muscle tissue 
Wild-type mice were sacrificed 3 weeks after the injections, whereas the transgenic 
mice were sacrificed at postnatal day 100 (P100), the expected time for symptom 
onset. The animals were euthanized by an intraperitoneal injection of 500 mg/kg of 
sodium pentobarbital (sodium pentobarbital, 20% w/v solution for injections, JML). 
An in vivo perfusion system (AutoMate Scientific) was used for an intracardiac 
perfusion of 10 mL of ice-cold PBS containing 5 units/mL heparin (2000 units/mL 
heparin, Sigma), after which collection of fresh muscles was undertaken rapidly; 
perfusion with 10 mL of 4% PFA for the collection of spinal cords and brains for 
histological analysis followed immediately after the collection of muscle tissue. For 
collection of fresh muscle tissue, the hind limbs were removed from the mouse body 
at the bone joints and the skin was stripped off. The GA muscles were harvested 
fresh from the left and right hind limbs from all wild type mice and from three 
transgenic mice (one injected with scAAV9-ssi-PTEN, one injected with scAAV9-
si-PTEN and one untreated), snap frozen in liquid nitrogen and subsequently stored 
at -80ºC for western blot analysis. Muscles used for immunohistochemistry (IHC) 
were immediately incubated in 4% PFA. For the NMJ study, the muscles were 
collected in the same way and then processed for immunofluorescence as described 
below. The brains and spinal cords were initially incubated overnight in 4% PFA at 
4ºC followed by further incubation in 30% sucrose in PBS for cryoprotection and 
then cryoembedded in optimum cutting temperature medium (OCT, Dako). 20 µm 
thick transverse sections of the lumbar spinal cord were cut using a Leica cryostat 
and then mounted onto glass slides. Frozen muscle tissue was cut into 10 µm 
transverse sections using a cryostat and mounted onto glass slides. 
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2.3.7 Histological analysis of the lumbar spinal cord   
 
2.3.7.1 Immunohistochemistry 
Immunofluorescence was used to identify transduced motor neurons and to 
determine PTEN knockdown in the transduced cells. The slides were initially  
allowed to dry for 30 minutes at room temperature and then hydrated using 3 x 10-
minute washes in PBS. To permeabilise the sections, they were incubated in 10% 
normal goat serum (NGS) and 0.5% Triton X-100 in PBS for 1.5 hours at 37oC. The 
sections were then incubated with 10% NGS and 0.25% Triton X-100 in PBS for 30 
minutes at room temperature. This was followed by incubation with the primary 
antibody overnight at 4°C (Table 2.2). Thereafter the samples were washed 3 x 5-
minute washes with PBS and then incubated with the secondary antibody containing 
Hoechst stain (Life Technologies; to visualise the nuclei) for 2 hours at room 
temperature (Table 2.2). All antibodies were diluted in 0.25% Triton X-100 in PBS. 
The slides were washed 5 x 5-minute washes and the edges of the glass slides were 
dried. Fluorescent mounting medium (Dako) was applied to the sections, which 
were then covered with glass coverslips and allowed to dry at room temperature. 
Throughout the staining, the sections were protected from light. Motor neurons in 
the lumbar spinal cord were identified with antibodies against Calcitonin gene 
related peptide (CGRP), which belongs to the family of calcitonin peptides that is 
mainly produced in the cell bodies of motor neurons of the ventral horn (Moore, 
1989). Double immunohistochemistry using anti-GFP and anti-CGRP antibodies 
was used to determine the transduction efficiency of the viral vectors. Sections were 
also stained with anti-PTEN and anti-GFP antibodies to determine PTEN expression 
in the transduced motor neurons. The PTEN, CGRP and GFP immunoreactivity 
were visualised with a fluorescence microscope (ZEISS fluorescence microscope). 
The settings for the pinhole were identical for all samples. Images were captured 
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using the OpenLab software (Improvision) at 63x magnification, and analysed with 
Image J. When available Confocal (Leica) images were also taken.   
 
For the scAAV9-si-PTEN study in transgenic mice, total motor neuron counts were 
determined by Nissl staining (0.1% Cresyl Fast Violet, BDH). The sections were 
first defatted using xylene for 5 minutes, and then hydrated by 1 minute washes in 
100%, 95%, 70%, and 50% ethanol. The sections were then washed with distilled 
water for 5 minutes and then incubated in 0.1% cresyl fast violet solution for 5 
minutes. Following a brief wash in distilled water, the sections were differentiated in 
95% ethanol for 2-15 minutes depending on the quality of staining seen under a light 
microscope. After dehydrating the sections in 100% ethanol for 1 minute, they were 
incubated in xylene for a further 5 minutes and then mounted onto coverslips with a 
permanent mounting medium (DPX). Motor neurons were counted under a light 
microscope and were identified by their morphology and size.   
 
2.3.7.2 Motor neuron cell counts 
Transduction efficiency. The total number of transduced (GFP positive) motor 
neurons was counted in wild-type mice treated with AAV6-si-PTEN (n=3) and 
scAAV9-si-PTEN (n=3,) and those treated with PBS (n=3), in all sections (20 µm 
thick) of every fifth slide spanning the lumbar spinal cord. Cell counts were 
performed using a fluorescent microscope (ZEISS, 40x magnification) by two 
independent assessors. Transduction efficiency was calculated as the percentage 
GFP-positive motor neurons relative to the total number of CGRP-positive cells 
(motor neurons). Similarly the transduction efficiency was determined in transgenic 
SOD1G93A  mice treated with scAAV9-ssi-PTEN (n=5) and scAAV9-si-PTEN (n=5). 
 
Motor neuron survival. Nissl-stained motor neurons were counted in all         
sections of every fifth slide (1 in 5 sections) throughout the lumbar spinal cord of 
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transgenic SOD1G93A mice treated with scAAV9-ssi-PTEN (n=5) and scAAV9-si-
PTEN (n=5) and in untreated wild type mice. Analysis of 5 mice per group was 
performed while being blinded to the treatment groups. Motor neuron counts were 
performed under a light microscope (20x magnification).  
 
2.3.8 Histological analysis of the gastrocnemius  muscle  
 
2.3.8.1 Haematoxylin and Eosin (H and E) staining 
To determine the morphology and pathology of the GA muscles of transgenic 
SOD1G93A mice, muscle sections were then warmed to room temperature before 
being fixed in 95% alcohol for 5 minutes and then rehydrated in tap water for 5 
minutes. The sections were then stained with haematoxylin for 2 minutes, washed in 
water, blued in Scott’s tap water  (minutes until the colour changes from purple to 
blue) and then stained with eosin for 5 minutes. Sections were then washed in water 
and dehydrated in graded series of alcohol (100% ethanol for 5 minutes, 95% 
ethanol for 5 minutes, 70% ethanol for 5 minutes), cleared in xylene and then 
mounted in DPX. 
 
2.3.8.2 Immunofluorescence 
Immunofluorescence was used to determine GFP expression in the injected and 
contralateral GA muscles of transgenic SOD1G93A. 1 in 10 slides from one mouse per 
experimental group were stained with anti-GFP antibodies and Hoechst for nuclear 
staining as described above for the spinal cords. Images were captured using a 
fluorescence microscope (Zeiss).  
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2.3.9 Western blot analysis of the gastrocnemius muscles 
For extraction of protein from muscle tissue, the muscles were homogenised using a 
sonicator (Bosch) in the presence of ice cold whole cell lysis buffer, and the tissue 
was further incubated at 4°C for 45 minutes and then centrifuged at 1300 g for 10 
minutes. The supernatant was collected and the samples were stored at -20°C until 
needed for western blotting. The protein samples were then analysed by western 
blotting as described above (section 2.2.5). 
 
2.3.10 NMJ Analysis 
Immunofluorescence was used for the labelling of neuromuscular junctions (NMJ) 
of the hind limb muscles from transgenic SOD1G93A mice. The mice were sacrificed 
at the appropriate times and the muscles were collected as described above. For the 
AAV6-si-PTEN NMJ study, NMJ analysis was performed on the lumbrical and 
flexor digitorum profundus (FDP) muscles and on the lumbrical and tibialis anterior 
(TA) muscles for the scAAV9-si-PTEN study. Dr Sophie Thompson performed all 
muscle dissections and immunohistochemistry was performed at Professor Thomas 
Gillingwater laboratories at the University of Edinburgh because of their expertise in 
this field.  
 
2.3.10.1 Dissections 
The hindlimb was first removed from the mouse, the skin was reflected and the limb 
was pinned out on a Sylgard dish using insect pins. All dissections were performed 
in 1x PBS. The muscles were then fixed with 4% PFA for 15 minutes before being 
washed three times with 1x PBS. Following fixation, the muscles of interest were 
identified and removed from the limb by blunt dissection. The lumbricals and FDP 
muscles were stored in PBS at 4°C until ready for immunohistochemistry, whereas 
the TA was cryoprotected in 30% sucrose solution overnight at 4ºC and then 
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sectioned on a freezing microtome at 100 µm before undergoing the same 
immunohistochemistry as the lumbricals and FDBs.  
 
2.3.10.2 Immunohistochemistry 
 
For labelling the NMJs, the muscles were first transferred into a 24 well plate 
containing 2% Triton-X in PBS for permeabilisation (250 µl per well). The muscles 
were left to float freely in the wells for 1.5 hours and then transferred into wells 
containing a blocking solution (4% Bovine Serum Albumin (BSA, Sigma) and 2% 
Triton in 1x PBS) and were left to incubate in a rocker for 30 minutes at room 
temperature. The muscles were then transferred into wells containing the primary 
antibodies anti-2H3 IgG1 (Developmental Studies Hybridoma Bank) for labelling 
the neurofilaments and anti-SV2 IgG1 (Developmental Studies Hybridoma Bank) 
for labelling the synaptic vesicle glycoprotein 2A, both at a concentration of 1:100. 
The samples were incubated for two nights with the primary antibodies on a rocker 
at 4ºC. Thereafter, the muscles were washed with ice-cold fresh 1x PBS every half 
an hour for 2 hours on the rocker at room temperature before they were incubated in 
TRITC-conjugated alpha-bungarotoxin (Biotium) to label the post-synaptic 
membranes, at a concentration of 1:100 in 1x PBS for 10 minutes on the rocker in 
the dark. All subsequent washes and incubations were performed in the dark. The 
samples were then transferred into individual wells containing Cy2 rabbit anti-
mouse secondary antibody (Millipore) at a concentration of 1:200 (diluted in PBS) 
for 4 hours on the rocker at room temperature and then washed in 1x PBS every 10 
minutes for half an hour. Finally, the muscles were mounted on glass slides using 
Mowiol mounting medium and covered with cover slips. The slides were left at 
room temperature overnight to allow the Mowiol to set. The samples were wrapped 
in tin foil through all steps of immunofluorescence to protect the tissue from light. 
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NMJs were visualised using a Zeiss LSM 710 laser scanning confocal microscope 
(40x objective/1.3NA oil objective; 63x objective/1.4NA oil objective).  
 
2.3.10.3  NMJ counts 
NMJ counts were performed in a blinded manner by Dr Sophie Thomson. For 
quantification of NMJs, a minimum of 100 NMJs was counted per muscle per 
mouse from confocal images using 40x objective. The NMJs were categorised as:  
fully occupied endplates when the nerve terminal (identified by the SV2 and 
neurofilament staining) covers more than 50% of the motor end plate (identified by 
the bungarotoxin staining), partially occupied when the nerve terminal covers less 
than 50% of the motor endplate but is still in contact with the motor endplate and 
unoccupied (vacant) when there is no contact between the nerve terminal and motor 
endplate. The data was analysed and plotted into bar chats using Graph Pad Prism 
v6.   
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3. The effect of viral-mediated PTEN knockdown in 
transgenic SOD1G93A mouse motor neurons in vitro 
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 3.1 Introduction 
Much of our understanding of the pathogenic mechanisms of neurodegenerative 
disorders came from studies in developing neurons (Mattson, 1989). During 
development, nearly half of the immature neurons die by programmed cell death, or 
apoptosis, which is also a characteristic feature of acute and chronic 
neurodegenerative diseases (Ghavami et al., 2014). Only those neurons, which are 
able to reach their targets in the presence of trophic support, are able to survive 
(Dekkers et al., 2013). Studies in models of developing neurons have shown that 
signalling pathways that are crucial for the survival of developing neurons are also 
involved in pathological neuronal cell death (Brunet et al., 2001). Therefore, a 
logical therapeutic strategy is to activate the anti-apoptotic signalling pathways in 
disease models of neurodegenerative disorders. The PI3K/Akt pathway is one of the 
most extensively studied signalling pathways involved in neuronal survival. The 
PTEN protein is an important negative regulator of PI3K and Akt. PTEN silencing 
leads to activation of PI3K and its downstream effectors and has been widely tested 
as a potential therapeutic strategy in various models of neurodegeneration. 
 
In the CNS, inhibition of PTEN activity is well known to play a crucial role in the 
pathogenesis of brain tumours (Endersby and Baker, 2008). However, extensive 
study of PTEN in the nervous system shows that PTEN has a broader role in the 
pathophysiology of the CNS. Indeed, a wealth of evidence exists to support its role 
in neuronal survival and axonal regeneration, which is predominantly mediated by 
the PI3K/Akt signalling cascade (Wyatt et al., 2014, Ning et al., 2010, Lai et al., 
2014). The neuroprotective effect of PTEN inactivation has been demonstrated in in 
vitro (Ning et al., 2010) and in vivo (Little et al., 2015) models of the childhood 
neuromuscular disease SMA, suggesting that targeting PTEN could be a novel 
strategy for protection against motor neuron degeneration. ALS shares similarity to 
SMA such that selective motor neuron loss is a pathological hallmark of both 
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diseases (Murray et al., 2008, d'Errico et al., 2013, Shaw and Eggett, 2000, 
Brockington et al., 2013), hence modulation of PTEN levels may also have a 
neuroprotective role in ALS. Therefore, it was hypothesised that reducing the 
expression of PTEN may prolong the survival of motor neurons in ALS by 
activating the PI3K/Akt signalling pathway. This section describes the in vitro 
studies performed to test this hypothesis. Purified mouse motor neurons from 
transgenic SOD1G93A mice were used as an experimental model of the disease. 
Lentiviral vectors were used to deliver siRNA against mouse PTEN for stable gene 
silencing. This in vitro model was also used to validate the efficiency of AAV9 
vectors expressing PTEN siRNA prior its use for in vivo studies  (Chapter 4).    
 
3.1.1 Purified motor neuron cultures as in vitro model of ALS 
Motor neuron cultures provide an excellent tool for studying motor neuron biology 
and in particular the mechanisms of cell death and survival. Indeed, studies in 
isolated motor neuron cultures played an important role in our understanding of the 
mechanisms of motor neuron degeneration (Ning et al., 2010, Fallini et al., 2010, 
Kirby et al., 2011a, Wang et al., 2013b).  
 
Ideally, cultures of human motor neurons from patients with ALS compared with 
those from healthy controls would provide a perfect in vitro model, but this is 
impossible to obtain from living patients and attempts to culture post-mortem tissue 
have been unsuccessful (Di Giorgio et al., 2008). Although explants of human 
embryonic spinal cord and dissociated cultures of human spinal cord neurons and 
glia cells have been successfully cultured for up to 7 weeks, their use was restricted 
by the limited availability of human embryos (Peterson et al., 1965, Hosli et al., 
1973, Kato et al., 1985, Kato and Lindsay, 1994). Motor neuron co-cultures with 
glia cells or fibroblast have also been used as in vitro models of ALS (Bar, 2000). 
                                                      104 
Spinal cord organotypic cultures provide a more physiological environment closer to 
the in vivo models and could survive up to 3 months in culture. However, during the 
preparation of the spinal cord slices, motor neurons are subjected to a degree of 
axotomy-induced stress and hence there is a selection of the surviving motor 
neurons, which could affect the interpretation of data (Bar, 2000). Moreover they are 
technically cumbersome and this hampered their use for drug screening experiments 
(Bar, 2000). 
 
Stem cell biologists have generated motor neurons from human embryonic stem 
cells (hESC), which provide a new in vitro model for studying disease mechanisms 
and drug screening for therapy development (Di Giorgio et al., 2008). When hESC-
derived motor neurons were co-cultured with glial cells harbouring mutant SOD1, 
selective motor neuron toxicity was observed (Marchetto et al., 2008). Furthermore, 
reprogramming of skin fibroblasts from healthy individuals and ALS patients was 
used to produce induced pluripotent stem cells (iPSC), which were then 
differentiated into motor neurons (Dimos et al., 2008). Of interest, iPSC-derived 
motor neurons from patients carrying SOD1 mutations, developed neurofilament 
inclusions and axonal degeneration (Chen et al., 2014). Other studies demonstrated 
that iPSC-derived motor neurons from patients with TARDBP mutations, showed 
cytoplasmic aggregation of TDP-43 and were more sensitive to oxidative stress 
(Egawa et al., 2012). These models proved to be very useful in investigating 
pathogenic mechanisms leading to motor neuron degeneration as well as for pre-
clinical drug testing.  
 
Schnaar first described purified motor neuron cultures in 1981(Schnaar and 
Schaffner, 1981). They are widely used as an in vitro model to study cellular 
mechanisms involved with motor neuron diseases such as ALS (Veyrat-Durebex et 
al., 2014, Bar, 2000) and SMA (Ning et al., 2010). In this project, to study the 
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effects of PTEN knockdown on motor neurons, lacking the trophic support of 
neighbouring cells, isolated motor neurons from transgenic SOD1G93A embryos and 
their non-transgenic littermates were prepared using the panning method as 
previously described (Amoroso et al., 2013, Camu and Henderson, 1992). The 
cultures were prepared at embryonic day 13 (E13), which is the time before 
developmental apoptosis occurs, and prior to the development of axonal branching  
(Schaffner et al., 1987). Although mouse motor neuron cultures are not ideal for 
testing long-term treatments for chronic  diseases, they provide an invaluable tool 
for drug screening and investigating cell signalling pathways. 
 
3.1.2 Lentiviral mediated PTEN silencing 
Chemical compounds based on Bisperoxovanadium (bpV) are potent inhibitors of 
PTEN and are commonly used as research tools to study PTEN signalling both in 
vitro and in vivo (Schmid et al., 2004, Mak and Woscholski, 2015). An issue 
concerning the use of these inhibitors is that they target other phosphatases and 
inhibit PTEN in nanomolar concentrations, which may result in non-specific 
phosphatase effects, whereas second generation vanadium-based inhibitors, such as 
VO-OHpic, show more specificity to PTEN (Rosivatz et al., 2006, Mak and 
Woscholski, 2015). The use of bpV-based small molecules may be challenging for 
the specific targeting of PTEN in neuronal cells due to the difficulties in delivering 
these compounds to the CNS at effective therapeutic concentrations in vivo. On the 
other hand, the use of RNA interference has been shown to be highly specific for 
gene manipulation (Boudreau et al., 2011) and has proved to be a powerful tool for 
PTEN inhibition in the CNS both in vitro and in vivo (Ning et al., 2010, Christie et 
al., 2010, Little et al., 2015). 
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Several methods have been used to deliver genes into neuronal cultures including 
calcium phosphate plasmid transfection, electroporation and commercially produced 
lipids (Royo et al., 2008). However, the use of these methods for gene delivery in 
primary neurons is limited by their transient and low efficiency of gene expression 
as well as cell toxicity (Royo et al., 2008). On the other hand, lentiviral vectors 
provide an excellent means for gene delivery in dividing and non-dividing cells and 
have been extensively used in translational research (Azzouz et al., 2004a, Lundberg 
et al., 2008). They have the capacity to provide long-term and stable gene 
expression, a large cloning capacity and can be pseudotyped with various envelope 
proteins, which widens their tropism and enables the production of high titre viral 
stocks (Carpentier et al., 2012). These characteristics favoured their use in vitro over 
AAV vectors, which have a slow gene expression in vitro and a limited transgene 
capacity. Several studies have shown that lentiviral vectors have the ability for long-
term expression of siRNA resulting in stable gene knockdown both in vitro and in 
vivo (Hutson et al., 2014, Boudreau et al., 2011). Previous studies in our lab utilised 
lentiviral vectors for gene therapy studies in cellular models of ALS and SMA with 
promising results (Nanou et al., 2013) (Ning et al., 2010). In particular, lentiviral-
mediated PTEN knockdown was demonstrated in cultures of wild type motor 
neurons and transgenic SMA motor neurons (Ning et al., 2010).  
 
In this project, third-generation HIV self-inactivating lentiviral vectors were used to 
deliver siRNA to knockdown PTEN (si-PTEN) in post-mitotic motor neurons. 
Lentiviral vectors expressing a PTEN siRNA or ssi-PTEN (as control) were 
previously used by our research group. Both vectors were pseudotyped with VSV-G 
and gene expression was driven by the H1 promoter (see materials and methods 
section 2.2.3 for details). 
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3.1.3 Green fluorescent protein as reporter gene 
In addition to scramble and PTEN siRNA genes, the lentiviral vectors also 
expressed Green Fluorescent Protein (GFP) as a reporter gene under the EF1α 
(Human elongation factor-1 alpha) promoter. This is a 27kDa fluorescent protein 
consisting of 280 amino acids, which is widely used to assess gene transfer 
efficiency, and for localising and labelling target proteins (Welsh and Kay, 1997). 
GFP has the advantage of low toxicity and does not interfere with the physiological 
reactions of cells (Welsh and Kay, 1997) although some reports showed that 
overexpression of GFP can result in cytotoxicity (Koike et al., 2013). Expression of 
GFP can be visualised with a fluorescent microscope and is very useful for 
measuring the transduction efficiency of viral vectors, and can be used as a marker 
of gene expression.  
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3.2 Aims of the study 
The aim of this study was to investigate the therapeutic potential of PTEN silencing 
in an in vitro model of ALS. It was hypothesised that PTEN silencing may enhance 
motor neuron survival in vitro. The effect of PTEN knockdown on the PI3K/Akt 
signalling pathway and its impact on motor neuron survival was studied in cultured 
motor neurons derived from transgenic SOD1G93A mice. 
 
Lentiviral vectors were used to deliver siRNA under the H1 promoter for stable 
PTEN knockdown in motor neurons. Vectors expressing scrambled PTEN siRNA 
were used as a controls to account for any vector-related effects. Furthermore, 
purified motor neuron cultures were also used to validate the efficiency of scAAV9 
mediated PTEN silencing prior to their use for the in vivo studies (chapter 4).  
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3.3 RESULTS 
 
3.3.1 Localisation of PTEN in motor neurons 
PTEN is a ubiquitous protein, which is predominantly expressed in the cytoplasm 
and nucleus of cells (Lachyankar et al., 2000). In the human brain, PTEN is mainly 
found in neuronal cell bodies particularly the nuclei (Sano et al., 1999). Similarly, 
PTEN is preferentially expressed in neurons in the adult mouse brain (Lachyankar et 
al., 2000).  
 
To examine the localisation of PTEN in purified spinal motor neurons, cells were 
prepared from E13 transgenic SOD1G93A embryos and their non-transgenic 
littermates, were cultured for seven days and then fixed for immunocytochemistry. 
Tubulin staining showed that the mutant and non-transgenic motor neurons have a 
similar morphology (Fig 3.1). PTEN was widely distributed throughout the motor 
neurons, with clear enrichment in the cell body, dendrites and growth cones in 
transgenic and non-transgenic motor neurons (Fig 3.2). These findings indicate that 
mutations in SOD1 do not alter the PTEN protein distribution in embryonic motor 
neurons. In addition, the predominant expression of PTEN within the cytoplasm and 
growth cones suggests it has an essential role in the cytoplasm as well as regulating 
motor axonal growth (Ning et al., 2010).  
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Figure 3.1. Representative images of SOD1G93A and non-transgenic motor 
neurons in purified motor neuron cultures at day 7 in vitro. Tubulin staining 
(red) shows the cell body, dendrites and axons of motor neurons. No morphological 
differences were seen between the transgenic and non-transgenic motor neurons 
(20x magnification, Scale bar = 100 µm). MNs: motor neurons. 
 
 
 
 
 
 
 
 
 
           Non-transgenic  MNs                                          Transgenic SOD1G93A MNs
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Figure 3.2. Localisation of PTEN in cultured non-transgenic and transgenic 
SOD1G93A motor neurons. (A) Overview images of the endogenous distribution of 
PTEN in day 7 in vitro (7DIV) in cultured non-transgenic motor neurons. (B) 
Representative images of PTEN localisation at growth cones. (C) Endogenous 
distribution of PTEN in 7DIV cultured SOD1G93A motor neurons. (D) Representative 
images of PTEN localisation at growth cones in SOD1G93A motor neurons. PTEN 
localises at the cell body, axons, dendrites and very fine processes of the growth 
cone in 7DIV cultured motor neurons (Scale Bar=20 µm). 
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3.3.2 Lentiviral-mediated PTEN silencing in motor neurons 
Next, the efficiency of lentiviral-mediated PTEN knockdown was assessed in motor 
neurons. The lentiviral vector expressing siRNA contained a 19-nucleotide sequence 
targeting the mouse PTEN gene (LV-si-PTEN). A control vector was generated by 
subcloning a scrambled 19 nucleotide PTEN target sequence in to the lentiviral 
vector (LV-ssi-PTEN). Both vectors also expressed the GFP reporter gene. Hence, 
expression of GFP was an indication of motor neuron transduction with the lentiviral 
vectors.  
 
Purified primary motor neurons were isolated from E13 transgenic SOD1G93A and 
non-transgenic embryos and plated at a density of 2x105 cells in 12 well plates. The 
cells were transduced 18-20 hours later with LV-si-PTEN or LV-ssi-PTEN using a 
multiplicity of infection (MOI) of 10. Optimisation studies were previously 
conducted in our laboratory and showed that at an MOI of 10 these viral vectors 
transduce motor neurons efficiently without reported cell toxicity (Ning et al., 2010). 
Non-transduced cells and cells transduced with LV-ssi-PTEN were used as controls. 
The cells were then either fixed for immunocytochemistry or harvested for western 
blotting at 5 days post-transduction.   
 
 Immunofluorescence with anti-PTEN antibodies showed effective PTEN depletion 
in motor neurons transduced with LV-si-PTEN (Fig 3.3A). The expression of the 
PTEN protein was quantified by western blotting using anti-PTEN antibodies and 
PTEN levels were then normalised to GAPDH (Glyceraldehyde 3-phosphate 
dehydrogenase) (loading control). As seen in Figure 3.3B, LV-si-PTEN mediated a 
66% reduction (**p<0.01, NTG-LV-si-PTEN vs. NTG no virus, one way ANOVA 
with Tukey’s post hoc-test) and 65% reduction (*p<0.05, G93A-LV-si-PTEN vs. 
G93A no virus, one-way ANOVA with Tukey’s post hoc-test) in PTEN levels in 
non-transgenic and mutant SOD1G93A motor neurons, respectively. Transduction 
                                                      113 
with LV-ssi-PTEN did not alter the expression of PTEN when compared to PTEN 
levels in non-transduced cells, suggesting that PTEN knockdown was specific to the 
LV-si-PTEN vector. In addition, there were no significant differences between the 
levels of PTEN in the transgenic and non-transgenic motor neurons, indicating that 
mutations in SOD1 gene do not alter the levels of PTEN at the embryonic stage. The 
representative western blots show GFP expression in the transduced cells only 
(Figure 3.3B). These results indicate that lentiviral vectors expressing si-PTEN 
effectively depleted PTEN protein levels in motor neurons.  
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Figure 3.3.A. PTEN silencing mediated by LV-si-PTEN in motor neurons. 
Primary motor neurons from non-transgenic and SOD1G93A transgenic embryos were 
cultured and transduced with Lentiviral vectors (LV-si-PTEN or LV-ssi-PTEN) 18-
20 hours after plating. Motor neurons were immune-stained with anti-PTEN (red) 
and anti-GFP (green) antibodies. Images show efficient transduction of motor 
neurons with the lentiviral vectors. Prominent PTEN staining can be observed in the 
cell body and growth cones (63x magnification, Scale Bar=20 µm). Transduction of 
motor neurons with LV-si-PTEN leads to reduction of the PTEN protein. NTG: non-
transgenic, TG: transgenic. 
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Figure 3.3B. PTEN silencing mediated by LV-si-PTEN in purified motor 
neurons (MN) from transgenic SOD1G93A and non-transgenic mice. Purified 
lumbar spinal cord motor neurons were transduced after 18-20 hours in culture with 
Lentiviral vector expressing si-PTEN and scrambled (ssi)-PTEN as a control vector. 
MNs were harvested at day 5 post-transduction and the protein lysate was analysed 
with western blotting for PTEN expression. PTEN levels were normalized to 
GAPDH (loading control). PTEN expression was reduced by 66% and 65% in non-
transgenic and transgenic motor neurons transduced with LV-si-PTEN. There were 
no significant differences between PTEN levels in the MNs transduced with the 
control vector (LV-ssi-PTEN) and the untreated cells. Data represents means ± 
SEM. ** P<0.01, * P<0.05, one way analysis of variance (ANOVA) with Tukey’s 
post hoc-test. Abbreviations: GAPDH, Glyceraldehyde 3-phosphate dehydrogenase, 
G93A, transgenic SOD1G93A motor neurons, kDa, kilo Daltons, LV-ssi-PTEN, 
lentiviral vector expressing scrambled-si-PTEN, LV-si-PTEN, lentiviral vector 
expressing PTEN siRNA, NTG, non-transgenic motor neurons. 
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3.3.3 PTEN silencing increases survival in purified SOD1G93A and non-
transgenic motor neurons  
The next step was to determine whether PTEN silencing prolongs the survival of 
SOD1G93A motor neurons. Purified motor neuron cultures were prepared from mutant 
embryos and their non-transgenic littermates and transduced after 18-20 hours with 
either LV-si-PTEN or the control vector LV-ssi-PTEN at an MOI of 10. Untreated 
cells were used as a control and the control vector was used to account for any viral-
mediated effects. The number of attached cells was counted after 6 hours of plating 
(prior to transduction with the viral vectors) and then at 5 days post transduction the 
cells were fixed and the total number of surviving cells was determined using a 
phase-contrast microscope. The transgenic SOD1G93A and non-transgenic motor 
neurons transduced with LV-si-PTEN showed a significant increase in survival 
when compared to the non-transduced motor neurons and those transduced with LV-
ssi-PTEN (**p=<0.01, *p=<0.05, one way ANOVA with Tukey’s post-hoc test) 
(Figure 3.4). In addition, there were no significant differences between the cells 
transduced with the control vector and the untreated ones, indicating that the 
survival effect was specific to LV-mediated PTEN silencing. These results suggest 
that lentiviral-mediated PTEN knockdown leads to activation of the PI3K/Akt 
pathway, which promotes motor neuron survival.  
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Figure 3.4. PTEN silencing increases survival in purified SOD1 G93A and non-
transgenic motor neurons. Purified lumbar spinal cord transgenic and non-
transgenic motor neurons (MNs) were transduced after 18-20 h in culture with 
Lentiviral vectors expressing si-PTEN or scrambled (ssi)-PTEN as control (MOI 
10). MNs were counted at day 0 and 5 days post-transduction. The percentage of 
surviving MNs  at 5 days post-transduction was compared between the treated and 
untreated cells and was found to be significantly increased in cells transduced with 
LV-si-PTEN (∗p =< 0.05, **p=<0.001 tested by one-way ANOVA, n=3 
independent experiments for NTG-C and G93A-c, n=4 NTG motor neurons 
transduced with LV-ssi-PTEN and LV-si-PTEN, n=6 for G93A motor neurons 
transduced with LV-ssi-PTEN and LV-si-PTEN). Results represent the mean ± 
SEM. (NTG= non-transgenic control (no virus), NTG ssi-PTEN= non-transgenic 
MNs transduced with LV-scrambled si-PTEN, NTG si-PTEN= non-transgenic MNs 
transduced with LV-si-PTEN, G93A Control= SOD1 G93A control (no virus) MNs, 
G93A ssiPTEN= SOD1 G93A MNs transduced with LV-scrambled PTEN, G93A 
si-PTEN= SOD1 G93A MNs transduced with LV-si-PTEN). 
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3.3.4 PTEN silencing activates the PI3/Akt pathway in motor neurons. 
The effect of PTEN knockdown on downstream proteins of the PI3K/Akt pathway 
was then investigated in purified motor neuron cultures from transgenic SOD1G93A 
and non-transgenic mice. Antibodies that recognise Akt phosphorylated at Serine 
473 (pAkt Ser473) were used to label activated Akt, which was used as a marker for 
activation of the PI3K/Akt pathway. Immunofluorescence revealed expression of 
pAkt (Ser473) in the cell body and neural processes of transgenic and non-
transgenic motor neurons (Figure 3.5 A and B). Increased expression of pAkt was 
observed in both the transgenic and non-transgenic motor neurons transduced with 
LV-si-PTEN (Figure 3.5 A and B). Western blot analysis confirmed a significant 
increase in the pAkt expression in PTEN depleted motor neurons when compared to 
cells transduced with LV-ssi-PTEN and non-transduced cells (*p<0.05, one-way 
ANOVA with Tukey’s post hoc-test, n=3) (Figure 3.5 C). There was no significant 
difference between the pAkt levels in non-transduced motor neurons and motor 
neurons transduced with LV-ssi-PTEN, suggesting a specific effect of LV-si-PTEN 
on activating the PI3/Akt pathway. In addition, there were no significant differences 
between the levels of pAkt in the transgenic and non-transgenic motor neurons, 
suggesting that at the embryonic stage, mutations in the SOD1 gene do not alter the 
PI3K/Akt signalling cascade. 
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Figure 3.5 (A and B). Activation of the PI3K/Akt pathway following PTEN 
silencing in motor neurons. Primary motor neurons from (A) non-transgenic and 
(B) transgenic SOD1G93A embryos were cultured and transduced with Lentiviral 
vectors (LV-si-PTEN or LV-ssi-PTEN) (MOI = 10) 18-20 hours after plating. Motor 
neurons were immuno-stained with anti-Tubulin (red) and pAkt (Ser473) antibodies 
(green) and Hoechst (for nuclear staining- blue). pAkt is predominantly expressed in 
the cell body. Motor neurons transduced with LV-si-PTEN showed an increase in 
the intensity of pAkt staining in the cell body and neural processes of non-transgenic 
and transgenic MNs. These findings suggest activation of the PI3K/Akt pathway 
following PTEN silencing (63x magnification, scale bar = 20 µm). 
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Figure 3.5 C. PTEN silencing in transgenic SOD1G93A and non-transgenic 
purified motor neurons leads to activation of the PI3K/Akt pathway. Purified 
lumbar spinal cord motor neurons were transduced after 18-20 hours in culture with 
Lentiviral vector expressing si-PTEN (LV-si-PTEN) and scrambled (LV-ssi-PTEN) 
as a control vector (MOI 10). MNs were harvested at day 5 post-transduction and 
protein extract was analysed using western blotting for pAkt expression. pAkt levels 
were normalized to total Akt. MNs transduced with LV-si-PTEN showed 
significantly increased pAkt expression. There were no significant differences 
between the pAkt levels in the untreated transgenic and non-transgenic MNs. These 
findings indicate that PTEN knockdown activates the PI3K/Akt pathway in MNs 
originating from SOD1 G93A transgenic and non-transgenic mice. Results represent 
the mean ± SEM from three independent experiments. *p < 0.05, tested by one-way 
ANOVA with Tukey’s post hoc-test. Abbreviations: GAPDH, Glyceraldehyde 3-
phosphate dehydrogenase, G93A, transgenic SOD1G93A motor neurons, kDa, kilo 
Daltons, LV-ssi-PTEN, lentiviral vector expressing scrambled-si-PTEN, LV-si-
PTEN, lentiviral vector expressing PTEN siRNA, MOI: multiplicity of infection, 
NTG, non-transgenic motor neurons, pAkt (473), phosphorylated Akt at Serine 473 
residue, SEM, standard error of mean. 
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The pro-apoptotic protein, BCL-2-antagonist of death (BAD) is inactive when 
phosphorylated at Serine-112 residue and Serine- 136 (Zha et al., 1996). PTEN 
knockdown was also associated with a significantly increased expression of the 
inactive phosphorylated form of BAD (pBAD) in motor neurons originating from 
non-transgenic and transgenic SOD1 mice (Figure 3.6). These findings correlated 
with elevated levels of pAkt and reduced PTEN levels. There was no significant 
difference between the total levels of pBAD in non-transduced motor neurons and 
motor neurons transduced with LV-ssi-PTEN. Moreover, there was no significant 
difference between the total levels of pBAD in transgenic and non-transgenic motor 
neurons, which provides more evidence that the PI3K/Akt signalling pathway is not 
activated in SOD1G93A at the early embryonic stage. Levels of  phosphorylated IKK, 
another downstream effector of Akt,  were too low to be quantified by western 
blotting (data not shown).  
 
 
 
 
 
 
 
 
 
                                                      122 
                               
                  
Figure 3.6 PTEN silencing in transgenic SOD1G93A and non-transgenic purified 
motor neurons leads to increased phosphorylation of BAD. Purified lumbar 
spinal cord motor neurons were transduced after 18-20 hours with Lentiviral vector 
expressing si-PTEN and scrambled (ssi)-PTEN as a control vector (MOI 10). MNs 
were harvested 5 days post-transduction and protein lysate was analysed with 
western blotting for pBAD levels. pBAD expression was normalized to total (non-
phosphorylated) BAD levels. MNs transduced with LV-si-PTEN showed a 
significant increase in pBAD expression. Results represent the mean ± SEM from 
three independent experiments (n=3).  **p<0.001, *p<0.05 tested by one-way 
ANOVA with Tukey’s post hoc-test test.  Abbreviations: BAD, Bcl-2-antagonist of 
death, GAPDH, Glyceraldehyde 3-phosphate dehydrogenase, G93A, transgenic 
SOD1G93A motor neurons, kDa, kilo Daltons, LV-ssi-PTEN, lentiviral vector 
expressing scrambled-si-PTEN, LV-si-PTEN, lentiviral vector expressing PTEN 
siRNA, MOI: multiplicity of infection, NTG, non-transgenic motor neurons, pBAD, 
phosphorylated BAD at serine 112 residue, SEM, standard error of mean. 
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3.3.5  Activation of the mTOR pathway following PTEN silencing 
Activated Akt leads to a cascade of events, which leads to the activation of the 
mammalian target of Rapamycin (mTOR), an essential regulator of protein synthesis 
in the soma and growing axons (Park et al., 2010, Liu et al., 2010). mTOR plays a 
crucial role in regulating protein synthesis in neuronal and non-neuronal cells 
(Wong, 2013). It is now well established that activation of mTOR by growth factors 
is mediated by activation of the PI3K/Akt pathway (Park et al., 2010).  
 
Studies in our lab have previously shown that PTEN silencing leads to activation of 
mTOR in wild type motor neurons (Ning et al., 2010). In the current study, the 
effect of lentiviral-mediated PTEN knockdown on the mTOR pathway was 
investigated in transgenic SOD1 motor neurons. Phosphorylated p70S6K at Thr389 
(phospho-p70S6K) was used as a marker for activation of the mTOR pathway. 
Immunocytochemistry demonstrated increased expression of phospho-p70S6K in 
transgenic SOD1 and non-transgenic motor neurons transduced with LV-si-PTEN 
compared with those transduced with LV-ssi-PTEN and non-transduced controls 
(Figure 3.7 A and B), suggesting that LV-mediated PTEN depletion activate the 
mTOR pathway. Attempts to quantify the levels of phospho-p70S6K in purified 
cultures of motor neurons by western blotting were unsuccessful because the levels 
of phospho-p70S6K were too low to be quantified (data not shown). As previously 
described in the material and methods section, motor neurons were extracted from 
each embryo and plated in separate wells, genotyped and then transduced with viral 
vectors the following day. Therefore, it was not possible to pool the protein 
extracted from the motor neuron cultures. Due to time restraints and limited 
availability of the viral vectors, quantification of phospho-p70S6K using 
immunocytochemistry was not possible.  
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Figure 3.7. Activation of the mTOR pathway following PTEN silencing. Primary 
motor neurons from non-transgenic (A) and transgenic SOD1G93A (B) embryos were 
cultured and transduced with either LV-si-PTEN or LV-ssi-PTEN 18-20 hours after 
plating. Motor neurons were stained with anti-Tubulin (red), phospho-p70S6K 
antibodies (green) and Hoechst for nuclear staining (blue). P70S6K is mainly 
localised to the cell body. Transduction of motor neurons with LV-si-PTEN leads to 
an increase in the intensity of phospho-p70S6K in the cell body and neural processes 
suggesting activation of the mTOR pathway following PTEN silencing (scale 
bar=20 µm). mTOR, mammalian target of rapamycin, phospho-p70S6K, 
phosphorylated p70S6K at Threonine-389.  
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3.3.6 The effect of lentiviral-mediated PTEN knockdown on the MAPK 
pathway in transgenic SOD1 motor neurons 
The mitogen-activated kinases (MAPK) are a family of protein kinases, which have 
a crucial role in cell proliferation and differentiation in response to several growth 
factors. In the CNS, MAPKs are involved with cell growth, neuronal plasticity and 
cell survival (Subramaniam and Unsicker, 2010). Extracellular signal-regulated 
kinases 1 and 2 (ERK 1/2) are among the most widely studied kinases. However, the 
exact role of ERK 1/2 in neuronal survival and death remains debatable 
(Subramaniam and Unsicker, 2010). PTEN is a negative regulator of the MAPK 
pathway (Weng et al., 2001b) and previous studies have shown that PTEN inhibition 
leads to activation and phosphorylation of ERK by mechanisms independent of the 
PI3K/Akt pathway (Chiu et al., 2005). PTEN dephosphorylates the adaptor proteins 
Sch and focal adhesion kinase, which is associated with inhibition of Ras and 
downstream inhibition of ER1/2 (Gu et al., 1999, Gu et al., 1998). 
 
In this study, the effects of PTEN silencing on the MAPK pathway were studied in 
SOD1G93A transgenic and non-transgenic motor neurons. Expression of activated 
(phosphorylated) ERK 1/2 (pERK 1/2) was determined using anti-pERK 1/2 
antibodies by western blot analysis and immunocytochemistry. Immunofluorescence 
staining showed that pERK 1/2 is predominantly expressed in the cell bodies of 
motor neurons (Figure 3.8 A and B). pERK 1/2 staining was noted to be weaker in 
non-transgenic motor neurons compared to the SOD1G93A motor neurons. Western 
blot analysis also showed a trend for increased expression of pERK1/2 in transgenic 
motor neurons compared to the non-transgenic ones, however this did not reach 
statistical significance. In addition, there was no significant difference between the 
pERK 1/2 level in non-transgenic and SOD1 motor neurons transduced with LV-si-
PTEN compared to the non-transduced motor neurons and those transduced with the 
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control vector (p>0.05, one-way ANOVA with Tukey’s post hoc-test, n=3) (Figure 
3.8 C), suggesting that PTEN depletion does not alter pERK 1/2 expression in motor 
neurons. These findings are consistent with Ning et al’s studies that showed no 
increase in pERK1/2 levels when PTEN levels were reduced in wild type motor 
neurons (Ning et al., 2010). Furthermore, pERK 1/2 expression was not significantly 
altered in the transduced motor neurons (transgenic and non-transgenic) when 
compared to the non-transduced cells. 
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Figure 3.8. Downstream effects of PTEN silencing on the MAPK pathway. 
Primary motor neurons from non-transgenic (A) and transgenic SOD1 G93A embryos 
(B) were cultured and transduced with Lentiviral vectors (LV-si-PTEN or LV-ssi-
PTEN) 18-20 hours after plating. Figures A and B show motor neurons immune-
stained with anti-Tubulin (red), anti-pERK1/2 antibodies (green) and Hoechst for 
nuclear staining (blue). pERK1/2 staining was predominantly observed in the cell 
bodies. There was no significant increase in pERK 1/2 staining in transduced motor 
neurons with LV-si-PTEN. (Scale bar =20 µm). (C) MNs were harvested at day 5 
post-transduction and protein lysate was analysed with western blotting for pERK 
1/2 levels, which were normalised to GAPDH. MNs transduced with LV-si-PTEN 
showed no significant difference in pERK 1/2 expression when compared to the 
non-transduced motor neurons  (p>0.05, one-way ANOVA with Tukey’s post hoc-
test, n=3). GAPDH was used as a loading control. pERK1/2, phosphorylated 
extracellular signal-regulated kinases 1 and 2, GAPDH, Glyceraldehyde 3-
phosphate dehydrogenase, G93A, transgenic SOD1G93A motor neurons, kDa, kilo 
Daltons, LV-ssi-PTEN, lentiviral vector expressing scrambled-si-PTEN, LV-si-
PTEN, lentiviral vector expressing PTEN siRNA, NTG, non-transgenic motor 
neurons. 
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3.4 Discussion  
The aim of this study was to investigate the effects of PTEN silencing on 
downstream signalling pathways and the survival of transgenic SOD1G93A motor 
neurons. Purified mouse motor neurons from transgenic SOD1G93A E13 embryos 
were used to model ALS in vitro and were transduced with lentiviral vectors 
expressing siRNA against mouse PTEN and the GFP reporter gene to determine the 
transduction efficiency. The results showed that the lentiviral vectors achieved an 
effective PTEN depletion in both transgenic and non-transgenic motor neurons. 
PTEN silencing was associated with activation of the PI3K/Akt pathway, which was 
evident by increased expression of pAkt and pBAD, and an increased motor neuron 
survival suggesting a neuroprotective effect of PTEN level reduction in transgenic 
and non-transgenic motor neurons.  
 
3.4.1 Localisation of PTEN in transgenic SOD1G93A motor neurons 
The distribution of PTEN in mutant SOD1 motor neurons was found to be 
predominantly localised to the cell body and tips of axons in a similar distribution to 
that of non-transgenic motor neurons, which suggests that mutant SOD1 does not 
alter the distribution of PTEN at the embryonic stage. It is important to note that 
triggers of neuronal apoptosis determine the distribution of PTEN within the cells. 
In fact, several studies suggest that PTEN is a dynamic protein and its sub-cellular 
distribution is strongly linked to the fate of neuronal cells. For instance, Lactacystin 
and ceramide-induced neuronal apoptosis is associated with increased levels of 
PTEN in the plasma membrane, suggesting that PTEN is recruited to its active site 
where it dephosphorylates PIP3 and antagonises PI3K and Akt (Cheung et al., 
2004c, Goswami et al., 2005, Choy et al., 2006b. PTEN was also found to 
accumulate in the mitochondria in close association with BCL-2 associated X 
protein, BAX, which is an essential apoptotic mediator {Zhu, 2006 #13, Zhu et al., 
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2006). The underlying mechanism remains unclear but indicates an association of 
PTEN with mitochondrial-induced apoptosis which is a well-known contributor to 
motor neuron degeneration in ALS (Carri et al., 2015). In addition, translocation of 
PTEN to the nucleus has been linked to excitotoxicity and traumatic brain injury 
(Howitt et al., 2012, Zhang et al., 2013, Goh et al., 2014); yet the study by Goh and 
Putz et al showed that in vivo PTEN translocates to the nucleus of surviving neurons 
in models of brain injury (Goh et al., 2014). Moreover, PTEN also localises to the 
endoplasmic reticulum in neuronal apoptosis (Kreis et al., 2014). The localisation of 
PTEN on axon tips is expected, as a large body of literature shows that PTEN plays 
an essential role in axonal growth and regeneration of central and peripheral neurons 
(Park et al., 2010, Christie and Zochodne, 2013). Indeed, Ning et al has previously 
reported a similar distribution of PTEN in transgenic SMA embryonic motor 
neurons and demonstrated that PTEN silencing enhances motor axonal growth in 
vitro (Ning et al., 2010). These findings suggest that at the early embryonic stage, 
PTEN distribution remains unchanged in diseased motor neurons including those 
expressing mutant SOD1G93A. Further studies are needed to determine whether 
PTEN co-localises with mutant SOD1 or whether it is re-distributed to particular 
subcellular compartments in the later stages of ALS, as this could provide clues to 
whether PTEN is closely associated with the motor neuron death.  
 
3.4.2 Lentiviral-mediated PTEN silencing effectively reduces PTEN 
expression in transgenic SOD1G93A motor neurons 
The effect of PTEN silencing was studied on purified cultures of mutant SOD1G93A 
or non-transgenic motor neurons and their non-transgenic littermates. To achieve our 
aim, lentiviral vectors expressing siRNA were produced in our laboratory for the 
stable knockdown of PTEN expression in motor neurons. Lentiviral system were 
chosen because previous studies in our laboratries have shown that these vectors 
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have the ability of transducing motor neurons with high efficiency and low toxicity 
and a 60% PTEN knockdown could be achieved using an MOI of 10 in non-
transgenic and mutant SMA motor neurons (Ning et al., 2010).  
 
In this study the motor neurons were transduced with LV-si-PTEN or LV-ssi-PTEN 
at an MOI of 10 leading to 66% and 65% knockdown of PTEN protein expression in 
non-transgenic and SOD1G93A motor neurons, respectively. There were no 
significant differences between the PTEN levels in the untreated transgenic and non-
transgenic cells, suggesting that at the embryonic stage mutant SOD1 has no effect 
on PTEN expression. Moreover, PTEN levels were unchanged in the motor neurons 
transduced with the control vector, LV-ssi-PTEN, indicating that the vectors do not 
alter PTEN expression and confirmed the specificity of our siRNA sequence (LV-si-
PTEN) targeted against the PTEN gene.  
 
3.4.3 Lentiviral-mediated PTEN silencing enhances motor neuron 
survival 
Lentiviral-mediated PTEN depletion was associated with a significant increase in 
both transgenic SOD1G93A and non-transgenic motor neuron  survival. These 
findings are consistent with Ning et al’s study which demonstrated enhanced 
survival of transgenic SMA motor neurons following lentiviral-mediated PTEN 
silencing (Ning et al., 2010). PTEN can also be inhibited by various substances such 
as peroxynitrite (Delgado-Esteban et al., 2007), oestrogen (Smith et al., 2009b) and 
bisperoxovanadium (Sury et al., 2011, Walker et al., 2012, Mao et al., 2013, Walker 
and Xu, 2014), which ultimately promote the survival of neurons in various models 
of neuronal damage and apoptosis. PTEN depletion also protects hippocampal cells 
from excitotoxic (Gary and Mattson, 2002) and ischaemic death (Ning et al., 2004). 
In addition, there is abundant evidence suggesting the neuroprotective role of PTEN 
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inhibition in murine models of cerebral ischemia (Zhao et al., 2006, Lai et al., 2014). 
Finally, conditional deletion of PTEN using the Cre-lox system rescues 
dopaminergic neurons from degeneration both in the embryonic stage (Diaz-Ruiz et 
al., 2009) and in adult mouse models of PD (Domanskyi et al., 2011). Taken 
together, the results of this study together with data from other studies shows that 
targeted PTEN depletion is a potential neuroprotective therapeutic strategy for 
neurodegenerative diseases. 
 
3.4.4 PTEN depletion activates the PI3K/Akt pathway in motor 
neurons 
To better understand the mechanism of lentiviral-mediated PTEN silencing on motor 
neuron survival, the expression of the main downstream effectors of the PI3K/Akt 
survival cascade was evaluated by immunocytochemistry and then quantified by 
western blotting in non-transgenic and transgenic SOD1G93A motor neurons. Akt is 
an essential component of the PI3K/Akt pathway and exists in three isoforms (Akt1, 
Akt2, and Akt3) (Nicholson and Anderson, 2002) of which Akt3 is highly expressed 
in the CNS (Yang et al., 2003). It mediates the trophic effects of various 
neurotrophins such as Nerve growth factor (NGF), insulin-growth factor (IGF-1) 
and Brain-derived growth factor (BDNF) (Brunet et al., 2001). Binding of the 
neurotrophins to tyrosine kinase receptors activates PI3K, which generates PIP3 and 
leads to recruitment of Akt to the plasma membrane. This results in phosphorylation 
and activation of Akt, which then acts directly or indirectly on several substrates to 
promote neuronal survival (Brunet et al., 2001). Moreover, a wealth of evidence 
exists for the role of the PI3K/Akt pathway in axonal regeneration (Read and 
Gorman, 2009). In the present study, western blot analysis showed that PTEN 
silencing was associated with a significant increase in the expression of pAkt in both 
the mutant SOD1G93A and non-transgenic motor neurons. Immunocytochemistry also 
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demonstrated an increase in the expression of pAkt in the motor neurons transduced 
with LV-si-PTEN. There was no significant difference between the levels of pAkt in 
the untreated mutant SOD1G93A motor neurons, the untreated non-transgenic motor 
neurons, and cells transduced with LV-ssi-PTEN, indicating that the viral vectors 
did not interfere with the signalling pathway, and the increase in pAkt levels was a 
result of PTEN silencing. These results also suggest that G93A mutations in the 
SOD1 protein do not affect the expression of pAkt in embryonic motor neurons. In 
line with these observations, Ning et al reported activation of Akt following PTEN 
silencing in mutant SMA motor neurons, which was associated with increased motor 
neuronal survival (Ning et al., 2010). These results suggest that the PI3K/Akt 
pathway is preserved in the early embryonic stages of diseased motor neurons.   
 
The expression of essential downstream effectors of Akt that mediate its pro-
survival effect was determined by western blotting. One of the mechanisms by 
which Akt exerts its anti-apoptotic effect is by inhibiting the pro-apoptotic protein 
BAD. The pro-apoptotic proteins BAX and BAD play a crucial role in 
mitochondrial dependant apoptosis. In the dephosphorylated form, BAD interacts 
with anti-apoptotic protein BCL-2, allowing BAX to induce apoptosis, whereas 
phosphorylation of BAD at serine 155 releases BCL-2 which then promotes cell 
survival (Brunet et al., 2001). In this study, the motor neurons with lowered levels of 
PTEN protein showed increased expression of the inactive and phosphorylated form 
of BAD (pBAD-serine 155) which correlated with increased expression of pAkt. 
There was no significant difference in the levels of pBAD in the mutant and non-
transgenic motor neurons. In addition, pBAD levels were similar in the cells 
transduced with LV-ssi-PTEN and untransduced controls, which provide more 
evidence that transduction with the viral vectors, did not affect the PI3K/Akt 
pathway. IKK is another member of the PI3K/Akt pathway, which is implicated in 
motor neuron survival (Ning et al., 2010). It is expected that activation of Akt 
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following PTEN silencing would result in increased levels of the phosphorylated 
form of IKK (pIKK, active form). Unfortunately, the levels of pIKK were 
undetectable with western blotting and hence it was not possible to determine 
whether IKK mediated the effect of PTEN knockdown on the survival of mutant 
SOD1 motor neurons.  
 
Although the expression of PTEN, pAkt and pBAD is unchanged in the embryonic 
stage of the SOD1 mouse ALS model, it is intriguing to know whether PTEN is 
directly involved with the life or death decision of a motor neuron. An important 
question, is do PTEN levels rise prior to the death of a motor neuron or decrease as a 
compensatory survival mechanism? Early studies in models of neuronal apoptosis 
have shown that expression of PTEN does not necessarily correlate with apoptosis. 
For example, in neuroblastoma-2a (Neuro-2a) cell cultures, serum withdrawal was 
associated with a reduction in PTEN mRNA expression, whereas okadeic acid and 
etopside had minimal effect on PTEN mRNA expression and no change in PTEN 
protein levels was observed (Kyrylenko et al., 1999). In cerebellar granule cell 
cultures, potassium withdrawal alone did not alter PTEN expression levels whereas 
when combined with serum withdrawal PTEN mRNA expression was reduced 
(Kyrylenko et al., 1999). Similarly etopside had no effect on PTEN expression. On 
the other hand, okadeic acid led to an initial transient increase in PTEN mRNA 
expression followed by reduced PTEN levels; and in hippocampal cells undergoing 
STS induced cell damage, PTEN levels were unaltered (Zhu et al., 2006). It is clear 
from these observations that PTEN expression is tightly regulated and varies 
according to the apoptotic inducer and to the neuronal cell type. Despite these 
observations, gene profile studies by Kirby et al found that in human mutant SOD1 
spinal cord motor neurons, there is increased expression of Akt3 and PI3K genes in 
association with decreased expression of PTEN genes (Kirby et al., 2011f). As Akt3 
was found to be neuroprotective in SOD1 models (Peviani et al., 2014), it is most 
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likely that activation of the PI3K/Akt pathway in the late stages of the disease is a 
compensatory mechanism in the surviving neurons rather than a cause of cell death.  
 
The findings of this study provides evidence that activation of the pro-survival 
PI3K/Akt signalling cascade by PTEN silencing leads to an increased survival of 
non-transgenic and SOD1G93A motor neurons. Lentiviral-mediated PTEN depletion 
also enhances the survival of mutant SMA motor neurons in vitro (Ning et al., 
2010). Evidence from previous reports indicated that activation of the PI3K/Akt 
signalling cascade promotes motor neuron survival in experimental models of ALS. 
For example, vascular endothelial factor (VEGF) was found to protect motor 
neurons from glutamate excitotoxic cell death (Tovar and Tapia, 2010) and serum 
withdrawal induced apoptosis (Tolosa et al., 2009) by activating the PI3K/Akt 
pathway. In addition, VEGF treatment protected NSC34 cells (Li et al., 2003) and 
rat spinal cord motor neurons from G93A SOD1- induced toxicity via PI3K/Akt 
activation (Dewil et al., 2007a). Transgenic SOD1 mice receiving intrathecal 
injections of IGF-1 developed increased expression of pAkt and ERK in the spinal 
cord motor neurons and showed a delayed onset of disease and prolonged survival 
(Manabe et al., 2002a). Similarly, angiogenin-mediated motor neuron survival was 
reported in experimental models of SOD1G93A ALS both in vitro and in vivo and was 
associated with activation of the Akt pathway (Kieran et al., 2008). Moreover, other 
compounds activating PI3K and Akt such as epigallocatechin act via Akt signalling 
to enhance SOD1 motor neuron survival in vitro (Koh et al., 2004) and delays the 
onset of symptoms and prolongs the survival of SOD1 mouse models (Koh et al., 
2004, Xu et al., 2006). Finally, a recent study by Peviani and colleagues 
demonstrated that expression of constitutively active Akt3 in transgenic SOD1 
motor neurons as well as transgenic SOD1 mice was neuroprotective (Peviani et al., 
2014). Therefore, the literature supports our evidence that the PI3K/Akt pathway is 
an essential mediator of motor neuron survival. Hence, PTEN silencing could be a 
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potential therapeutic target for rescuing motor neuron degeneration in 
neurodegenerative disorders such as ALS.  
 
3.4.5 The effect of PTEN silencing on the mTOR pathway in motor 
neurons 
The mammalian target of Rapamycin, mTOR, is a key downstream effector of the 
Akt signalling pathway, which has an essential role in protein synthesis and cell 
growth. In the nervous system, mTOR activity plays a pivotal role in  
autophagy (Wong, 2013) and axonal growth and regeneration (Park et al., 2010, 
Yang and Yang, 2012).  
 
Cytoplasmic proteins are degraded and cleared by either the ubiquitin-proteasome 
pathway or by autophagy. There are several types of autophagy, of which macro-
autophagy (here referred to as autophagy) is the most widely studied (Maiese et al., 
2012). The mTOR pathway is a negative regulator of the autophagy system and 
Rapamycin, a potent inhibitor of mTOR, enhances autophagy (Maiese et al., 2012). 
Accumulating evidence on the role of autophagy in neurodegenerative disorders has 
focused attention on mTOR as a potential therapeutic target for diseases such as 
Huntington’s disease (HD), Alzheimer’s disease (ALZ) and ALS. Increased 
autophagosome formation has been found in experimental models of ALS 
(Morimoto et al., 2007), which has led to several theories implicating its role in the 
clearance of protein aggregates within motor neurons or the possibility of defective 
clearance of autophagosomes. Hence, whether enhanced autophagy is a 
compensatory mechanism or an effect of the disease remains controversial. 
Increased autophagy in association with increased phosphorylation of p70S6 was 
found in transgenic SOD1 mice (Carunchio et al., 2010). Studies in models of ALS 
showed that enhancing autophagy by Rapamycin was neuroprotective and reduced 
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aggregation of SOD1 in motor neurons. Similar results were found in experimental 
models of TDP-43 proteinopathies (Wang et al., 2013a). In addition, Rapamycin 
was reported as neuroprotective in experimental models of HD (Floto et al., 2007).  
 
Contrary to these studies, a recent report by Zhang et al showed that Rapamycin 
accelerated motor neuron degeneration in rodent models of ALS and did not reduce 
the levels of aggravated SOD1 (Zhang et al., 2011). These studies suggest a complex 
regulation of autophagy by the mTOR pathway and possible other mTOR-
independent pathways mediating the effects of Rapamycin in ALS.  
 
In addition to autophagy, a large body of evidence suggests that mTOR mediates the 
effects of PTEN inhibition on axonal growth and regeneration (Park et al., 2008). In 
our laboratory, the effect of PTEN depletion on mTOR activity has been 
demonstrated in experimental models of SMA and wild type mice (Ning et al., 
2010). PTEN depletion was associated with an increase in cone size and axonal 
length in wild type and SMN-deficient motor neurons. Rapamycin reversed these 
effects, suggesting that activation of the mTOR pathway is essential for axonal 
growth in healthy and diseased motor neurons. Of note, Rapamycin did not reverse 
the effect of PTEN depletion on motor neuron survival, indicating its predominant 
role in axonal growth (Ning et al., 2010).  
 
In this study the activity of mTOR was studied in SOD1G93A and non-transgenic 
motor neurons transduced with LV-si-PTEN and compared with motor neurons 
transduced with LV-ssi-PTEN and untreated cells. The phosphorylated form of 
p70S6K was used as a marker for the activity of mTOR (phospho-p70S6K). 
Immunocytochemistry demonstrated a similar expression of phospho-p70S6K in 
untreated motor neurons and those transduced with LV-ssi-PTEN vector indicating 
that addition of the viral vectors did not alter the expression of the mTOR 
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downstream effectors. Similarly, the expression of phospho-p70S6K was similar in 
the mutant and non-transgenic motor neurons suggesting that SOD1 has no effect on 
the mTOR at the early embryonic stage. However, an increased intensity of 
phospho-p70S6K staining was observed in motor neurons transduced with LV-si-
PTEN indicating activation of mTOR. Unfortunately, the levels of phospho-p70S6K 
were too low to be quantified by western blotting and due to time restrictions and 
availability of the viral vectors; quantification using immunocytochemistry was not 
possible. Activation of the mTOR signalling cascade following PTEN silencing was 
implicated in abnormal neuronal morphology (Kwon et al., 2003), however there 
were no obvious morphological changes observed in the motor neurons transduced 
with LV-si-PTEN.  
 
3.4.6 The effect of PTEN silencing on the MAPK pathway in motor 
neurons 
The mitogen-activated protein kinases, MAPK, are a family of serine/threonine 
kinases which regulate various cellular activities including survival and apoptosis. 
The extracellular-regulated kinases, ERK 1 and ERK2, are members of the MAPK 
family and have been implicated in regulating neuronal survival; however, their 
exact role is a matter of debate (Subramaniam and Unsicker, 2010). Initially, it was 
accepted that activation of ERK 1/2 promotes neuronal survival and axonal 
regeneration, however an increasing number of studies have contradicted this fact 
and showed that activation of ERK 1/2 is also associated with neuronal death 
(Subramaniam and Unsicker, 2010). Some authors suggest that several factors 
determine the fate of neuronal cells in response to ERK1/2 activation which 
includes: neuronal cell type, the apoptotic stimuli and the duration and magnitude of 
ERK activation (Subramaniam and Unsicker, 2010). Recently, Parker and 
colleagues found that activated ERK1/2 is closely associated with TDP43 aggregates 
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in experimental models of ALS; the authors implicate a role for the ERK signalling 
pathways in TDP43 homeostasis (Aschauer et al., 2013, Parker et al., 2012). 
 
A large body of evidence exists suggesting cross talk between the PI3K/Akt 
pathway and the ERK pathway. PTEN is known to inhibit ERK 1/2 independently of 
the PI3K/Akt pathway (Ong et al., 2001, Weng et al., 2001a). The effect of PTEN 
knockdown on ERK 1/2 was investigated in transgenic SOD1 and non-transgenic 
motor neurons in the present study. Immunocytochemistry showed increased 
staining for  pERK 1/2 in SOD1G93A motor neurons compared to the non-transgenic 
ones. Although quantification using western blot analysis showed a trend of 
increased expression of pERK 1/2 in the transgenic motor neurons, there was no 
significant difference in pERK 1/2 expression between the two groups. In addition, 
no significant differences were found between the levels of pERK1/2 in non-
transduced motor neurons and those transduced with either LV-ssi-PTEN or LV-si-
PTEN vectors. These findings are consistent with the results of Ning et al (Ning et 
al., 2010) and suggests that lentiviral-mediated PTEN silencing does not alter the 
expression of pERK 1/2 in motor neurons.  
 
3.5 Conclusion 
The findings of this study showed that lentiviral mediated PTEN silencing enhances 
the survival of transgenic SOD1G93A and non-transgenic motor neurons in vitro by 
activating  the PI3K/Akt survival pathway. These results suggest that PTEN 
depletion could be a novel neuroprotective therapeutic strategy for preventing motor 
neuron loss in ALS.  
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4. The effect of AAV-mediated PTEN silencing on motor 
neuron survival in vivo 
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4.1   Introduction 
 
The in vitro studies in the previous chapter showed that PTEN silencing prolongs 
the survival of transgenic SOD1G93A and non-transgenic cultured motor neurons. 
Similarly, other studies in our laboratory have demonstrated that PTEN inhibition 
promotes the survival of transgenic Smn-deficient motor neurons both in vitro and 
in vivo (Ning et al., 2010, Little et al., 2015). These promising data indicate that 
PTEN modulation could be a novel therapeutic strategy that may prevent motor 
neuron loss in motor neuron diseases. Therefore, it was hypothesised that PTEN 
silencing may prevent spinal cord motor neuron loss in an ALS mouse model. 
 
To date, the lack of effective treatments available for ALS patients could be 
attributed to its complex pathogenic mechanisms. Extensive research has identified 
several potential therapeutic agents that have been proven to promote motor neuron 
survival in vitro but the same effect could not be reproduced in animal models of 
ALS (Benatar, 2007). This could be partly be due to the fact that in vitro 
experiments are performed in controlled conditions that may not recapitulate the in 
vivo environment, and partly due to the loss of the complex interactions between the 
cells of the nervous system. The lack of effective therapy delivery systems could 
also account for difficulties in translation of these strategies in vivo. Since animal 
models resemble human disease more closely, they provide an essential tool for 
testing novel therapeutic strategies not only for their efficacy but also to test their 
safety before they can be taken further to the clinic.  
 
The blood brain barrier (BBB) constitutes a major obstacle for many compounds, 
and one of the major challenges in ALS research is to identify a safe route for the 
delivery of potential therapeutic compounds to a sufficient number of motor neurons 
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in the brain and spinal cord, a site which is difficult to access. Gene therapy has thus 
gained attraction as a means for gene therapeutic delivery in ALS models and in the 
last decade has been a main focus of research in ALS studies. Through a simple 
intramuscular (i.m) injection, some viral vectors can be taken up by nerve terminals 
and transported in a retrograde manner along the axons to the soma of motor 
neurons in the spinal cords (Hollis et al., 2008, Towne et al., 2010, Towne et al., 
2011). This strategy has the advantage of delivering a transgene both to the injected 
muscles and to a specific motor neuron pool located distally from the injection sites 
(Figure 4.1) and hence can provide useful information for non-invasive proof-of-
principle studies. This section describes the in vivo studies conducted to test whether 
PTEN silencing would prolong motor neuron survival in the transgenic SOD1G93A 
mouse model of ALS.  
 
                            
 
Figure 4.1. Retrograde transport of viral particles. Viral particles delivered 
intramuscularly can be taken up by the nerve terminals and transported along the 
motor neuron axons to the cell bodies located in the ventral horn of the spinal cord. 
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4.1.1 The transgenic SOD1 mouse model 
The breakthrough discovery of mutations in the SOD1 gene (Rosen et al., 1993) not 
only identified the causative gene in a subset of familial ALS patients but has also 
led to the generation of transgenic rodent models, which has contributed immensely 
to our understanding of ALS pathogenesis (Gurney et al., 1994). The first transgenic 
mouse model was reported by Gurney et al. in 1994 and was called the “Gurney” 
mouse (Gurney et al., 1994). These mice were genetically engineered to express 
mutant human SOD1 with glycine to alanine substitution (G93A) and they 
resembled the pathological and clinical phenotype of human ALS. They initially 
develop hind limb tremors, followed by progressive muscle weakness and wasting 
leading to early death. Studies have shown that in these mice, NMJ denervation 
occurs prior to the onset of symptoms leading to axonal degeneration and motor 
neuron death (Fischer et al., 2004). Degeneration of motor neurons is not only 
confined to the spinal cord, but also affects the brain and brainstem as well as other 
areas such as the substantia nigra in the late stages of the disease (Angenstein et al., 
2004, Zang et al., 2004).   
 
Motor neuron loss is associated with microgliosis and astrocytosis in the spinal cord 
that develop after the onset of symptoms (Hall et al., 1998). Other pathological 
features found in the affected motor neurons include, mitochondrial vacuoles and 
degeneration (Dal Canto and Gurney, 1994), Golgi fragmentation (Mourelatos et al., 
1996), accumulation of ubiquitin and SOD1 cytoplasmic aggregates (Johnston et al., 
2000) as well as the formation of aberrant neurofilament inclusions (Tu et al., 1996). 
 
Several transgenic mice expressing other mutations in SOD1 such as G85R (Bruijn 
et al., 1998), G37R (Wong et al., 1995), G127X (Jonsson et al., 2006), D90A 
(Jonsson et al., 2006) and H46R (Sasaki et al., 2007) mutations were generated to 
model familial ALS. All these mice showed motor neuron degeneration similar to 
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human ALS, although they differed in disease onset and progression. However, 
because the SOD1G93A mouse model was the first transgenic mouse produced to 
model ALS, it was extensively studied and well characterised and became one of the 
most widely used rodent models in ALS research.  
 
In the study described in this chapter, the congenic line of SOD1G93A mice was used. 
These mice are produced by backcrossing the hybrid line to C56BL/6J mice for 
more than 10 generations and are referred to as B6.Cg-Tg (SOD1*G93A) 1Gur/J. 
This generates transgenic mice in a uniform background such that all mice within a 
strain are genetically identical. These mice were maintained by breeding 
hemizygous transgenic males to wild type C57BL/6J females. The congenic line 
was chosen for the in vivo studies because there are minimal genetic and phenotype 
variations between individual mice, which enhances the reproducibility of data and 
fewer animals are needed for in vivo studies (Mead et al., 2011). Generally speaking, 
a disadvantage of congenic mice is that they tend to be sensitive to environmental 
stresses (Olsson and Dahlborn, 2002), nonetheless, the C57BL/6J congenic line used 
in ALS research shows small variations in a number of readouts including disease 
onset, survival, weight and motor function and offers a reliable model for pre-
clinical drug screening (Mead et al., 2011). 
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4.1.2 AAV vectors for in vivo gene delivery  
 
4.1.2.1 AAV serotype 6 
The AAV6 virus was first discovered as a contaminant of a laboratory AAV5 viral 
stock (Rutledge et al., 1998, Halbert et al., 2000). Sequence analysis showed that 
AAV6 was almost identical to AAV1 and although it shares some sequence 
homology with AAV2, it is capable of transducing cells in the presence of anti-
AAV2 serum. Similar to AAV2, AAV6 interacts with heparan sulfate proteoglycans 
for cell binding and internalization. AAV6 vectors have a wide host tropism and in 
particular they transduce liver (Grimm et al., 2003), skeletal muscles (Chao et al., 
2000, Blankinship et al., 2004) and motor neurons with high efficiency (Towne et 
al., 2008). In addition, they exhibit a relatively rapid onset of transgene expression, 
which peaks in approximately 4 weeks following transduction of skeletal muscles 
and spinal cord motor neurons (Towne et al., 2010). One of the characteristic 
features of AAV6 is its ability to be transported in a retrograde manner, and several 
studies have shown that with a simple i.m. injection, AAV6 can effectively deliver 
shRNA to lumbar spinal cord motor neurons (Towne et al., 2011, Ning et al., 2010).  
 
4.1.2.2 AAV serotype 9 
AAV9 vectors have gained popularity for delivering transgenes to the CNS due to 
their unique biological features that allow it to cross the BBB, in addition to their 
ability to transduce skeletal muscles, neuronal cells and astrocytes with high 
efficiency (Foust et al., 2009, Benkhelifa-Ziyyat et al., 2013, Katwal et al., 2013). 
AAV9 is capable of infecting cells by binding to a galactose receptor and it has been 
shown that desialation (enzymatic removal of silaic acid) of its receptors enhances 
its transduction efficiency (Bell et al., 2011, Bell et al., 2012). Systemic 
administration of AAV9 via intravenous injections results in robust transduction of 
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neurons in the brain and spinal cord in neonatal (Foust et al., 2009) and adult mice 
(Gray et al., 2011a) as well as in non-human primates (Samaranch et al., 2012). 
Benkhelifa-Ziyyat et al. have shown that after a single i.m. injection AAV9 is also 
capable of retrograde transport with widespread transduction of spinal motor 
neurons (Benkhelifa-Ziyyat et al., 2013), although a previous study had not found 
effective retrograde transport of AAV9 (Foust et al., 2009). Moreover, intracisternal 
injections of AAV9 can result in high levels of gene expression throughout the brain 
and spinal cord in non-human primates (Hinderer et al., 2014). 
 
4.2 Aims of the study 
 
The aim of this study was to evaluate the potential neuroprotective role of PTEN 
inhibition in transgenic SOD1G93A motor neurons in vivo. It was hypothesised that 
PTEN silencing may enhance motor neuron survival in vivo. To test the 
neuroprotective effect of PTEN knockdown, two AAV-based vectors were used, 
AAV6 and scAAV9, to deliver siRNA against mouse PTEN to the hind limb 
muscles and spinal cord via intramuscular injections. Wild-type (WT) mice were 
used to test the transduction efficiency of both vectors for spinal motor neurons and 
their ability to knock down PTEN in both muscles and motor neurons. AAV9 
vectors were used for PTEN silencing in the mutant mice.  
 
The aims of the study are summarised as follows: 
1. To validate the efficiency of scAAV9-mediated PTEN knockdown in vitro. 
2. To determine the efficiency of AAV6-si-PTEN and AAV9-si-PTEN to knock down  
PTEN expression in skeletal muscles of WT mice.  
3. To evaluate the transduction efficiency of AAV6-si-PTEN and AAV9-si-PTEN in 
spinal cord motor neurons of WT mice. 
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4. To investigate whether AAV9-mediated PTEN silencing prevents spinal cord motor 
neuron loss in transgenic SOD1G93A mice after i.m injections 
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4.3  Results 
 
4.3.1  In vitro validation of AAV9-mediated PTEN knockdown 
AAV viral vectors are known to transduce neurons in vivo with high efficiency and 
low toxicity (Weinberg et al., 2013). However, there are few studies exploring the 
use of scAAV9 for gene delivery to the CNS via retrograde transport in the 
SOD1G93A mouse model. In this project, AAV9 was utilised to deliver siRNA to 
knockdown mouse PTEN in skeletal muscles and lumbar spinal cord motor neurons. 
Prior to its use for the in vivo studies, the efficiency of the scAAV9-si-PTEN vector 
to reduce the levels of PTEN expression was initially verified in vitro. Two doses 
(MOI 1.5x105 and 3.5x105 ) of either scAAV9-ssi-PTEN or scAAV9-si-PTEN 
vectors were added to purified SOD1G93A motor neuron cultures 18-20h after plating 
(n=2 per vector). These doses were chosen according to previous studies that 
characterised the toxicity and tropism of AAV9 vectors among other AAV 
serotypes, in primary neuronal cultures (Howard et al., 2008). Expression of GFP 
fluorescence was seen in motor neurons at day 3 post-transduction and up to the day 
the cells were harvested at day 5 post-transduction. GFP expression in motor 
neurons was visualised by live imaging using the In Cell analyser (Figure 4.2) 
before the cells were harvested for western blotting. Motor neurons transduced with 
the higher dose of the vector (3.5x105 vg/cell) showed a 40% reduction of PTEN 
expression compared to those transduced with the control vector and the untreated 
motor neurons, whereas only 20% PTEN depletion was achieved with the lower 
dose (MOI 1.5x103) (Figure 4.3). AAV9-mediated PTEN protein reduction in vitro 
was less efficient than that achieved with lentiviral vectors, most likely due to the 
slower expression of the AAV vectors in vitro. PTEN levels were similar in the non-
transduced motor neurons and those transduced with scAAV9-ssi-PTEN indicating 
                                                      149 
that the PTEN knockdown was the result of a specific effect of the scAAV9-si-
PTEN vector. AAV9-mediated PTEN silencing was further validated in vivo 
(Chapter 4). 
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Figure 4.2. Transduction of SOD1G93A motor neurons with scAAV9- ssi and si-
PTEN. Purified motor neurons prepared from E13 transgenic SOD1G93A and non-
transgenic embryos were plated in 12 well plates at a density of 200,000 cells per 
well. The motor neurons were transduced with two concentrations of scAAV9-ssi- 
and si-PTEN (MOI 1.5X105 and 3.5x105 for each vector) after 18-20h of plating 
(Figure A and B). GFP expression was detected at 72 hours post-transduction. Live 
images were captured using the In CELL analyser at day 5 post-transduction prior to 
harvesting the motor neurons (20x magnification, scale bar=100µm). (N=2 for each 
MOI).  
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Figure 4.3. Dose transduction response of scAAV9 mediated PTEN knockdown 
in purified motor neurons. Purified motor neurons were transduced with scAAV9-
ssi-PTEN and AAV9-si-PTEN using two MOIs (1.5x105 and 3.5x105) 18-20h after 
plating and motor neurons were harvested 5 days post-transduction. Protein lysate 
was analyzed by western blot using anti-PTEN antibodies to determine PTEN 
expression. PTEN levels were normalized to GAPDH, which was used as a loading 
control. Representative western blot shows analysis shows that PTEN expression 
was reduced by 40% with scAAV9-si-PTEN at an MOI of 3.5x10^5 (N=2).  
 
 
4.3.2 Validation of AAV6-mediated PTEN silencing in wild-type mice 
To determine whether AAV6 is capable of delivering PTEN siRNA effectively to 
skeletal muscles and spinal cord motor neurons, AAV6-based vectors were 
generated to express either PTEN siRNA (AAV6-si-PTEN) or scrambled PTEN 
siRNA (AAV6-ssi-PTEN) driven by the H1 promoter, and the GFP reporter gene 
under the CMV promoter. Wild-type C57BL/6 mice, recruited to two groups, 
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received unilateral administration of either AAV6-si-PTEN or AAV6-ssi-PTEN 
(control vector) into the left gastrocnemius muscle (GA) (2 x1010 vg in a total of 
20µl per injected muscle) at 4 weeks of age (n=3 per group). A third group of age-
matched C57BL/6 mice received injections of 20µl PBS into the left GA muscle 
(n=3). Three weeks later, the mice were sacrificed and both the left (injected) and 
right (uninfected) GA muscles and lumbar spinal cords were examined for GFP and 
PTEN expression.  
 
4.3.2.1  AAV6-mediated PTEN silencing in the hind-limb muscles of 
adult wild –type mice 
To assess the efficiency of AAV6-mediated PTEN silencing, we first analysed 
protein extracts from the GA muscles by western blotting. As expected, GFP 
expression was detected in the muscles injected with the viral vectors, indicating 
effective transduction of the injected muscles; whereas those muscles injected with 
PBS showed no evidence of GFP expression (Figure 4.4A). PTEN levels were 
normalised to GAPDH (loading control) and expressed as folds of PTEN levels in 
mice treated with PBS (control group). As shown in Figure 4.4B, AAV6-si-PTEN 
achieved a significant 48.7% reduction in PTEN expression compared with PBS 
injection (p<0.05, one-way ANOVA with Tukey’s post-test, n=3), whereas no 
significant difference was found between PTEN levels in muscles injected with 
AAV6-ssi-PTEN, and those injected with PBS, suggesting that PTEN silencing was 
specific to AAV6-si-PTEN.  
 
To investigate whether PTEN silencing activates the PI3K/Akt signalling pathway 
in skeletal muscles, the expression of phosphorylated Akt (pAkt Ser473) was 
quantified in the injected GA muscles and expressed as folds of pAkt levels in mice 
injected with PBS (control group). Figure 4.4C demonstrate that PTEN depletion 
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was associated with a significant increase (~62%) in pAkt (Ser473) expression 
indicating activation of the PI3K/Akt pathway (p<0.05 AAV6-si-PTEN vs. PBS, 
one-way ANOVA with Tukey’s post-test, n=3). There was no significant difference 
between the levels of pAkt in the muscles injected with PBS and the control vector 
AAV6-ssi-PTEN (Figure 4.4C). Western blot analysis of protein extracts from the 
contralateral GA (right) showed no evidence of GFP expression suggesting that 
there was no significant systemic spread of the vectors following i.m. administration 
(Figure 4.5). 
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Figure 4.4. AAV6-mediated PTEN silencing in the gastrocnemius muscle of 
wild-type C57BL/6 mice. Four-week-old mice were injected with AAV6-si-PTEN, 
AAV6-ssi-PTEN (2 x1010 vg in a total of 20µl) or PBS into the left GA muscle. The 
mice were sacrificed 3 weeks later and muscle protein extracts were analysed by 
western blotting. (A) Representative western blots shows reduced expression of 
PTEN in muscles injected with AAV6-si-PTEN and GFP expression in the injected 
muscles. (B) PTEN levels were normalised to GAPDH (loading control) and 
expressed as PTEN folds relative to PTEN levels in mice injected with PBS. PTEN 
expression was significantly reduced in muscles injected with AAV6-si-PTEN 
(*P<0.05, one-way ANOVA with Tukey’s post-test) compared to those injected 
with PBS or the control vector. No significant difference was found between PTEN 
levels in muscles injected with control vector or PBS. (C) pAkt levels were 
normalised to GAPDH (loading control) and expressed as folds relative to levels in 
mice injected with PBS (control group). Levels of pAkt (Ser473) were significantly 
increased in muscles injected with AAV6-si-PTEN (*P<0.05, one-way ANOVA 
with Tukey’s post-hoc test). No significant difference was found between pAkt 
levels in muscles injected with the control vector or PBS. Data represent means, 
error bars=SEM. AAV6-si, adeno-associated virus serotype 6 expressing PTEN 
siRNA; AAV6-ssi, adeno-associated virus serotype 6 expressing scrambled PTEN 
siRNA; GA, gastrocnemius; GAPDH, glyceraldehyde 3-phosphate dehydrogenase; 
GFP, green fluorescent protein; pAkt, phosphorylated Akt; PBS, phosphatase 
buffered saline, SEM, standard error of means; vg, vector genome.  
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Figure 4.5 Representative western blot of the right (contralateral) gastrocnemius 
muscle showing lack of GFP expression in the mice injected with either AAV6-si-
PTEN or AAV6-ssi-PTEN, indicating no systemic spread of the AAV vectors (n=3).  
 
 
 
4.3.2.2  Spinal cord transduction by AAV6 vectors in wild-type mice 
We next investigated the efficiency of the AAV6 vectors in transducing lumbar 
spinal cord motor neurons after i.m vector delivery in mice (n=3 per group). One in 
5 sections of the lumbar spinal cord (total of 12-14 slides per animal) were analysed 
by co-localising GFP fluorescence with CGRP, a marker for motor neurons (Figure 
4.6). Despite effective PTEN knockdown in the injected GA muscles, co-
localisation of GFP and CGRP was not readily observed (<10 MNs per mouse) 
suggesting marginal transduction efficiency of lumbar spinal cord motor neuron. 
These findings suggest inefficient axonal retrograde transport of AAV6 to motor 
neurons after i.m delivery in adult wild-type mice.  
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Figure 4.6. AAV6-mediated transduction of spinal cord motor neurons in adult 
wild type mice. Representative images showing transverse sections of the lumbar 
spinal cord analysed by double-immunofluorescence (GFP-positive motor neurons 
in green, CGRP-positive motor neurons in red, Hoechst nuclear stain in blue). Co-
localisation of GFP and CGRP indicates motor neuron transduction. 40x 
magnification, Scale bars=50µm. CGRP, calcitonin gene-related peptide, GFP, 
green fluorescent protein.  
 
 
 
4.3.2.3  AAV6-mediated PTEN silencing in spinal cord motor 
neurons of wild-type mice 
The efficiency of AAV6-mediated PTEN silencing was examined in the transduced 
motor neurons. Transverse sections of the spinal cord (1 in 5) were stained with anti-
PTEN and anti-GFP antibodies and motor neurons were identified by their typical 
morphology and localisation in the ventral horn of the lumbar spinal cord. As shown 
in Figure 4.7, there was no clear difference in PTEN staining in GFP-positive motor 
neurons when compared to the non-transduced cells. PTEN expression was not 
quantified due to the scarcity of transduced spinal motor neurons. These findings 
suggest inefficient PTEN depletion by AAV6-si-PTEN, which is most likely due 
low efficiency of vector delivery via retrograde transport. 
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Figure 4.7 AAV6-mediated PTEN silencing in murine spinal cord motor 
neurons. Representative images of transverse sections of the lumbar spinal cord 
collected from WT mice injected with PBS or scAAV6-si-PTEN. Double 
immunofluorescence shows co-localisation of GFP and PTEN in mice injected with 
scAAV6-si-PTEN (white arrows). Motor neurons were identified by their 
morphology and location. PTEN expression was detected predominantly in the 
cytoplasm of motor neurons. No clear difference was observed in PTEN staining 
between transduced and non-transduced cells. (GFP-positive motor neurons=green, 
PTEN-positive cells = red, Hoechst nuclear stain=blue). 20x magnification, Scale 
bar=100µm.  
 
 
 
4.3.3 Validation of AAV9-mediated PTEN silencing in wild-type mice 
 
4.3.3.1 AAV9-mediated PTEN silencing in the hind-limb muscles of 
adult wild-type mice 
Following the marginal transduction efficiency observed with AAV6 vectors, an 
alternative vector system was explored to improve retrograde transport following 
i.m delivery. To evaluate whether AAV9-mediated PTEN silencing effectively 
reduces the expression of muscle PTEN, WT C57BL/6 mice received unilateral 
injections of either scAAV9-si-PTEN or the control vector scAAV9-ssi-PTEN into 
the left GA muscle (2x1010 viral genomes in 20µl per injected muscle) at 4 weeks of 
age (n=3 per treatment group). Another group of age-matched WT mice received 
PBS injections into the left GA (20µl) to account for any injection-related effects 
  PBS 
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     PTEN 
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(n=3). The mice were sacrificed 3 weeks post-gene transfer and protein extracts 
from the right (non-injected) and left GA was analysed by western blotting. PTEN 
levels were normalised to GAPDH and the means were expressed as folds relative to 
PTEN levels in mice injected with PBS (control group). As shown in Figure 4.8A, 
GFP was only detected in the muscles injected with scAAV9-si-PTEN. Western blot 
analysis shows a significant reduction of PTEN expression (45%) in the muscles 
injected with scAAV9-si-PTEN when compared to those injected with the control 
vector scAAV9-ssi-PTEN or PBS (p<0.05, PBS vs. scAAV9-si-PTEN one-way 
ANOVA with Tukey’s post-test, n=3) (Figure 4.8B). These results indicate that 
scAAV9-si-PTEN effectively silences PTEN in skeletal muscles. GFP was also 
detected on the contralateral GA muscles in mice treated with the scAAV9-si-PTEN 
suggesting there was systemic spread of the viral particles (Figure 4.9).  
 
The effect of PTEN silencing on downstream effectors of the PI3K/Akt signalling 
pathway was investigated by quantifying the levels of pAkt (Ser473), which were 
normalised to GAPDH and the means were expressed as folds relative to pAkt 
levels in mice treated with PBS (control group). As expected, western blot analysis 
revealed a significant increase in pAkt expression in the GA muscles injected with 
scAAV9-si-PTEN when compared to those injected with PBS or the control vector 
(p<0.05, one–way ANOVA with Tukey’s post-test, n=3) (Figure 4.8C). The 
increased levels of pAkt correlated with the reduced levels of PTEN suggesting a 
specific effect of the scAAV9-si-PTEN vector. These findings suggest that 
following i.m injections, scAAV9 mediates effective PTEN silencing resulting in 
activation of the PI3K/Akt pathway in the muscle.  
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Figure 4.8. AAV9-mediated PTEN silencing in the gastrocnemius muscle of 
wild-type C57BL/6 mice. Four-week-old mice were injected with either 20µl 
containing 2x1010vg of either scAAV9-si-PTEN, or scAAV9-ssi-PTEN. A PBS 
treated group has been included as control. The mice were sacrificed 3 weeks later 
and protein extracts from the injected (left) and contralateral (right) muscles were 
analysed by western blotting. (A) Representative western blot showed a significant 
reduction of PTEN expression in muscles injected with scAAV9-si-PTEN. GFP 
expression was mainly detected in the GA muscles treated with the scAAV9-si-
PTEN vectors only. (B) PTEN expression was significantly reduced in muscles 
injected with scAAV9-si-PTEN compared to those injected with PBS or the control 
vector (*P<0.05, one-way ANOVA with Tukey’s post-test, n=3). (C) Levels of 
pAkt (Ser473) was significantly increased in muscles injected with scAAV9-si-
PTEN suggesting that PTEN silencing was associated with activation of the 
PI3K/Akt pathway (*P<0.05, one-way ANOVA with Tukey’s post-hoc test, n=3). 
No significant difference was found in pAkt levels in muscles injected with PBS and 
those treated with the control vector. Data represents means, error bars=SEM. 
AAV9-si, adeno-associated virus serotype 9 expressing PTEN siRNA, AAV9-ssi, 
adeno-associated virus serotype 9 expressing scrambled PTEN siRNA.  
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Figure 4.9. GFP expression in the right (contralateral) gastrocnemius muscle of 
wild-type mice injected with AAV9 vectors. Representative western blot of the right 
GA showing GFP expression indicating systemic spread of the AAV viral particles 
to the contralateral muscles (n=3).  
 
 
 
4.3.3.2 Transduction of wild-type spinal cord motor neurons by 
AAV9 vectors 
To investigate whether AAV9 vectors are capable of transducing spinal cord motor 
neurons following i.m administration, double-immunofluorescence was performed 
in 20µm transverse spinal cord sections from mice treated with scAAV9-si-PTEN 
(n=3) and compared to those injected with PBS (control group, n=3). Due to the 
inefficient transduction of scAAV9-ssi-PTEN in the GA muscles, analysis of the 
spinal cords from this group was not performed. GFP and CGRP double labelling of 
spinal cord sections is reported in Figure 4.10A. Similar to AAV6, AAV9-mediated 
transduction of spinal cord motor neurons was low (<10 GFP-positive motor 
neurons per mouse) suggesting poor efficiency of retrograde axonal transport. 
Occasional GFP-positive, star-shaped cells with numerous processes were found in 
the lumbar spinal cord (Figure 4.10B). Double immunostaining with glial fibrillary 
acidic protein (GFAP), an astroglial marker, showed that these cells were astrocytes 
(Figure 4.17).  
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Figure 4.10 AAV9 transduction of spinal cord motor neurons and astrocytes in 
adult wild type mice. (A) Representative images of transverse sections of the 
lumbar segment of WT mice injected with PBS or scAAV9-si-PTEN. Double 
immunofluorescence shows co-localisation of GFP and CGRP indicating 
transduction of motor neurons via retrograde axonal transport (GFP-positive motor 
neurons in green, CGRP-positive cells in red, Hoechst nuclear stain in blue), 40x 
magnification, scale bar=50µm. (B) Images show a GFP-positive cell (white arrow) 
with an astrocyte-like morphology in the lumbar spinal cord. 40x magnification, 
scale bar=50µm.  
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4.3.3.3 AAV9-mediated PTEN silencing in wild-type spinal cord 
motor neurons 
To determine whether motor neurons transduced with scAAV9-si-PTEN vectors 
have lower PTEN expression compared to the non-transduced motor neurons, 1 in 5 
spinal cord sections (20µm thick) were analysed by double immunofluorescence 
using anti-PTEN antibodies to determine PTEN expression and anti-GFP antibodies 
to detect the transduced motor neuron. Motor neurons were identified by their 
morphology (polygonal, large cells with a distinct nucleus in the ventral horn). 
PTEN expression was predominantly found in the cytoplasm and nucleus of motor 
neurons (Figure 4.11). Although not formally quantified, there was no clear 
difference in between PTEN staining in the transduced and non-transduced cells 
suggesting low expression of PTEN siRNA (Figure 4.11).  
 
 
      
Figure 4.11 AAV9-mediated PTEN silencing in adult wild type mice spinal cord 
motor neurons. Representative images of transverse sections of the lumbar segment 
of WT mice injected with PBS or scAAV9-si-PTEN. Double immunofluorescence 
shows co-localisation of GFP motor neurons and PTEN in mice injected with 
scAAV9-si-PTEN (white arrows). Motor neurons were identified by their 
morphology and location. PTEN expression was detected predominantly in the 
cytoplasm and nucleus of motor neurons. No significant difference was observed in 
PTEN staining between transduced and non-transduced cells. (GFP-positive motor 
neurons in green, PTEN-positive cells in red, Hoechst nuclear stain in blue). 40x 
magnification, Scale bar=50µm.  
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4.3.4 AAV9-mediated PTEN silencing in SOD1 G93A transgenic mice 
The in vitro results showed that PTEN silencing significantly increased motor 
neuron survival, most likely through activation of the PI3K/Akt pathway (Chapter 
3). It was therefore hypothesised that PTEN depletion may prolong the survival of 
spinal cord motor neurons in vivo. To test this hypothesis, scAAV9 vectors were 
used to deliver PTEN siRNA to the spinal cords of transgenic SOD1G93A mice. In 
order to maximize the potential neuroprotective effects of i.m scAAV9 delivery of 
PTEN siRNA, a higher dose (3x1010 vector genomes in a total of 30µl per injected 
muscle) of either scAAV9-si-PTEN or scAAV9-ssi-PTEN was injected into the left 
GA and tibialis anterior (TA) of transgenic SOD1 mice (n= 6 per treatment group) at 
26 days of age (P26), and were sacrificed when they were 100 days old (P100). P26 
was chosen because this is the time where no significant NMJ degeneration is 
expected to occur (this cohort of mice were also used to study the effect of PTEN 
inhibition on the NMJs (Chapter 5) and P100 was chosen as significant motor 
neuron loss is expected to take place (Fischer et al., 2004, Mead et al., 2011). 
Untreated age-matched WT littermates were also included in this study.  
 
4.3.4.1 The effect of AAV9-mediated PTEN silencing on transgenic 
SOD1G93A spinal cord motor neuron survival 
To investigate whether AAV9-mediated PTEN silencing prolongs motor neuron 
survival in vivo, motor neuron counts were performed on Nissl stained transverse 
sections of the lumbar spinal cords (1 in 3 slides) of the treated transgenic SOD1 
mice and compared with non-injected controls. Motor neurons were identified by 
their typical morphology, location and size. Nissl stained motor neurons appeared as 
darkly stained large cells located in the ventral horn, with a pale nucleus and a 
distinct darkly stained nucleolus (Figure 4.12A). As expected, there was a 
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significant reduction (50%) of motor neuron counts in the transgenic mice when 
compared to the WT mice, indicating pathological motor neuron loss (p<0.0001, 
one-way ANOVA with Tukey’s post-test, n=5) (Figure 4.12B). However, there was 
no significant difference between the motor neuron counts in transgenic mice treated 
with scAAV9-si-PTEN when compared to those injected with the control vector 
(Figure 4.12B). These findings suggest either that: PTEN inhibition alone was 
insufficient to enhance motor neuron survival in the transgenic mice; or there was a 
low efficiency of retrograde axonal transport of the viral vectors.  
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Figure 4.12. The effect of AAV9-mediated PTEN silencing on motor neuron 
survival in transgenic SOD1G93A mice Transgenic SOD1G93A mice were injected 
into the left GA and TA a total of 30µl of either scAAAV9-ssi-PTEN (1x1012 vg/ml) 
or scAAV9-si-PTEN (1x1012 vg/ml) at P26, untreated age-matched WT mice were 
also included in the study. The mice were sacrificed at P100 and 1 in 5 sections of 
lumbar the spinal cord were Nissl stained for motor neuron counts. Representative 
images showing Nissl stained motor neurons in transverse sections of the lumbar 
spinal cord of WT (A) and transgenic SOD1G93A mice (B). A significant reduction in 
motor neuron survival (50%) was observed in the transgenic SOD1G93A mice 
indicating motor neuron loss secondary to ALS (C) (***P<0.0005, one-way 
ANOVA with Tukey’s post-test, n=5). No significant difference between motor 
neuron survival in the transgenic mice treated with scAAV9-si-PTEN when 
compared to those treated with the control vector scAAV9-ssi-PTEN (P>0.05, one-
way ANOVA with Tukey’s post-test, n=5). GA, gastrocnemiusP26/P100, postnatal 
day 26/100, TA, tibialis anterior, WT, wild-type. 
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4.3.4.2  AAV9 transduction of skeletal muscles in transgenic 
SOD1G93A 
To investigate the lack of effect observed on motor neuron survival, first the 
efficiency of muscle transduction was examined in the hind limb GA; this was 
performed only in one mouse per treatment due to limitations in viral vector 
quantity. Immunohistochemistry showed GFP expression in the injected muscles, 
which indicates efficient transduction by the scAAV9 viral vectors (Figure 4.13A 
and B). Haematoxylin and eosin staining showed no evidence of inflammation in the 
injected muscles; however, grouped atrophy of the GA muscles was observed in the 
mutant mice (Figure 4.13C). The grouping of muscle fibres is a characteristic 
feature of denervation, which is observed in ALS patients as well as in mouse 
models (Fischer et al., 2004). The denervated muscles become re-innervated by 
collateral axons sprouting from neighbouring motor neurons.  
 
To validate the efficiency of scAAV9–mediated PTEN knockdown, protein extracts 
from the GA muscles was analysed by western blotting, which also confirmed the 
presence of GFP in the injected muscles (4.14D). The expression of PTEN was 
reduced in the GA muscles transduced with scAAV9-si-PTEN, indicating that the 
scAAV9-si-PTEN vector can effectively silence PTEN in the transgenic hind limb 
muscles (Figure 4.14D). Moreover, PTEN knockdown was associated with an 
increase in pAkt expression and phospho-p70S6K, suggesting activation of the 
PI3K/Akt/mTOR signalling pathway; however, the levels of pERK 1/2 were 
unchanged with PTEN inhibition (Figure 4.13B). Due to the limited sample size, 
statistical analysis of the levels of PTEN and its downstream effectors was not 
possible. 
                                                      168 
  
 
 
 
 
 
 
 
Right (non-injected) GA 
Left (injected) GA 
No virus 
  GFP                                      Hoechst                               Merge 
GFP                                      Hoechst                               Merge 
No virus 
 Right (non-injected) GA 
Left (injected) GA 
B 
A 
                                                      169 
                
 
 
 
                 
Figure 4.13. Transduction of gastrocnemius muscles by scAAV9. Age-matched 
transgenic SOD1G93A mice were injected at P26 with 30µl of scAAV9-ssi-PTEN and   
scAAV9-si-PTEN into the left tibialis anterior (TA) and GA muscle (n=3 per 
group). A group of untreated WT mice were also included in the study (n=3). Mice 
were sacrificed at P100 and the GA muscles from one mouse per group were 
analyzed for GFP expression (A). Representative images showing GFP 
immunofluorescence in transverse sections of the left (injected) and right (non-
injected) GA muscles of mice injected with scAAV9-ssi-PTEN (scale bar=50µm) 
(B) Representative showing GFP immunofluorescence in transverse sections of the 
left (injected) and right (non-injected) GA muscles of mice injected with scAAV9-
GFP-si-PTEN. GFP was detected in the injected muscles (scale bar=50µm) (C) 
Haematoxylin and eosin staining of transverse sections of the left GA muscles 
showing grouped atrophy in the transgenic mice and no evidence of inflammation in 
the injected muscles (scale bar=50µm). (D) Western blot analysis of protein extracts 
from the GA muscles showing reduced PTEN expression in muscles injected with 
scAAV9-si-PTEN. PTEN inhibition was associated with increased pAkt, and 
phospho-p70S6K suggesting activation of the PI3K/Akt/mTOR pathway, however 
there was no increase in p-ERK1/2 expression. GFP expression was detected in the 
GA muscles injected with the AAV9 only. ERK, extracellular-regulated kinase, GA, 
gastrocnemius, GAPDH, glyceraldehyde 3-phosphate dehydrogenase, GFP, green 
fluorescent protein, pAkt, phosphorylated Akt, WT, wild-type.  
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4.3.4.3  Transduction of the lumbar spinal cord following i.m 
injections of scAAV9 vectors in transgenic SOD1G93A 
Given the findings of robust GFP expression in the injected GA muscles, the next 
step was to evaluate the efficacy of the i.m route for delivering AAV9 vectors to the 
lumbar spinal cord motor neurons via retrograde axonal transport. Since a higher 
concentration was used one would expect a more efficient transduction than that 
observed in the WT mice. Transverse sections of the lumbar segment of the spinal 
cord were examined by double immunofluorescence (1 in 5 sections, total of 12- 14 
slides per mouse) using anti-GFP antibodies to identify the transduced cells and 
anti-CGRP antibodies to label the motor neurons in the ventral horn of the spinal 
cord. Unfortunately, the expression of GFP in motor neurons was almost negligible 
for both scAAV9-si-PTEN and scAAV9-ssi-PTEN (<5 per mouse). GFP was rarely 
detected on the injected side of the lumbar spinal cord suggesting poor retrograde 
transport of the vectors; and occasionally, GFP-positive motor neurons were seen on 
the contralateral spinal cord indicating that they were targeted by AAV9 through 
systemic delivery (Figure 4.14). GFP expression was also seen in a few axons in the 
dorsal horn, which could either be due to retrograde transport of AAV9 via sensory 
neurons supplying the skin overlying the injected muscles or via systemic spread of 
the vectors (Figure 4.15). These results suggest that following i.m injections, the 
delivery of AAV9 to the spinal cord via retrograde transport is inefficient in the 
transgenic mice, which could explain the lack of effect seen on motor neuron 
survival. 
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Figure 4.14 transduction of lumbar spinal cord motor neurons via retrograde 
transport of AAV9 vectors in transgenic SOD1G93A . Transverse sections of the 
lumbar spinal cord were analysed by double immunofluorescence (GFP-positive 
cells in green, CGRP-positive motor neurons in red (white arrows), Hoechst nuclear 
stain in blue). Representative images show co-localisation of GFP with CGRP 
indicating transduction of the motor neurons by scAAV9-ssi-siPTEN and scAAV9-
si-PTEN. (63x magnification, scale bar= 20µm).  
 
 
 
 
          
Figure 4.15 Transduction of dorsal horn cells by AAV9 vectors. Representative 
images show expression of GFP in a dorsal horn neuron and axons (white arrows, 
63x magnification, scale bar=20µm).  
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4.3.4.4 The effect of AAV9-mediated PTEN knockdown on 
transgenic  SOD1G93A  spinal cord motor neurons 
The efficiency of scAAV9-si-PTEN to silence PTEN in the transduced (GFP-
positive) lumbar spinal cord motor neurons was analysed using double 
immunohistochemistry with anti-PTEN and anti-GFP antibodies. Motor neurons 
were identified by their morphology, size and location. PTEN was predominantly 
expressed in the cytoplasm of motor neurons. As shown in Figure 4.16, there was no 
obvious difference in PTEN expression in motor neurons transduced with scAAV9-
ssi-PTEN, scAAV9-si-PTEN or non-transduced motor neurons. These results 
suggest that the viral vector concentration reaching the motor neurons is insufficient 
for effective PTEN silencing.  
                
 
Figure 4.16 AAV9-mediated PTEN silencing in lumbar spinal cord motor 
neurons. Transverse sections of the lumbar spinal cord were analysed by double 
immunofluorescence (GFP-positive cell in green (arrows), PTEN in red, Hoechst 
nuclear stain in blue). Representative images show co-localisation of GFP with 
PTEN (arrows). Motor neurons were identified by their morphology, size and 
location. PTEN is predominantly expressed in the cytoplasm of motor neurons. 
There was no clear difference in PTEN expression in motor neurons transduced with 
scAAV9-si-PTEN and those transduced with the control vector, scAAV9-ssi-
siPTEN, indicating inefficient PTEN silencing (63x magnification, scale bar= 
20µm). N=5 mice per group.  
 
 
 
 
 scAAV9-  
GFP-ssi-
PTEN 
scAAV9-
GFP-si-
PTEN 
PTEN GFP Hoechst  MERGE 
                                                      173 
  
4.3.4.5 Transduction of spinal cord astrocytes by AAV9 vectors in 
transgenic SOD1G93A 
AAV9 is known for its ability to transduce astrocytes in adult mice (Foust et al., 
2009). In this study, GFP-positive astrocytes were occasionally found in the lumbar 
spinal cord (<20 per animal) suggesting systemic spread of the viral particles 
(Figure 4.17). Double immunohistochemistry was used for labelling GFP (green) 
and glial-acidic fibrillary protein (GFAP) (red), an astroglial marker. Co-localisation 
of GFP with GFAP was occasionally seen, indicating transduction of astrocytes by 
AAV9 (Figure 4.15B). Despite the paucity of transduced astrocytes, there were still 
more GFP-expressing astrocytes than GFP-positive motor neurons indicating that 
systemic delivery was more efficient than retrograde axonal transport.   
 
 
             
 
 
Figure 4.17 AAV9-mediated transduction of astrocytes in the lumbar spinal 
cord of transgenic SOD1G93A. (A) Representative images of transverse sections of 
the lumbar spinal cord show GFP-positive astrocytes (green) (x63 magnification, 
scale bar=20µm). (B) Double immunofluorescence using anti-GFP (green), anti-
GFAP (red) for labelling astrocytes and Hoechst for nuclear staining shows co-
localisation of GFP with GFAP indicating transduction of astrocytes by AAV9 
vectors. (X63 magnification, scale bar= 20µm). GFAP, glial fibrillary acidic protein, 
GFP, green fluorescent protein. 
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4.4 Discussion 
 
The major findings of this study are: i) AAV6 and AAV9 transduced the GA 
muscles of WT mice with high efficiency; ii) PTEN expression was significantly 
reduced in muscles injected with AAV6 and AAV9 expressing siRNA against the 
mouse PTEN gene; iii) examination of the lumbar spinal cords however showed 
very low GFP positive cells, indicating low efficiency of retrograde transport and 
thus it was challenging to study PTEN silencing in the spinal motor neurons; iv) low 
levels of transgene expression were also observed in SOD1G93A mice injected with 
AAV9 vectors expressing PTEN siRNA, which may have contributed to the lack of 
effect on spinal cord motor neuron survival observed in mice treated with scAAV9-
si-PTEN. Taken together, these findings suggest inefficient retrograde axonal 
transport by AAV6 and AAV9 vectors in adult WT and transgenic SOD1G93A mice.  
 
4.4.1 In vitro validation of AAV9 viral vectors for the delivery of PTEN 
siRNA 
Lentiviral vectors have the ability of delivering genes to spinal cord motor neurons 
via retrograde transport (Mazarakis et al., 2001, Ralph et al., 2005c) however; AAV 
vectors have gained attraction for systemic gene delivery due to their low toxicity 
and low immunogenicity. Among the AAV viral vectors, AAV viral vector serotype 
9 (AAV9) is well known for its high transduction efficiency of motor neurons in 
vivo (Duque et al., 2009, Foust et al., 2009, Valori et al., 2010, Federici et al., 2012, 
Benkhelifa-Ziyyat et al., 2013, Foust et al., 2013). The enhanced motor neuron 
survival observed with lentiviral-mediated PTEN knockdown led to the hypothesis 
that PTEN silencing may prolong the survival of mutant SOD1G93A spinal cord 
motor neurons in vivo. Thus, AAV9 vectors expressing PTEN siRNA (scAAV9-si-
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PTEN) and scrambled-si-PTEN (scAAV9-ssi-PTEN) were generated for our gene 
transfer in vivo studies. Prior to their use for the in vivo studies, the efficiency of the 
vectors was first validated in vitro by transducing transgenic SOD1G93A motor 
neurons with two doses of each vector. The viral vectors also expressed GFP as a 
reporter gene. GFP-expressing motor neurons were visualised on day 3 post-
transduction with a fluorescent microscope and live pictures were taken using the In 
Cell analyser prior to harvesting the cells on day 5-postransduction. Although 
AAV9 has been shown to transduce cortical and hippocampal neurons with high 
efficiency (Royo et al., 2008), to our knowledge this is the first report describing 
transduction of purified motor neuron cultures with AAV9 vectors. Moreover, no 
toxicity was detected even with the highest concentration of the vectors. PTEN 
levels were reduced by 40% with MOI of 3.5x105 vg and only 20% reduction was 
observed using the lower MOI of 1.5x105vg. PTEN expression in motor neurons 
was not affected by the scAAV9-ssi-PTEN vector. These results suggest that 
scAAV9-si-PTEN could effectively knockdown PTEN in transgenic and non-
transgenic motor neurons in vitro. However, the scAAV9-mediated PTEN silencing 
was less efficient when compared to lentiviral-mediated PTEN inhibition (Ning et 
al., 2010). This may be dose-related, such that higher MOIs may achieve more 
efficient knockdown, or it may be due to the slow gene expression mediated by 
AAV vectors. These AAV9 vectors were further validated in vivo.  
 
4.4.2  AAV-mediated PTEN silencing in the hind limb muscles of wild-
type mice 
AAV6-based vectors were generated to deliver either siRNA against PTEN or 
scrambled PTEN siRNA, into the hind limb muscles of young adult WT mice. The 
AAV6 vector was chosen after studies in our laboratories revealed efficient 
retrograde transport of these vectors following i.m administration in neonatal SMA 
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mouse models, with ~40% transduction of lumbar spinal cord motor neurons (Ning 
et al., 2010). Other studies have also demonstrated efficient motor neuron 
transduction in neonatal ALS mice (Towne et al., 2011) as well as in non-human 
primates (Towne et al., 2010) following peripheral administration of AAV6 vectors. 
In this study, western blot analysis of the injected GA muscles showed strong GFP 
expression in mice injected with AAV6 vectors which is consistent with previous 
reports showing a high tropism of AAV6 for skeletal muscles (Blankinship et al., 
2004, Gregorevic et al., 2004). More importantly, a significant reduction in PTEN 
levels was found in the GA muscles of mice treated with AAV6-si-PTEN. The lack 
of significant difference between PTEN expression in mice injected with the AAV6-
ssi-PTEN and those injected with PBS suggests that the vectors did not alter the 
expression of PTEN and confirms the specific effect of AAV6-mediated PTEN 
silencing in the muscle (Figure 4.2) In addition, PTEN silencing was associated with 
increased expression of pAkt (active from) indicating activation of the PI3K/Akt 
signalling cascade. There were no significant differences between the levels of pAkt 
in mice treated with the control vector and those treated with PBS, providing more 
evidence for the specificity of the AAV6-mediated PTEN silencing. In addition GFP 
was not detected in the contralateral GA muscles indicating there was no significant 
systemic spread of the vectors. Thus, injection of AAV6-si-PTEN into the muscle 
successfully reduced PTEN expression in the muscle and activated the Akt pathway.  
 
To explore the efficiency of AAV9-mediated PTEN silencing in vivo, scAAV9-
based vectors expressing PTEN siRNA and ssi-PTEN were generated and validated 
in WT mice. The vectors were selected because of their high neuronal as well as 
skeletal muscle tropism, and to test their ability to deliver PTEN siRNA to the spinal 
cod more efficiently than AAV6. In addition, a study by Benkhelifa-Ziyyat et al. 
showed that AAV9 is capable of retrograde axonal transport, and demonstrated 
robust gene expression of spinal cord motor neurons following i.m injections both in 
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adult wild type and transgenic neonatal SMA mice (Benkhelifa-Ziyyat et al., 2013). 
In this study, western blot analysis showed GFP expression and a significant 
reduction of PTEN levels in the muscles injected with scAAV9-si-PTEN vectors. 
GFP expression was also observed in the contralateral GA muscles after injections 
of scAAV9-si-PTEN, indicating systemic spread of the vectors following i.m 
injections. In addition, PTEN silencing was associated with a significant increase in 
pAkt levels in the injected GA muscles suggesting activation of the PI3K/Akt 
pathway. There was no significant difference between PTEN and pAkt levels in 
muscles injected with either PBS or the control vector, suggesting a specific effect 
of scAAV9-mediated PTEN silencing. Hence, these findings demonstrate that i.m 
administration of scAAV9-si-PTEN successfully reduces PTEN expression in 
skeletal muscles and activates Akt similar to AAV6-mediated PTEN silencing.  
 
4.4.3  Delivery of AAV vectors to the spinal cord 
The next step was to determine whether the AAV6 vectors were efficiently 
delivered to the spinal cord motor neurons after peripheral administration. 
Unexpectedly, despite efficient muscle transduction, analysis of the lumbar segment 
of the spinal cords using double-immunofluorescence showed a very low level 
(almost negligible) of motor neuron transduction, and hence it was challenging to 
study PTEN silencing in spinal cord motor neurons. These findings are consistent 
with other studies in our laboratories that demonstrated low efficiency (<5%) of 
lower motor neuron transduction via retrograde transport in adult SOD1G93A mice 
(Nanou et al., 2013). It could be hypothesised that immaturity of the blood-brain 
barrier and the shorter motor neuron axons in neonatal mice may have enhanced 
neuronal spinal cord transduction by AAV6 observed in other studies. Since these 
vectors transduce skeletal muscles with high efficiency, they were utilised for a 
study investigating the effects of PTEN silencing on the NMJs in the SOD1G93A 
mouse model (see Chapter 5). Like AAV6, the efficiency of retrograde transport of 
                                                      178 
the AAV9 vectors in adult WT mice was also very low and occasional GFP-positive 
astrocytes were seen which were most likely targeted by systemic spread of the 
vectors. In line with these findings, Foust et al. (Foust et al., 2009) reported low 
transduction efficiency of spinal cord motor neurons after i.m injections of AAV9 
vectors expressing GFP in adult mice. In their study they showed that AAV9 targets 
neuronal cells in neonatal mice with high efficiency following intravenous 
administration. In contrast, Benkhelifa-Ziyyat et al. demonstrated high levels of 
gene expression through the spinal cord following a single i.m injection of AAV9 
(Benkhelifa-Ziyyat et al., 2013). It is possible that systemic spread of AAV9 could 
have contributed to the enhanced transduction; nevertheless, they showed that most 
of the ventral horn motor neurons in the lumbar spinal cord were selectively 
transduced (compared to other spinal cord regions), related to the muscles that that 
segment innervated, which would indicate retrograde transport.  
 
Although a direct comparison between this study and other reports is difficult due to 
differences in several parameters including the timing of injections and experimental 
mouse models, nevertheless, the discrepancies seen may are more likely to be due to 
differences in vector preparation and purification, vector dose and promoters used to 
drive gene expression, as these factors have been shown to affect AAV vector 
tropism (Fitzsimons et al., 2002, Klein et al., 2008, Burger et al., 2004, Choi et al., 
2005).  
 
In this study, the vectors were purified using Cesium Chloride (CsCl) ultrahigh 
speed density gradient centrifugation, a traditionally used method for the 
purification of AAV vectors, which can be used for different serotypes (Guo et al., 
2013). One of the drawbacks of this method is that impurities and cellular non-viral 
proteins may be present in the vector stocks which may cause toxicity to the cells 
and may affect the transduction efficiency (Guo et al., 2013, Klein et al., 2008). 
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Although some authors showed that neuronal transduction by AAV9 vectors was 
not particularly affected by CsCl purification (Klein et al., 2008), it is difficult to 
exclude that impurities in the vector preparations could have interfered with axonal 
uptake and retrograde transport of the vectors. Iodoxinol gradient based purification 
methods were shown to produces preparations which are less toxic and contain less 
impurities (Klein et al., 2008), and this method was used to purify vectors in 
Benkhelifa-Ziyyat et al.’s study. However, the latter group proposed that the 
enhanced spinal cord transduction observed following i.m injections of AAV9 may 
be due to “pseudo transduction” or artificial transduction, which occurs due to the 
presence of contaminants containing the transgene protein (such as GFP) in their 
viral preparations (Alexander et al., 1997, Benkhelifa-Ziyyat et al., 2013). 
Furthermore, despite the fact that Q-PCR quantifies only the particles containing 
DNA, the vector preparations may be contaminated by particles containing only 
fragments of the viral genome which may not be detected by commonly used PCR 
assays (Grimm et al., 1999). The presence of empty capsids (devoid of DNA) in the 
viral stocks may also affect the biological activity of the active viral particles 
hindering their delivery via the i.m route. In addition, some studies have shown that 
errors in Q-PCR can occur during the quantification of scAAV vectors resulting in 
unreliable viral titres (Fagone et al., 2012), which in turn may affect the injected 
viral load and the overall transduction efficiency.  
 
Other factors such as the promoters used to drive gene expression may also affect 
the transduction efficiency. While in Foust et al.’s study the chicken beta-actin 
(CBA) promoter was used to drive GFP expression (Foust et al., 2009), the CMV 
promoter was used in this study as well as in Benkhelifa-Ziyyat et al.’s study 
(Benkhelifa-Ziyyat et al., 2013). The CMV and CBA promoters are both strong 
ubiquitous promoters that mediate prolonged gene expression in the CNS although 
some studies showed that with time CMV silencing could occur (Lentz et al., 2012). 
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Some studies showed that with AAV8-based vectors, gene expression was stronger 
when driven by the CBA promoter, however no significant differences were seen 
with AAV9-based vectors (Klein et al., 2008). Further work will be needed to 
investigate these issues to determine the contribution of these factors and the overall 
quality of vectors on retrograde axonal transport.  
 
Another factor that might contribute to the low transduction efficiency is the viral 
load of AAV9 used in this study (2x1010 and 3x1010 vg per injected muscle), which 
is lower than that used in Benkhelifa-Ziyyat et al.’s study (9 × 1010 vg per injected 
muscle) (Benkhelifa-Ziyyat et al., 2013). Thus, dose response studies are required to 
determine the dose that would result in efficient AAV9 retrograde transport and 
effective AAV9-mediated PTEN silencing.   
 
4.4.4 AAV9-mediated PTEN silencing in SOD1G93A mice 
As there is limited experience on the delivery of transgenes to spinal cord motor 
neurons using AAV9 vectors through the i.m route, scAAV9-based vectors were 
used for a proof-of-principle study to investigate the therapeutic potential of PTEN 
silencing in transgenic SOD1 G93A mice. A higher dose (3 x 1010 vg per animal) was 
used to increase the transduction efficiency. As expected, analysis of spinal cord 
sections showed a significant reduction in motor neuron survival in the transgenic 
mice compared to the wild type mice indicating pathological motor neuron loss as 
result of SOD1G93A mutations. Unfortunately, there was no significant difference 
between motor neuron survivals in the transgenic mice injected with scAAV-si-
PTEN compared to those treated with the control vector. The lack of effect observed 
was attributed either to inefficient delivery of PTEN siRNA to spinal cord motor 
neurons by the AAV9 vectors or due to the fact that PTEN silencing alone may be 
insufficient to enhance motor neuron survival in vivo. To investigate this, analysis of 
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the injected GA muscle showed GFP positive staining in the injected as well as in 
the contralateral GA indicating efficient transduction of the injected muscle by 
AAV9 and systemic dissemination of the vectors. In addition, western blot analysis 
of the injected GA showed reduced PTEN expression in the muscles injected with 
scAAV9-si-PTEN associated with increased expression of pAkt and phosph-
p70S6K suggesting activation of the PI3K/Akt/mTOR signalling pathway. Of 
interest, expression of pERK was unchanged in the muscles injected with scAAV9-
si-PTEN compared to the non-injected muscles and those injected with the control 
vector. Due to a limited sample size (n=1 per experimental group), statistical 
analysis was not performed. 
 
Double immunofluorescence of lumbar spinal cord sections showed an almost 
negligible transduction of motor neurons (<5 per mouse), suggesting a low 
efficiency of retrograde transport by AAV9. Hence, the finding of very low levels of 
motor neuron transduction may explain the lack of effect on motor neuron survival, 
as the transduction efficiency was well below the threshold required to have a 
significant effect. It could be argued that a proportion of the transduced motor 
neurons `(GFP-positive) could have died as a result of the disease process in the 
transgenic mice or the possibility that retrograde transport is less efficient in 
SOD1G93A mice; however, these results are similar to the findings in WT mice, 
suggesting that the poor retrograde transport is unlikely to be related to the mouse 
models. Injected viral load, production and purification of the vectors, as discussed 
above for WT mice, are potential contributing factors to poor retrograde transport. 
Due to the low levels of gene expression, it was not possible to determine the 
silencing of PTEN in the spinal cord motor neurons.  
 
Occasional astrocytes, as well as contralateral ventral horn motor neurons, showed 
GFP-positive staining suggesting there was some systemic spread. On the other 
                                                      182 
hand, Foust et al. showed a predominant transduction of astrocytes in adult WT 
mice (Foust et al., 2009); thus, the scarcity of astrocyte transduction observed in this 
study may be related to the viral load injected. Since astrocytes contribute to the 
pathogenesis of ALS (Pirooznia et al., 2014), their targeting by AAV9 vectors may 
be required for other therapeutic strategies such SOD1 silencing (Foust et al., 2013); 
however, PTEN silencing in astrocytes predisposes to tumourogeneis and may lead 
to undesirable effects on the long-term (Westhoff et al., 2014). Therefore, vectors 
with neuron-specific promoters to limit the expression of PTEN siRNA in neurons 
may be required to avoid these potential complications.  
 
The low efficiency of retrograde axonal transport and transduction of spinal cord 
motor neurons observed with the AAV vectors made it difficulty to ascertain 
whether PTEN silencing is neuroprotective in the SOD1G93A mouse model. The i.m 
route of delivering genes has the advantage of being a safe and simple procedure as 
well as allowing targeting of both muscles and a specific spinal cord motor neuron 
pool, which is a practical approach for proof-of principle studies. On the other hand, 
it may not be practical for gene delivering in patients with ALS, as this will require 
multiple injections. Moreover, this study showed that i.m delivery of AAV6 and 
scAAV9-based vectors is not a reliable route for delivering siRNA against PTEN in 
young adult mice. Nevertheless, widespread and robust gene delivery of AAV9 to 
the brain and spinal cord was observed with other routes of administration such as 
intrathecal (Hirai et al., 2012, Schuster et al., 2014) and intracisternal (Hinderer et 
al., 2014) delivery and although these routes are more invasive than the i.m route, 
they could provide useful information for proof-of principle studies. 
 
                                                      183 
4.5 Conclusion 
The results of this study showed efficient transduction of GA muscles by AAV6 and 
AAV9 vectors in WT mice. AAV-mediated delivery of siRNA against PTEN 
achieved a significant reduction of PTEN expression and activation of the PI3K/Akt 
pathway in the injected muscles. However, a low efficiency of spinal motor neuron 
transduction was observed with both AAV6 and AAV9 after i.m delivery suggesting 
inefficient retrograde axonal transport. Furthermore, there was no significant effect 
of scAAV9-mediated PTEN silencing on spinal cord motor neuron survival in the 
SOD1G93A mouse model. The low levels of gene expression observed in the lumbar 
spinal cord motor neurons of the transgenic mice, for both the control vector and 
scAAV9-si-PTEN, may explain the lack of effect on motor neuron survival. 
Therefore it was difficult to determine whether PTEN silencing has neuroprotective 
effects on transgenic motor neurons in vivo. These findings suggest that the poor 
retrograde transport observed is unlikely to be related to the mouse models used. It 
is possible that vector-related factors such as production and purification, titration 
and viral dose may contribute to the low efficiency of retrograde axonal transport.  
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5. The effect of PTEN silencing on NMJ degeneration in the 
SOD1G93A  mouse model 
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5.1 Introduction 
 
5.1.1 The neuromuscular junction (NMJ) 
When a motor neuron axon reaches muscle fibres, it divides into several terminal 
branches and each branch targets a skeletal muscle fibre. This close connection 
between lower motor neurons and skeletal muscle fibres forms a highly specialised 
synapse called the neuromuscular junction (NMJ), which serves to transmit 
electrical impulses from the motor neurons to the muscles (Hughes et al., 2006). It 
consists of three major components: the presynaptic membrane which is formed by 
the motor neuron axon terminals, the synaptic cleft or synaptic basal lamina which 
consists of extracellular matrix and the post synaptic membrane formed by the 
muscle fibre membrane (Figure 5.1). In vertebrates, a mature NMJ has a pretzel-like 
appearance where the post-synaptic membrane of the muscle fibre invaginates into 
junctional folds. Within the pre-synaptic membrane, synaptic vesicles release 
neurotransmitters that bind to receptors that are highly expressed on the post-
synaptic membranes. These neurotransmitters are small molecules, which differ 
according to species. For example, in Caenorhabditis elegans there are two types of 
NMJs: one is excitatory where acetylcholine (ACh) causes muscle contraction, and 
the other is inhibitory where gamma-aminobutyric acid (GABA) causes muscle 
relaxation (Wu et al., 2010). Acetylcholine and glutamate are the excitatory 
neurotransmitters resulting in muscular contractions in vertebrates and Drosophila, 
respectively (Wu et al., 2010). Another essential component of the NMJ are the 
terminal Schwann cells, which regulate the stability and remodelling of 
neuromuscular synapses (Kang et al., 2003)(Figure 5.1).  
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Figure 5.1. The components of the neuromuscular junction (NMJ). A motor 
neuron terminal synapsing with a muscle fibre. Terminal schwann cells play a role 
in the stabilty and remodelling of the NMJ. (Adapted from Moloney et al (Moloney 
et al., 2014)). 
 
 
 
5.1.2 Signalling pathways in NMJ development and maturation 
Development of the neuromuscular junction starts as early as embryonic day 13 
(E13) in mice and continues up to the first two weeks of postnatal life (Slater, Wu et 
al., 2010). Analysis of NMJ development and maturation has shed light into 
pathogenic mechanisms that may be involved in the breakdown of neuromuscular 
synapses. Several lines of evidence suggest that the PI3K/Akt signalling pathway 
plays an essential role in NMJ development and maturation. PI3K was found to be 
highly expressed in post-synaptic membranes of skeletal muscles (Nizhynska et al., 
2007) and increased expression is essential for synapse formation and stability. 
During the development of the NMJ, the clustering of acetylcholine receptors 
(AChR) on muscle fibres is an essential step regulated by agrin, an extracellular 
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protein produced and secreted by lower motor nerve endings into the synaptic cleft 
and binds to its receptors (MUSK) on the post-synaptic membrane (Schmidt et al., 
2012). Studies in adult and cultured myotubes showed that agrin binds to receptors 
on the post-synaptic membrane activates the PI3K signalling cascade, resulting in 
inactivation of GSK3-β leading to the assembly of myotubes and clustering of 
AChR (Schmidt et al., 2012). Another study showed that blocking PI3K leads to 
inhibition of agrin-induced AChR aggregation in cultured myotubes (Nizhynska et 
al., 2007). In addition, the generation of PIP3 leads to activation of the 
Rho/GTPases, which also mediate the actions of agrin (Nizhynska et al., 2007). 
Furthermore, neurotrophins are important factors for synaptic development and 
plasticity and they mediate their actions via activation of Akt and its downstream 
effectors (Je et al., 2005). Studies in mouse models of Duchenne muscular 
dystrophy (mdx mouse) have reported that increased expression of Akt regulates the 
expression of glycoproteins that are essential for the stability of skeletal muscle 
post-synaptic membranes (Kim et al., 2011).  
 
Activation of Akt plays an essential role in muscle hypertrophy (Glass, 2003). In 
fact, dephosphorylation of Akt was found in various diseases causing muscle 
atrophy (Sandri et al., 2004). In the context of ALS, mutant SOD1G93A is associated 
with reduced expression of phosphorylated Akt and its downstream effectors 
(Dobrowolny et al., 2011). Since PTEN inhibition is associated with axonal 
regeneration of motor neurons (Ning et al., 2010), it is plausible that activation of 
the PI3K/Akt signalling pathway via PTEN silencing could be a novel therapeutic 
strategy to prevent NMJ degeneration in neuromuscular diseases such as ALS and 
SMA. To the best of our knowledge, our current study is the first to report the effect 
of PTEN silencing on neuromuscular junctions in experimental models of ALS.  
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5.1.3 ALS is a distal axonopathy 
Historically, it was believed that ALS is a disease of the motor neuron; however, 
early studies in human muscle tissue showed that neuromuscular synapses are 
affected in ALS (Tsujihata et al., 1984). It remains a matter of debate, which starts 
first, motor neuron death or NMJ degeneration. It was only after the generation of 
transgenic models that researchers were able to study the progression of 
neuromuscular damage in ALS. A large body of evidence suggests that ALS is a 
distal axonopathy where neuromuscular junction dysfunction occurs early prior to 
the onset of symptoms. Previous electrophysiological studies by Kennel et al. have 
reported loss of motor units in SOD1G93A mice at 47 days (Kennel et al., 1996). 
Consistent with these data, progressive thinning of fast-fatigable motor neuron 
axons were detected in mouse models of ALS at P30-P40 (Frey et al., 2000). Later 
studies by Fisher et al. demonstrated significant denervation of synapses at 47 days 
in SOD1G93A mice, long before motor neuron death and manifestation of clinical 
symptoms, which were detected after 80 days (Fischer et al., 2004). Moreover, 
Fisher et al. published the first pathological report of distal axonopathy in a patient 
with ALS; they described denervation of muscles where the connected motor 
neurons were unaffected (Fischer et al., 2004). Further evidence comes from studies 
that demonstrated that prolonging motor neuron survival alone does not increase the 
overall survival of transgenic SOD1 models (Kostic et al., 1997, Gould et al., 2006). 
These findings and data from other studies suggest that both functional and 
morphological changes in motor axons start distally and progress proximally early 
on the disease (Schaefer et al., 2005). The evidence from these studies led to the 
“dying –back” theory, which is now widely accepted as a cause for motor neuron 
death not only in ALS but also in other motor neuron disorders. For example, 
pathological changes in NMJs were found in SMA (Murray et al., 2010), 
progressive motoneuropathy (pmn) and the motor neuron degeneration mouse 
models (Ferri et al., 2003). Dog models of hereditary MND also show 
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presymptomatic involvement of NMJs (Rich et al., 2002). Similarly early disruption 
of neuromuscular synapses was reported in C. elegans (Wang et al., 2009) and 
Drosophila (Chai et al., 2008) models of familial ALS. What remain unclear are the 
pathogenic mechanisms of the selective vulnerability of NMJs in motor neuron 
disorders. Hence, there is a need for further studies to unravel the molecular changes 
that render neuromuscular synapses an early target for motor neuron diseases.  
 
5.1.4 Analysis of NMJ morphology 
To better understand the molecular and pathological changes that affect NMJs in 
ALS, rodent models provide an invaluable tool for detailed analysis of NMJs at 
different stages of the disease. In addition they allow candidate target molecules to 
be tested for potential use as therapeutic treatments for ALS. There are three types 
of motor neurons that supply the skeletal muscles, namely: fast fatigable (FF), fast 
resistant (FR) and slow (S) fibres. In both human and rodent models of ALS, the 
fast-fatigable fibres in the hind limb muscles are one of the earliest muscle groups to 
be affected (Marcuzzo et al., 2011). The gastrocnemius (GA) muscle is a large 
hindlimb muscle, which is easily accessible and is commonly used for studying 
NMJ morphology. However, the thickness of the muscle allows poor penetration of 
antibodies and it is difficult to mount for microscopy. The muscles will need to be 
sectioned for better staining and mounting and this would require a longer time for 
muscle preparation and may lead to disruption of the NMJ architecture causing 
artefacts that may affect the data interpretation (Sleigh et al., 2014). The deep 
lumbrical muscles are four small thin muscles found between the digits of the hind 
limbs that originate from the flexor digitorum longus (FDL). They could be easily 
dissected and whole mounted without the need for sectioning, and their small size 
allows better antibody absorption and better quality immunofluorescence staining 
allowing a more accurate analysis of NMJ morphology (Sleigh et al., 2014). 
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Similarly the flexor digitorum brevis (FDB) could also be dissected and whole 
mounted and are commonly used for analysis of NMJs. 
 
5.2 Aims of study 
The aim of this study is to investigate the effect of PTEN knockdown on 
neuromuscular degeneration in transgenic SOD1G93A mouse models. It was 
hypothesised that PTEN knockdown could prevent neuromuscular degeneration in 
the early pre-symptomatic stage. We propose that intramuscular (i.m) administration 
of AAV vectors expressing PTEN-siRNA might have the additional advantage of 
axonal retrograde transport leading to PTEN silencing in motor neurons, which may 
ultimately prevent motor neuron death and promote motor axon regeneration.  
 
To achieve PTEN knockdown two viral vectors, AAV6 and scAAV9 were used to 
deliver siRNA to specifically deplete the expression of PTEN mRNA and ultimately 
reduce the level of PTEN protein in the transduced muscles (si-PTEN). In both 
studies the vectors were used to express scrambled PTEN siRNA (ssi-PTEN) that 
was used as a control vector. The vectors also express GFP (green fluorescent 
protein) as a reporter gene, which was used to assess transduction efficiency. In a 
pilot study, AAV6-based vectors were injected directly into the foot muscles of 
transgenic SOD1G93A mice, whereas in a separate group of transgenic mice AAV9 
vectors were injected into the GA and tibialis anterior (TA) muscles. The mice 
received i.m injections of the viral vectors at pre-symptomatic stage (P26). Animals 
were culled and muscles tissues harvested for NMJ analysis at P100 when mice 
exhibit significant motor neuron loss and NMJ degeneration (Fischer et al., 2004). 
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5.3 RESULTS 
 
5.3.1 The morphology of NMJs in SOD1G93A mice  
The pathological changes affecting the NMJs of mutant SOD1G93A mice were 
studied using whole mounts of the tibialis anterior (TA), flexor digitorum brevis 
(FDB) and lumbrical muscles. The muscles were immunostained with anti-
neurofilament  (NF, 2H3, red) and anti-synaptic vesicle 2 (anti-SV2, red), for 
labelling presynaptic axons and nerve terminals. SV2 is a transmembrane 
glycoprotein found in all synaptic vessels (SS, 2000) . Tetramethylrhodamine 
(TRITC)-conjugated alpha-bungarotoxin (BTX, blue), which selectively binds to 
acetylcholine receptors, was used to visualise the post-synaptic motor-endplates 
(Figure 5.2).   
 
Immunofluorescence showed the presence of healthy and denervated NMJs in the 
hind muscles of the transgenic SOD1G93A mice. As shown in Figure 5.2 (A-C), a 
normally innervated NMJ has a pretzel-like structure with close association between 
the motor neuron terminal axons and the muscle fibre post-synaptic membranes (or 
motor end plates). Here the terminal axon overlies the majority (>50%) of the motor 
endplate. In addition, the characteristic features of neuromuscular degeneration were 
observed in all the muscles that were analysed. Unoccupied motor endplates 
(vacant), which have no connection with terminal axons, were seen and are 
considered pathological, indicating denervation of the muscles (Figure 5.2 D-F). 
Partially denervated NMJs were also observed where the terminal axons occupied a 
small area (<50%) of the post-synaptic membrane (Figure 5.2 D-F). In addition, 
abnormal accumulation of neurofilament in the axons, a pathological hallmark of 
sporadic and familial ALS (Al-Chalabi et al., 1999), was detected on the pre-
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synaptic axons (Figure 5.2 G-I). Finally, thinning of terminal axons was also 
observed (Figure 5.2 G-I), another feature of dying back axonopathy in ALS 
(Fischer et al., 2004). GFP expression was seen as a fluorescent green colour in the 
muscles without immunostaining indicating transduction of the muscles with the 
viral vectors (Figure 5.3). Large-scale images were used for the quantification of the 
NMJs (Figure 5.3). 
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Figure 5.2 Representative images showing immunostaining of the NMJs (scale 
bar=25µm). (A-C); (A) A merged image of B and C - an example of a fully 
occupied endplate (unaffected) NMJ, with the axonal terminal (red) overlying the 
majority (more than 50%) of the motor endplate (blue).  (B) Neurofilament and SV2 
staining showing full occupation of the motor endplate.  (C) Bungarotoxin staining 
showing the acetylcholine receptors forming the motor endplate on the muscle fiber. 
(D-F): (D) A merged image of E and F - examples of partially occupied and vacant 
motor endplates. (E) Neurofilament (2H3) and SV2 staining showing partial 
occupation of the motor endplates by the nerve terminal. (F) Bungarotoxin staining 
showing the acetylcholine receptors that makes up the motor endplate. Two 
endplates are contacted but not completely occupied by a nerve terminal these, are 
considered partially occupied. Two endplates, which are not contacted by a nerve 
terminal at all, are considered to be vacant or unoccupied, which is pathological. (G-
H): (G) A merged image of H and I showing axonal thinning and neurofilament 
accumulation (white arrows).  (H) Neurofilament and SV2 staining showing axonal 
thinning in the distal axon. (I) Bungarotoxin labelling of the motor endplate. 
SV2=synaptic vesicle protein 2. 
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Figure 5.3. Representative large-scale images from (A) the right (non-injected) 
and (B) left (injected) lumbrical of transgenic SOD1G93A mice injected with 
AAV6-ssi-PTEN (x20 magnification, scale bars=50µm). The muscles were stained 
with anti-neurofilament (2H3,red), anti-SV2 (red) for labelling the pre-synaptic 
axons and nerve terminals and IR-bungarotoxin (blue) to label the acetylcholine 
receptors on the motor endplate (n=5). GFP expression was observed as a green 
colour in the background, without immunostaining for GFP, indicating transduction 
of the muscle with the viral vector (B). These large-scale images were used for 
quantification of the NMJs. GFP= Green Fluorescent Protein, AAV6-ssi-PTEN= 
adeno associated virus type 6 expressing scrambled si-PTEN, SV2=synaptic vesicle 
protein 2.   
                                       
 
5.3.2 The effect of AAV6-mediated PTEN silencing on the lumbrical 
and FDB muscles of SOD1G93A mice 
To address the question of whether PTEN depletion may protect the NMJs from 
degeneration in SOD1G93A mice, AAV6 was used to deliver scrambled or si-PTEN 
directly into the left foot muscles of the transgenic mice. Age and sex-matched 
transgenic SOD1G93A mice (six mice in each group) were randomly recruited to two 
groups, the control group and treatment group, which received 10µl (1x1010 vector 
genomes (vg) per foot) of AAV6- ssi-PTEN and AAV6-si-PTEN, respectively. Both 
viral vectors expressed GFP as a marker for transduction. All injections were 
A B 
50 µm    
          Right (non-injected) Lumbrical               Left (injected) Lumbrical!
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performed by a blinded investigator (Dr Ke Ning) prior to the onset of symptoms at 
P26. At P100, the mice were sacrificed and the lumbrical and FDB muscles were 
dissected from the left (injected side) and the right (non-injected side) hind limbs. 
The muscles were then whole mounted and immunostained to label the NMJs as 
described above. The motor end plates were quantified and categorised into three 
groups:  a fully occupied end-plate (FO) was defined as a motor end-plate 
completely covered by the pre-synaptic axon terminal labelled with anti-
neurofilament and anti-SV2, a partially occupied end-plate was defined as a motor 
end-plate only partially covered by the axonal nerve terminal (<50%) and a vacant 
(denervated) end-plate was defined as a motor end-plate which has no contact with 
an axonal nerve terminal. For each muscle preparation, a minimum of 100 total 
endplates per mouse was counted randomly. The percentage of FO, vacant and 
partially denervated endplates in each muscle were calculated relative to the total 
number of endplates. Comparisons were made between the control and treatment 
groups and statistical analysis was performed using the Mann Whitney U test as 
shown below. 
 
5.3.2.1 The effect of AAV6-mediated PTEN silencing on the NMJs of 
the lumbrical muscles in SOD1G93A mice 
 
The effect of PTEN inhibition was studied in the lumbrical muscles. If PTEN 
silencing had a neuroprotective effect one would expect an increase in the 
percentage of FO and a decrease in the vacant and partially unoccupied endplates as 
well as attenuation of axonal thinning in the NMJs of mice injected with AAV6-si-
PTEN. Although there was an apparent increase in the percentage of FO end-plates 
of the AAV6-si-PTEN injected (left) lumbrical muscles when compared to the mice 
injected with AAV6-ssi-PTEN (Figure 5.4 A) (AAV6-si-PTEN median=25.6%, 
AAV6-ssi-PTEN median=4.3%), the difference did not reach statistical significance 
(Mann Whitney, U=17, p=0.8939, n=6 per group). Similarly, there was no 
                                                      196 
significant difference in the percentage of FO motor end plates of the non-injected 
(right) lumbricals when the two groups were compared (Mann Whitney, U=17, 
p=0.8939, n=6 per group) (Figure 5.4 B). As shown in Figure 5.4, there is 
considerable variability between animals, which accounts for the overall lack of 
significance between the two groups.  
 
The next question was whether PTEN depletion would reduce the quantity of 
denervated endplates (diseased) in the lumbrical muscles of SOD1G93A mice. Figure 
5.4 C-D shows that treatment with AAV6-si-PTEN had no significant effect on the 
percentage of partially denervated endplates in the injected (Mann Whitney, 
U=15.5, p=0.7381,n=6) and non-injected lumbricals (Mann Whitney, U=12, 
p=0.3874, n=6.). Unfortunately, no significant difference was found in the 
percentage of vacant endplates in either the left (Mann Whitney, U=15.5, p=0.7381, 
n=6) or right lumbricals (Mann Whitney, U=15, p=0.6753, n=6) when the treatment 
and control groups were compared (Figure 5.4 E-F).  
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Figure 5.4 Quantification of NMJs in the lumbrical muscles of transgenic 
SOD1G93A mice following AAV6-si-PTEN and AAV6-ssi-PTEN treatment.. 
Scatter plot graph showing data from mice in control and treatment groups, 
horizontal lines= medians. Comparison between mice injected with AAV6-ssi-
PTEN and AAV6-si-PTEN showed no significant difference in the percentage of 
FO endplates in the (A) injected lumbricals (p =0.8939, Mann Whitney and (B), 
non-injected (p=0.8939, Mann Whitney U test) lumbricals, no significant difference 
in the percentage of PO endplates in the (C) injected lumbricals (p=0.7381, Mann 
Whitney) and (D), non-injected (p=0.3874, Mann Whitney,) lumbricals, no 
significant difference in the percentage of vacant endplates in the (E) injected 
lumbricals (p=0.7381, Mann Whitney) and (F) and non-injected (p=0.6753, Mann 
Whitney ), no significant differences in axonal thinning in the (G) injected 
(p=0.305, Mann Whitney) and (H). non-injected (Mann Whitney, U=17, p=0.898) 
lumbricals. AAV6-ssi-PTEN= adeno-associated virus type 6 expressing scrambled 
si-PTEN, AAV6-si-PTEN=Adeno-associated-virus serotype 6 expressing PTEN si-
RNA, PO=partially occupied, ns= non significant, NMJs=neuromuscular junctions.  
 
 
 
AA
V6
-ss
i-P
TE
N
AA
V6
-si
-P
TE
N
0
20
40
60
80
100
%
 V
ac
an
t N
M
Js
Uninjected Lumbricals
ns
AA
V6
-ss
i-P
TE
N
AA
V6
-si
-P
TE
N
0
20
40
60
80
100
%
 V
ac
an
t N
M
Js
Injected Lumbricals
ns
AA
V6
-ss
i-P
TE
N
si-
scA
AV
6-P
TE
N
0
20
40
60
80
100
%
 A
xo
na
l T
hi
nn
in
g
Injected Lumbricals 
ns
AA
V6
-ss
i-P
TE
N
si-
AA
V6
-P
TE
N
0
20
40
60
80
100
%
 A
xo
n
al
 T
h
in
n
in
g
Uninjected Lumbricals
ns
E! F!
G! H!
                                                      199 
  
To exclude the possibility that the sex of mice may account for the variation in the 
results, separate data analysis was performed in females and males. There was more 
variation seen when the NMJs were quantified in males only, and data analysis 
showed no significant differences in the quantity of FO, PO and vacant endplates or 
percentage of axonal thinning (Figure 5.5). In the females, despite less variability in 
the results, there were no significant differences between the mice treated with 
AAV6-si-PTEN and controls (Figure 5.5).  
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 Figure 5.5 Quantification of NMJs in the left lumbrical muscles of male and 
female SOD1G93A mice injected with AAV6-si-PTEN or AAV6-ssi-PTEN. Scatter 
plot graphs showing data from left lumbricals only in both groups, horizontal 
bars=medians. (A) and (B) Quantification of FO NMJs in males (, p=0.6, Mann 
Whitney,) and females (p=0.4, Mann Whitney) showed no significant difference 
between the two groups. (C) and (D) Quantification of PO NMJs in males (p=0.7, 
Mann Whitney) and females (p=0.7, Mann Whitney) showed no significant 
difference between the two groups. (E) and (F) Quantification of vacant NMJs in 
males (p=0.7, Mann Whitney) and females (p=>0.9, Mann Whitney) showed no 
significant difference between the two groups. (G) and (H) Quantification of axonal 
thinning in males (p=0.4, Mann Whitney) and females (p=0.9, Mann Whitney) 
showed no significant difference between the two groups. AAV6-ssi-PTEN= adeno-
associated virus type 6 expressing scrambled si-PTEN, AAV6-si-PTEN=Adeno-
associated-virus type 6 expressing PTEN si-RNA, FO=Fully Occupied, 
PO=partially occupied, ns= non-significant. NMJs=neuromuscular junctions.  
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Overall, the marked variability in the data seen in both groups, particularly in male 
mice, made it difficult to conclude the effect of PTEN knockdown in the lumbricals 
of transgenic mice. However, the data from male and female mice combined (Fig 
5.4B) and female mice alone (Fig. 5.5B) suggested a marginal non-significant FO 
NMJs increase in mice treated with AAV6-si-PTEN, indicating that PTEN silencing 
may have a small neuroprotective effect on the NMJs.              
     
5.3.2.2 The effect of AAV6-mediated PTEN silencing on the NMJs of the 
FDB muscles in SOD1G93A mice 
The effect of PTEN inhibition was then examined on the NMJs of FDB muscles in 
the treatment and control groups. Among the mice treated with AAV6-si-PTEN 
(n=6), only two mice had an increase in the percentage of FO endplates in the left 
FDBs (36.4% and 29.56% respectively, median=1.963) compared to the other mice 
(range 0-2.4%) as shown in Figure 5.6 B. Interestingly, the increase in FO endplates 
was not seen in the non-injected (right) FDBs (5.29% and 13.53% respectively), nor 
in mice injected with the control vector suggesting that this is most likely an effect 
of PTEN inhibition. In addition, one of these mice had a concomitant increase in the 
FO endplates in the lumbricals (54%) suggesting a neuroprotective effect of PTEN 
silencing. The effect of PTEN inhibition observed only in two mice could be 
explained by a variation in transduction of the injected muscles with the viral 
vectors. However, due to these variations, over all there was no significant 
difference in the percentage of FO endplates in the FDBs injected with AAV6-si-
PTEN when compared to the control group (Mann Whitney, U=7, p=0.06, n=6). As 
expected, similar findings were observed in the contralateral leg (Figure 5.6 A).  
 
We next investigated whether PTEN inhibition would attenuate the pathological 
effects of the disease. The quantity of partially denervated endplates was found to be 
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similar in both groups (Figure 5.6 C-D) and the percentage of vacant endplates in 
the right and left FDB showed no significant differences between the treatment and 
control groups (Mann Whitney, U=14, p=0.5, n=6) (Figure 5.6 E-F). In addition, 
PTEN inhibition had no effect on axonal thinning in the injected legs (Mann 
Whitney, U=12, p=0.38, n=6) (Figure 5.6 G-H). The results were also analysed in 
males and females separately and similar to the lumbricals data, there was no 
difference in the NMJ quantification in both groups (data not shown).  
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Figure 5.6 Scatter plot graphs showing quantification of NMJs in the injected 
(left) and uninjected (right) FDB muscles of SOD1G93A mice injected with either 
AAV6-si-PTEN or AAV6-ssi-PTEN. (A) and (B) Percentage of FO NMJs in the 
injected (p=0.06, Mann Whitney) and non-injected (p=0.588, Mann Whitney) FDBs 
showed no significant difference between the two groups. (C) and (D) Percentage of 
PO NMJs in the injected (p=0.733, Mann Whitney) and non-injected (p=0.132, 
Mann Whitney) FDBs showed no significant difference between the two groups. (E) 
and (F) Percentage of vacant NMJs in the injected (p=0.192, Mann Whitney) and 
non-injected (p=0.571, Mann Whitney) FDBs showed no significant difference 
between the two groups. (G) and (H) Percentage of axonal thinning in the injected 
(p=0.387, Mann Whitney) and non-injected (p=0.474, Mann Whitney) and FDBs 
showed no significant difference between the two groups. Horizontal lines=medians.  
 
 
 
Comparisons between the left and right FDBs in the control and treated groups 
showed no significant differences in NMJ quantification. Despite the fact that there 
may be some intravascular spread of the vectors, there was no evidence of vector 
toxicity. In summary, these findings are consistent with the data obtained from the 
lumbrical muscles suggesting a limited neuroprotective effect of PTEN inhibition on 
the NMJs.      
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5.3.3 The effect of AAV9-mediated PTEN silencing on the NMJs of 
SOD1G93A mice 
In the previous study, the results showed a slight increase in the percentage of 
normally innervated (fully occupied) NMJs, suggesting a limited neuroprotective 
effect of PTEN inhibition; however, the results did not reach statistical significance. 
In addition, we observed poor transduction efficiency of spinal cord motor neurons 
with the AAV6 vector indicating inefficient retrograde transport of the viral vectors 
(Figure 4.4). This has prompted us to use an alternative vector, self-complementary 
AAV9 (scAAV9) to investigate the effects of PTEN depletion on NMJs in vivo . 
 
In this study transgenic SOD1G93A mice were recruited to two groups: the first group 
was treated with intramuscular injection of sc-AAV9-si-PTEN (1x1012 vg/ml), while 
the second group of animals received sc-AAV9-ssi-PTEN using the same route of 
delivery (1x1012 vg/ml). A third group of non-transgenic mice (C57BL/6J) which 
did not receive any treatment was recruited simultaneously and was used as a 
control group.. All mice were age and litter-matched when possible and a 
combination of males and females were used. The mice were injected at the 
presymptomatic stage (P26) and sacrificed at P100, at the onset of symptoms. Due 
to changes in the Home Office regulations, the mice were injected into the 
gastrocnemius and tibialis anterior (TA) muscles rather than the foot muscles. Each 
mouse received 30µl of the vector (total of 3x1010 viral particles for GA and TA 
muscles). We assumed that following transduction of TA and gastrocnemius 
muscles, the viral vector will diffuse into the surrounding muscles in addition to 
systemic spread leading to transduction of neighbouring muscles such as the 
lumbricals. A minimum of 100 plates was counted per mouse for each muscle that 
was analysed. The percentage of fully occupied, partially occupied and vacant 
endplates were quantified relative to the total NMJs counted. Quantification of 
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axonal thinning showed marked variations and was considered inappropriate for 
statistical analysis. 
 
5.3.3.1 The effects of scAAV9-mdiated PTEN silencing on the tibialis 
anterior (TA) muscles in SOD1G93A mice 
The TA muscles from the transgenic and non-transgenic mice were sectioned and 
immunostained for the NMJs as described above. In the SOD1G93A mice, 
pathological features of NMJ degeneration were observed such as the presence of 
vacant endplates, neurofilament accumulation and axonal thinning as well as 
partially innervated NMJs (Figure 5.7). In the non-transgenic group, the vast 
majority of the NMJs were fully innervated as shown in Figure 5.7. Although not 
formally analysed, there were no obvious morphological differences in the NMJs of 
mice injected with scAAV9-si-PTEN and those injected with scAAV9-ssi-PTEN or 
WT mice. 
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Figure. 5.7 NMJs analysis in the TA following scAAV9-si-PTEN treatment. 
Representative images of immunoflourescent staining of NMJs in the right (non-
injected) and left (injected) TA muscles of SOD1G93A mice injected with either 
scAAV9-ssi-PTEN or scAAV9-si-PTEN and their non-injected wild type 
littermates. Merged images (x40 magnification) show SV2 and neurofilament 
staining (red) and motor endplates (blue). In wild type mice the majority of the 
NMJs are FO, whereas in the transgenic mice, PO and vacant NMJs, neurofilament 
accumulation and axonal thinning was observed indicating NMJ degeneration. Scale 
bar=50µm. TG, transgenic, WT, wild type. 
 
 
 
To ascertain whether PTEN inhibition would increase the quantity of healthy and/or 
reduce the quantity of vacant and partially denervated (diseased) motor endplates, 
the NMJs of the TA muscles were quantified in both right and left legs in the three 
groups of mice. Although there was an apparent decrease in the percentage of FO 
NMJs in the right (non-injected) TA muscles of transgenic mice, unexpectedly there 
was no significant difference when they were compared to their wild type littermates 
(Figure 5.8 A-B). In line with these findings, there was no significant difference in 
the percentage of vacant and partially innervated endplates in the non-injected TA 
(Figure 5.8 C-F) suggesting a lack of significant NMJ degeneration. These findings 
          WT (no virus)          TG- scAAV9-ssi-PTEN      TG- scAAV9-si-PTEN!
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could be attributed to compensatory axonal regeneration (Son and Thompson, 1995, 
Love et al., 2003, Kang et al., 2003). Similarly, in the injected left TA, there were no 
significant differences in the percentage of FO, partially innervated and vacant 
NMJs, between the three groups (Figure 5.8 A-F). In particular there were no 
differences in the NMJ quantification between the transgenic mice injected with the 
control vector and those injected with scAAV9-si-PTEN.   
 
Of interest, two of the transgenic mice injected with scAAV9-si-PTEN showed a 
considerable increase in the FO endplates (100% and 84%) compared to the 
contralateral TA (0% and 27.14% respectively) and a decrease in the vacant (0% 
and 16% respectively) and partially occupied (0% and 0% respectively) endplates. 
These findings suggest that PTEN inhibition may be preventing NMJ degeneration 
in these two SOD1G93A mutant mice. Although these findings could be due to 
chance, the significant pathology found in the non-injected (right) TA of the latter 
mice suggests it is likely to be an effect of PTEN inhibition. It is important to note 
that unexpectedly we found some variations in the NMJ counts within the wild type 
group where one of the mice had 56% vacant endplates in the left TA compared to 
the rest of the group that had none (0%) and another had 100% vacant endplates in 
the right TA. These mice appeared healthy and were asymptomatic. This variability 
could account for the results not reaching statistical significance when the data was 
summarised and analysed.      
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Figure 5.8. Quantification of NMJs in the TA of transgenic SOD1G93A mice 
injected with scAAV9-ssi-PTEN or scAAV9-si-PTEN and their wild-type 
littermates. Scatter plot graphs showing data from individual mice in each group 
and their means. No significant difference was found in the percentage of FO (A 
and B), PO (C and D) and vacant (E and F) endplates when the three groups were 
compared (one-way ANOVA, Tukey’s multiple comparisons, p>0.05, wild-type 
n=5, scAAV9-ssi-PTEN n=6, scAAV9-si-PTEN n=5). Horizontal lines=means.  
 
As shown in Figure 5.9 when the right and left TA were compared in each group 
separately, there were no significant differences in the NMJ quantification. In the 
injected transgenic mice, this may implicate there was no vector-induced toxicity.   
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Figure 5.9 Scatter plot graphs showing comparisons between the right (non-
injected) and left (injected) TA in SOD1G93A mice injected with either AAV9-
ssi-PTEN or AAV9-si-PTEN and wild-type non-injected littermates. No 
significant difference was found in the percentage of FO, PO and vacant endplates 
when the right and left TA were compared in the wild type mice (A), transgenic 
mice injected with scAAV9-ssi-PTEN (B), and transgenic mice injected with 
scAAV9-si-PTEN(C). (One-way ANOVA, Tukey’s multiple comparisons, p>0.05, 
wild-type n=5, scAAV9-ssi-PTEN n=6, scAAV9-si-PTEN n=5) in each group 
separately.  
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5.3.3.2. The effects of AAV9-mdiated PTEN silencing on the NMJs of the 
lumbrical muscles in SOD1G93A mice 
The effect of PTEN inhibition was then explored in the lumbrical muscles of 
transgenic SOD1G93A mice. With intramuscular injections of the TA, one would 
expect some dissemination of the AAV9 viral vectors from the injection site into the 
neighbouring muscles such as the lumbricals (Asokan et al., 2008). Hence it was 
hypothesised that transduction of the lumbrical muscles with sc-AAV-9-si-PTEN 
would result in PTEN knockdown and prevention of neurodegeneration of NMJs. 
The percentage of FO, vacant and partially occupied endplates in the lumbricals of 
the right and left leg was quantified and the tree groups were compared. Similar to 
the findings in the TA muscles, the majority of NMJs in the wild-type mice were 
normally innervated whereas features of denervation were observed in the 
transgenic mice (Figure 5.10). There were no obvious morphological differences in 
the NMJs of mice injected with the control vector and those injected with scAAV9-
si-PTEN (Figure 5.10).  
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 Figure. 5.10.  NMJs of the right and left lumbricals. Representative images 
showing immunofluorescence analysis of NMJs in the right (non-injected) and left 
(injected) lumbrical muscles of SOD1G93A mice injected with either scAAV9-ssi-
PTEN or scAAV9-si-PTEN and their non-injected wild type littermates. Merged 
images (x40 magnification) show SV2 and neurofilament staining (red) and motor 
endplates (blue). Scale bar=50µm. TA, tibialis anterior, WT, wild-type. 
 
 
 
When the percentage of FO (healthy) endplates in the right lumbricals was 
compared between three groups there was no significant difference between the non-
transgenic group and the transgenic groups treated with scrambled si-PTEN (Figure 
5.11 A). This is consistent with the results obtained from the TA, suggesting no 
significant degeneration of the NMJs in this group of transgenic mice. On the other 
hand, there was a significant reduction in FO endplates in the si-PTEN group when 
compared to the non-transgenic mice and to those transgenic mice injected with the 
control vector (Figure 5.11 A). Consistent with these findings, there was a parallel 
significant increase in the vacant endplates in the latter group suggesting significant 
NMJ degeneration (Figure 5.11 E and F). Analysis of FO endplates in the left 
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lumbricals showed no significant difference between the three groups (Figure 5.11 
B), indicating that PTEN inhibition did not result in a significant increase in the 
quantity of normal NMJs in the injected lumbricals. Quantification of partially 
occupied endplates showed large variations in the left lumbricals of the wild-type 
mice (Figure 5.11 C and D) and there was no significant difference in the percentage 
of partially innervated motor end plates in the right and left lumbricals between the 
three groups (Figure 5.11 C and D).  
 
In the right lumbricals, there was no significant difference in the percentage of 
vacant endplates between the non-transgenic mice and the transgenic group injected 
with the control vector (scAAV9-ssi-PTEN), which provides more evidence of 
absence of significant pathology in this cohort of mice (Figure 5.11 E). However, 
there was a significant increase in the quantity of vacant endplates in the left 
lumbricals (injected side) in the scAAV9-ssi-PTEN group (Figure 5.11 F). As 
shown in Figure 5.11 E and F, transgenic mice treated with sc-AAV9-si-PTEN had 
a significant increase in the percentage of vacant endplates in the injected and non-
injected lumbricals. Together these findings suggest NMJ degeneration secondary to 
vector toxicity. Systemic spread of the scAAV9-si-PTEN vector possibly resulted in 
adverse effects on the contralateral muscles, and the observations of an increase in 
vacant endplates indicate that the PTEN knockdown vector is more toxic than the 
control vector. Comparisons of the same parameters between the injected and non-
injected lumbricals in each group separately showed no significant differences 
(Figure 5.12 A and F). 
 
It is worth mentioning, that two of the transgenic mice injected with scAAV9-si-
PTEN showed a considerable reduction in the percentage of vacant plates associated 
with an increased percentage of FO endplates in the left lumbricals. As mentioned 
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above, they showed similar findings in the left TA muscles suggesting that PTEN 
inhibition in these mice had a neuroprotective role.                 
                              
   
 
                          
Figure 5.11. Quantification of NMJs in the lumbrical muscles of transgenic 
SOD1G93A mice injected with scAAV9-ssi-PTEN or scAAV9-si-PTEN and their 
wild-type littermates. Scatter plot graphs showing data from individual mice in 
each group, horizontal lines= means. No significant difference was found in the 
percentage of FO (A and B), PO (C and D) and vacant (E and F) endplates when 
the three groups were compared (one-way ANOVA, Tukey’s multiple comparisons, 
p>0.05, wild-type n=5, scAAV9-ssi-PTEN n=6, scAAV9-si-PTEN n=5).  
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Figure 5.12. Scatter plot graphs showing comparisons between the right and 
left lumbricals in SOD1G93A mice treated with either AAV6-ssi-PTEN or AAV6-
si-PTEN and wild-type non-injected littermates. No significant difference was 
found in the percentage of FO, PO and vacant endplates when the right and left 
lumbricals were compared in the wild type mice (A), transgenic mice injected with 
scAAV9-ssi-PTEN (B), and transgenic mice injected with scAAV9-si-PTEN(C) 
(one-way ANOVA, Tukey’s multiple comparisons, p>0.05, wild-type n=5, 
scAAV9-ssi-PTEN n=6, scAAV9-si-PTEN n=5) in each group separately.  
 
 
In summary, the data from this study using the AAV9 vector showed less variability 
than the study achieved using AAV6 vector. Unexpectedly, the transgenic mice did 
not have significant pathological changes when the NMJs were analysed. The 
observations showed that the scAAV9 vector was toxic to the lumbrical muscles 
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making it difficult to assess whether PTEN inhibition can rescue NMJ degeneration 
in SOD1G93A mice.  
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5.4 Discussion 
To date, this is the first report describing the effect of AAV-mediated PTEN 
silencing on the NMJs in SOD1G93A transgenic mice. In the first study, the results 
showed a trend of increased fully occupied NMJs in mice injected with AAV6-si-
PTEN, suggesting a potential neuroprotective effect of PTEN silencing. Overall 
there was no significant difference in the NMJ quantification between mice injected 
with the control vector and those injected with AAV6-si-PTEN. In addition, the 
previous chapter demonstrated that despite efficient transduction of muscles with 
AAV6, and effective PTEN knockdown achieved with AAV6-si-PTEN, there was 
poor retrograde transport of the vectors. These findings prompted the use of an 
alternative vector, AAV9, which has a high tropism for skeletal muscles, to test our 
hypothesis. In the subsequent study, unexpectedly we found no significant NMJ 
degeneration in the transgenic SOD1G93A mice. In addition there was evidence of 
AAV9 vector-related toxicity. Unfortunately it was difficult to conclude whether 
PTEN inhibition plays a role in preventing NMJ degeneration in SOD1G93A mouse 
models.  
 
Age and litter-matched congenic SOD1G93A mice were randomly assigned to the 
experimental groups. In the second study, C57BL/6J wild-type mice were used as a 
control group. Despite no major difference between males and females in the strain 
used for this project {Wooley, 2005 #287;Heiman-Patterson, 2005 #286}, it was 
essential to study this therapeutic strategy in each gender and hence a combination 
of males and females were chosen.  
 
The majority of studies described the progression of disease in the mutant mice with 
a mixed background where NMJ denervation was reported to occur around P45-P47 
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(Fischer et al., 2004, Frey et al., 2000, Kennel et al., 1996) and more recently others 
showed it occurs as early as P25 (Vinsant et al., 2013). In contrast, the congenic 
SOD1G93A mice are known to have a delayed onset of disease and a longer survival 
compared to the mutant mice in a hybrid background (Veldink et al., 2003). 
Hayworth et al reported that in the congenic strain, muscle atrophy develops at P55 
and measurement of muscle girth provides indirect evidence of denervation 
(Hayworth and Gonzalez-Lima, 2009). As this is a proof-of principle study, the 
timing of injections at P26 was chosen before significant NMJ occurs and the mice 
were sacrificed at P100 when they start to develop symptoms (Hayworth and 
Gonzalez-Lima, 2009).  
 
5.4.1 The effect of AAV6-mediated PTEN silencing on the NMJs of 
SOD1G93A mice 
To achieve stable PTEN knock down in the hind limb muscles, the AAV6 vector 
was chosen to deliver PTEN siRNA due to its known efficiency of transducing 
skeletal muscles (Towne et al., 2010, Towne et al., 2011). In order to eliminate any 
effects that may occur secondary to vector administration, another AAV6 vector 
expressing a scrambled sequence of PTEN siRNA was used as a control vector.  
 
Consistent with previous studies, the pathological features of NMJ degeneration 
were observed in the FDB and lumbrical muscles (Vinsant et al., 2013). Axonal 
thinning, a characteristic feature of dying- back axonopathy (Frey et al., 2000), was 
detected in some of the terminal branches of motor neuron axons. It is considered a 
sign of synaptic weakening and is known to occur in the presymptomatic stage of 
SOD1 mice (Frey et al., 2000). Staining with anti-neurofilament antibodies showed 
the presence of abnormal accumulation of neurofilament in the motor axons, another 
pathological hallmark of sporadic and familial ALS (Al-Chalabi et al., 1999). 
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Furthermore, evidence of complete denervation was observed with loss of contact 
between the axons and post-synaptic motor endplates and partial detachment of 
axons from the synapses was also seen in both muscles. 
 
As expected, analysis of the FDB muscles showed that the majority of the NMJs 
were either partially innervated or denervated (vacant endplates) indicating on-going 
degeneration of the NMJs. However there was variation in the percentage of 
denervated endplates between the mice in each group suggesting that not all the 
mice had significant degeneration by the time they were sacrificed at P100. Since 
this strain of transgenic mice are known to have a uniform genetic background, 
changes in the transgene copy number may account for the variability observed in 
the muscle denervation.  
 
Interestingly, one female and one male transgenic mice injected with AAV6-si-
PTEN showed a considerable increase in the percentage of fully occupied endplates 
(29.56% and 36.43% respectively) compared to the other mice receiving the same 
treatment (0-2.4%). This was associated with a concomitant reduction in vacant 
endplates. Similar findings were found in the lumbrical muscles of the latter male 
mouse. On the other hand, these mice showed no apparent reduction in axonal 
thinning compared to the mice injected with the control vector. While these findings 
could be due to chance alone, PTEN inhibition is known to enhance axonal growth 
and regeneration. Hence, it could be hypothesised that reducing the expression of 
muscle PTEN may enhance the terminal branches to regain their connections with 
the motor endplates leading to a delayed onset of NMJ degeneration. It is also 
possible that the extent of PTEN inhibition in the injected muscles may be 
insufficient to prevent axonal thinning and synaptic weakening. The effect of PTEN 
inhibition seen in only two mice could be due to factors other than gender since 
analysis of the data in either sex separately showed no significant differences in the 
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quantification of the NMJs. These findings agree with previous studies which 
demonstrated no major differences between males and female mice in a congenic 
C57BL/6J background (Heiman-Patterson et al., 2005, Wooley et al., 2005), in 
contrast to mice in a hybrid background (C57BL/6JxSJL/J) where gender influences 
disease onset and survival (Veldink et al., 2003). However, subsequent studies by 
Hayworth et al have shown a delayed onset of symptoms in congenic SOD1G93A 
female mice (Hayworth and Gonzalez-Lima, 2009). A most likely explanation is 
variations in transduction of the injected muscles. With intramuscular injections, 
local diffusion of the vectors into the neighbouring muscles could vary from mouse 
to mouse and this may lead to variations in the extent of muscle transduction and 
PTEN inhibition. Indeed, binding of the AAV vectors to receptors on muscle cells 
may restrict their dissemination from the site of injections (Asokan et al., 2008). 
There was no evidence of vector related toxicity since comparison of the muscles 
injected with either AAV6-ssi or AAV6-si-PTEN with the contralateral muscles 
showed no significant differences in the NMJ quantification. Although silencing of 
the transgene may occur with time, it is unlikely to explain the lack of effect as 
AAV vectors are known for their stable and sustained gene expression (at least 8 
months) after i.m injections (Kessler et al., 1996, Herzog et al., 1997). Another 
plausible explanation is that prolonged reduction in PTEN expression may activate 
negative feedback mechanisms that may counter act its neuroprotective effect (Birle 
et al., 2002, Georgescu, 2010).  
 
Analysis of the NMJs in the lumbrical muscles showed an increased percentage of 
fully occupied endplates in one mouse (41.98%) as mentioned above. Otherwise 
there were large variations in the data and no significant differences were detected 
between the two groups of mice.  
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The results of this study hint towards a possible neuroprotective effect of PTEN 
silencing on the NMJs of SOD1G93A mouse models. However, the variability of the 
data and the lack of significant results make it difficult to rule out that the effect of 
PTEN silencing observed could be due to chance alone. As this study was not 
conclusive, this was a motivation to conduct a similar study using a different vector 
(scAAV9) with high tropism for skeletal muscles (Katwal et al., 2013, Bostick et al., 
2007, Inagaki et al., 2006, Pacak et al., 2006) further study the effects of PTEN 
silencing on the NMJs.  
 
5.4.2 The effect of scAAV9-mediated PTEN silencing on the NMJs of 
transgenic SOD1G93A mice 
The AAV9 vector effectively transduces skeletal muscles and preferentially 
transduces fast-twitch fibres (Bostick et al., 2007). Hence in the present study it was 
utilised for the expression of PTEN shRNA (scAAV9-si-PTEN) and a scrambled 
sequence of PTEN siRNA (scAAV9-ssi-PTEN) into the TA and gastrocnemius   
muscles. The latter vector was used as a control vector to eliminate any effects that 
may occur secondary to vector administration.  
 
In the wild-type mice, immunostaining of the TA and lumbrical muscles as expected 
showed that the majority of the NMJs were normally innervated (fully occupied) 
whereas denervated and partially denervated endplates were rarely seen. 
Surprisingly when the NMJs were quantified an increased percentage of denervated 
endplates was observed in one of the TA muscles of two wild-type mice, however 
no evidence of denervation was found in the ipsilateral lumbricals nor the 
contralateral TA or lumbricals. It is possible that these mice could have sustained a 
minor injury to the hind limbs causing this focal denervation although all mice 
appeared healthy and no evidence of trauma was seen when they were sacrificed. 
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While denervated endplates were more obvious in all the muscles analysed in the 
transgenic mice, unexpectedly quantification showed no significant differences 
when they were compared to their wild-type littermates. The lack of significant 
pathology seen in this cohort of transgenic mice could be explained by 
compensatory axonal regeneration, a process that has been observed after partial 
denervation in transgenic SOD1G93A mice (Son and Thompson, 1995, Kang et al., 
2003, Love et al., 2003, Lubischer and Thompson, 1999). Here, axons sprouting 
from intact motor neurons form new synapses with denervated motor endplates and 
can lead to a delayed phenotype. This compensatory mechanism makes it difficult to 
detect significant NMJ degeneration, however with time the disease pathogenesis 
overwhelms the regenerative capacity of neurons and clinical symptoms start to 
manifest (Hayworth and Gonzalez-Lima, 2009). In support of this hypothesis is the 
finding of grouped atrophy found in the GA muscle indicating the presence of 
denervation. Another possible explanation is an undetected drop in the copy number 
of the mutant SOD1G93A transgene in this group of mice. Previous studies 
demonstrated that with time, meiotic rearrangement of the mutant gene could lead to 
a reduction in the transgene copy number, which was associated with prolonged 
survival in transgenic SOD1 mouse models (Alexander et al., 2004).  
 
A significant increase in the quantity of denervated (vacant) NMJs was detected in 
the left lumbricals of the transgenic mice injected with scAAV9-ssi-PTEN as well as 
those injected with scAAV9-si-PTEN. It could be argued that the NMJ degeneration 
is an effect of SOD1G93A mutations, however the lack of significant degeneration in 
the contralateral lumbricals of mice injected with scAAV9-ssi-PTEN suggest that 
this is most likely secondary to vector toxicity. On the other hand, mice injected 
with scAAV9-si-PTEN had significant denervation in the contralateral (right) 
lumbricals, which may be due to viral-induced toxicity secondary to systemic spread 
of the vector. It is interesting that vector toxicity was more evident in the lumbricals 
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rather than the TA muscles, which were directly injected with the vector. This could 
be due to a combination of factors such as the smaller size of the lumbricals and the 
efficient transduction of skeletal muscles via intravascular AAV9 infection (Bostick 
et al., 2007) leading to high levels of transduction and vector induced toxicity. 
 
Unfortunately due to the absence of significant pathology in the muscles of 
transgenic mice in addition to vector toxicity, it was a challenge to assess any effects 
of scAAV9-mediated PTEN inhibition on the NMJs of SOD1G93A mice.  
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6. Discussion and Conclusions 
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6.1 Project outcomes 
 
Amyotrophic lateral sclerosis is a fatal disease characterised by progressive loss of 
motor neurons in the brain and spinal cord. To date, there is no cure for ALS and 
much of the research is focused on identifying the molecular pathways involved 
with motor neuron injury in an attempt to find novel therapeutic strategies. Although 
the exact underlying mechanism remains unclear, the evidence shows that a 
complex interplay between multiple pathogenic mechanisms ultimately result in 
motor neuron death. Altered signalling of the survival PI3K/Akt pathway has been 
shown in ALS post-mortem tissue (Wagey et al., 1998, Leger et al., 2006, Kirby et 
al., 2011a) as well as in animal models (Warita et al., 2001, Nagano et al., 2002, 
Carunchio et al., 2010) suggesting a role in the pathophysiology of the disease. The 
tumour suppressor gene, PTEN, is a crucial negative regulator of the PI3K/Akt 
pathway, which has a crucial role in CNS pathophysiology, and its downregulation 
promotes neuronal survival and axonal regeneration. Indeed, previous studies in our 
laboratories showed that targeting of PTEN prolongs the survival of a mouse model 
of the childhood neuromuscular disease, SMA (Little et al., 2015). Since ALS and 
SMA are both characterised by selective motor neuron vulnerability, it was thus 
hypothesised that PTEN targeting may have a neuroprotective effect in ALS.  
 
Purified motor neuron cultures from transgenic SOD1G93A embryos and their non-
transgenic littermates were used as an in vitro model to study the effects of PTEN 
silencing in ALS. In transgenic motor neurons, PTEN was found to be 
predominantly expressed in the cytoplasm and growth cones, in a similar 
distribution to that in non-transgenic motor neurons suggesting that G93A mutations 
in the SOD1 gene do not alter the distribution of PTEN at the embryonic stage.  
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To ascertain the potential neuroprotective effects of PTEN silencing in transgenic 
motor neurons, siRNA against PTEN were delivered to purified transgenic 
SOD1G93A and non-transgenic motor neurons using lentiviral vectors. This approach 
achieved a statistically significant reduction in PTEN levels in transgenic and non-
transgenic motor neurons, which was associated with a concomitant significant 
increase in the phosphorylated form of the anti-apoptotic protein, Akt (active form) 
and the pro-apoptotic BAD (inactive form) suggesting activation of the PI3K/Akt 
pathway. In addition PTEN silencing was associated with a significant increase in 
motor neuron survival, which is most likely mediated by activation of the survival 
PI3K/Akt signalling cascade. Furthermore, no significant differences in the 
expression of PTEN and its downstream effectors, pAkt and pBAD, were found 
between transgenic and non-transgenic motor neurons, suggesting that SOD1G93A 
mutations do not alter this survival pathway at the embryonic stage. However, 
earlier studies demonstrated alterations of the PI3K/Akt pathway at the 
presymptomatic and end-stage of ALS in humans as well as in transgenic models. 
For example, Kirby et al showed a reduced expression of the PTEN gene and 
evidence of activation of this survival pathway in surviving motor neurons at the 
late stages of the disease suggesting that activation of the survival pathway occurs as 
a compensatory mechanism to motor neuron injury (Kirby et al., 2011a). One could 
postulate that with progression of the disease, this adaptive mechanism becomes 
overwhelmed by the multiple pathogenic mechanisms and ultimately fails to prevent 
motor neuronal loss. Therefore, targeting PTEN in spinal motor neurons may prove 
to be an effective approach to prevent motor neuron degeneration. On the other 
hand, others have shown loss of Akt in spinal cord motor neurons in 
presymptomatic SOD1G93A mice suggesting that inhibition of the PI3K/Akt pathway 
may contribute to motor neuron death (Dewil et al., 2007a). Although the 
discrepancies between the studies may be attributed to differences in underlying 
pathogenic mechanisms of the disease in murine models and humans, the conflicting 
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results suggests tight regulation of the PI3K/Akt signalling cascade in motor 
neurons. In addition, immunocytochemistry showed increased expression of 
phospho-p70S6K in association with reduced PTEN levels, indicating mTOR 
activation. Due to the limited amount of protein extracted from purified motor 
neurons in culture, it was not possible to quantify the expression of phospho-
p70S6K and other anti-apoptotic components of the signalling cascade such as IKK. 
Furthermore, PTEN depletion did not alter the expression of pERK 1/2  in 
transgenic and non-transgenic motor neurons. Studies have shown a cross-talk 
between PTEN and the MAPK/ERK pathway (Gu et al., 1999, Chiu et al., 2005); 
nevertheless, Ning et al also showed that with PTEN suppression, the expression of 
pERK1/2 was unchanged in purified WT motor neurons (Ning et al., 2010), 
implicating that the effects of PTEN depletion on ERK may be tissue-specific. 
 
Overall, the in vitro studies demonstrated that lentiviral-mediated PTEN silencing 
activates the pro-survival PI3K/Akt signalling pathway in embryonic SOD1G93A as 
well as non-transgenic motor neurons and significantly promotes their survival.. 
These findings provide evidence that targeting PTEN may be a novel therapeutic 
strategy to prevent motor neuron degeneration in ALS.  
 
To validate the potential neuroprotective effect of PTEN silencing in vivo, wild-type 
(WT) mice were used to determine the efficiency of adeno-associated virus serotype 
6 (AAV6) and 9 (AAV9), to deliver PTEN siRNA to spinal cord motor neurons 
after intramuscular administration. Analysis of the GA muscles injected with either 
AAV6-si-PTEN or the control vector AAV6-ssi-PTEN, showed strong GFP 
expression and a significant knockdown of PTEN expression was observed in 
muscles injected with AAV6-si-PTEN. PTEN inhibition was associated with a 
significant increase in pAkt levels, suggesting activation of the PI3K/Akt pathway. 
The robust muscle transduction by the viral vectors is consistent with other studies 
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that showed AAV6 has a high tropism for skeletal muscles (Blankinship et al., 2004, 
Towne et al., 2008, Towne et al., 2011). However, in contrast to reports that 
demonstrated efficient transduction of spinal motor neurons (~40% transduced 
motor neurons) after i.m injections of AAV6 in neonatal mice (Towne et al., 2011, 
Ning et al., 2010), the number of transduced motor neurons in the lumbar spinal 
cord was very low (<10 per mouse) in this study, indicating low efficiency of 
retrograde transport. Similarly, other studies in our laboratories showed poor 
retrograde axonal transport of AAV6 in young adult SOD1G93A mice (<5% 
transduced spinal motor neurons) (Nanou et al., 2013). Together these findings 
suggest that AAV6 does not deliver transgenes efficiently via retrograde axonal 
transport to spinal cord motor neurons in adult mice. Moreover, there was no 
significant reduction in PTEN staining in motor neurons transduced with AAV6-si-
PTEN compared to the non-transduced cells, which is most likely related to a low 
number of vector particles expressing PTEN siRNA targeting the motor neurons. 
Nevertheless, these data validated the efficiency of AAV6-mediated PTEN silencing 
in skeletal muscles and hence these vectors were used for a pilot study, which 
investigated the effect of PTEN silencing on NMJs in transgenic SOD1G93A mice.  
 
Accumulating evidence demonstrates that AAV9 transduces skeletal muscles and 
neurons with high efficiency, and studies by Benkhalifa-Ziyatt showed robust 
retrograde transport of AAV9 in WT and SMA mouse models (Benkhelifa-Ziyyat et 
al., 2013). Based on this evidence, AAV9-based vectors were generated to deliver 
PTEN siRNA and scrambled-si-PTEN as a control vector. Like AAV6, the AAV9 
vectors were tested in WT mice and compared to mice treated with PBS. The mice 
that received i.m injections of scAAV9-si-PTEN showed a significant reduction of 
PTEN expression and activation of the PI3K/Akt pathway in the injected GA 
muscles when compared to those treated with the control vector or PBS. Similar to 
AAV6, transduction of spinal cord motor neuron was inefficient and occasional 
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GFP-positive-astrocytes were seen indicating vascular spread of the vectors. In 
support of these findings, GFP expression was also detected in the contralateral 
muscles. In line with these results, Foust et al observed inefficient transduction of 
spinal motor neurons after i.m injections in adult WT mice (Foust et al., 2009).  
 
The efficiency of AAV9-mediated PTEN silencing was then explored in the 
transgenic SOD1G93A mouse model. The transgenic mice received a higher viral load 
to maximise the transduction efficiency (3x1010 vg per injected muscle). There was 
no significant effect on the survival of lumber spinal cord motor neurons in mice 
treated with scAAV9-si-PTEN. The lack of effect seen was attributed to either 
inefficient motor neuron transduction or to the fact that that PTEN inhibition alone 
does not enhance motor neuron survival in vivo. Analysis of the injected muscle 
showed expression of GFP and reduced PTEN levels associated with activation of 
PI3K/Akt/mTOR pathway in muscles injected with scAAV9-si-PTEN. However, 
examination of the lumbar spinal cord using immunohistochemistry showed very 
low transduction of motor neurons indicating poor retrograde transport of AAV9, 
which may explain the lack of effect observed on motor neuron survival. In addition, 
there was no clear difference in PTEN staining in the transduced cells when 
compared to the non-transduced motor neurons, which can be due to a low 
concentration of the vectors targeting the motor neurons. Furthermore, GFP-positive 
astrocytes were observed in the spinal cord suggesting vascular spread of the 
vectors. While the non-autonomous pathogenic mechanisms in ALS may require a 
global gene delivery for therapeutic strategies, transduction of astrocytes may be an 
undesirable effect since PTEN suppression causes astrocyte proliferation in vivo and 
thus may lead to the development of brain tumours (Furnari et al., 1997, Fraser et 
al., 2004, Xu et al., 2014). Further studies are needed to elucidate the safety of 
PTEN silencing in non-neuronal cells in animal models of ALS.  
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Taken together these results showed that both AAV6 and AAV9-based vectors were 
not effectively delivered to the spinal cord via retrograde transport despite efficient 
muscle transduction. More importantly, similar findings were observed in WT mice 
as well as in the transgenic mouse models suggesting that the genetic background is 
unlikely to affect the axonal transport of the vectors. The conflicting results seen 
between the data of this study and that from other studies showing robust spinal cord 
transduction following i.m transduction could be due to several reasons. First, direct 
comparison between the studies is difficult due to differences in experimental 
designs, timing of injections and variations in vector load. More importantly, factors 
that affect the overall quality of the vectors such as methods of production, 
purification and titration may play an essential role in the transduction efficiency 
and may affect the uptake and delivery of the vectors along motor neuron axons. 
Finally, contamination of the vector stocks by the transgene proteins and impurities 
from cell lysates can result in artifactual transduction, or “pseudotransduction”  
(Alexander et al., 1997), which must be considered when AAV vectors stocks have 
been utilised. This artifactual transgene expression can be avoided by further 
purification of vector stocks (Alexander et al., 1997). 
 
Several studies have shown that enhancing motor neuron survival alone does not 
prolong the overall survival of the SOD1G93A mice. Indeed, ALS is considered as a 
distal axonopathy with degeneration of the NMJ prior to motor neuron loss (Fischer 
et al., 2004). In a pilot study, the effect of AAV6-mediated PTEN silencing on NMJ 
degeneration was investigated in the left hind limb lumbricals and FDB muscles of 
SOD1G93A mice. As expected, NMJ analysis showed abundance of denervated motor 
endplates secondary to the disease. NMJ quantification showed no statistical 
difference between the muscles injected with AAV6-si-PTEN and those injected 
with the control vector. However, a considerable increase in FO (normally 
innervated) endplates was observed in the FDB muscles of 2 mice only and in the 
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lumbricals of one mouse, which explains the lack of statistical significance. 
Although these findings may be due to chance alone they hint towards a potential 
neuroprotective effect of PTEN silencing. It is not clear why the effect was not seen 
consistently, however it is unlikely to be due to gender differences, as no statistical 
difference was found when data was analysed in each sex separately. It is possible 
that variations in muscle transduction may result in variable PTEN depletion, such 
that in some muscles PTEN expression was not effectively reduced. Another 
plausible explanation is that with prolonged PTEN silencing, triggering of negative 
feedback mechanisms may counteract its neuroprotective effect (Birle et al., 2002, 
Georgescu, 2010).  
 
Since the pilot study was inconclusive, scAAV9-based vectors were employed to 
study the potential neuroprotective effect of PTEN silencing on the NMJs of 
SOD1G93A mice. Unexpectedly, quantification of the NMJs in the TA and lumbricals 
showed no significant difference in the FO and vacant endplates when compared to 
the WT mice. The finding of grouped atrophy in the GA muscles of the transgenic 
mice indicates the presence of denervation with compensatory re-innervation from 
collaterals sprouting from neighbouring motor axons, which may explain the lack of 
significant NMJ degeneration in the transgenic mice (Son and Thompson, 1995, 
Kang et al., 2003, Love et al., 2003). A significant increase in the denervated 
(vacant) motor endplates was observed in the lumbricals of the injected hind limb 
suggesting the possibility of vector-related toxicity. Hence, due to the absence of 
significant NMJ pathology and possible vector-related toxicity it was not possible to 
conclude whether or not PTEN inhibition prevents NMJ degeneration. 
 
In conclusion,   the in vitro work of this project demonstrated that lentiviral 
mediated PTEN silencing enhances motor neuron survival of transgenic SOD1G93A 
motor neurons by activating the PI3K/Akt survival pathway. However, the i.m route 
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for AAV-mediated siRNA delivery to the spinal cord was insufficient for effective 
PTEN silencing in spinal motor neurons despite efficient transduction of skeletal 
muscles. Furthermore, due to variability in the data and possible vector toxicity, no 
significant neuroprotective effect was seen on NMJ quantification. Hence, it was not 
possible to draw conclusions on whether PTEN inhibition can prevent NMJ 
degeneration and motor neuron loss in the SOD1G93A mouse model. The multiple 
and complex molecular pathways involved in ALS pathogenesis makes it 
challenging for the development of effective therapeutic strategies. Nevertheless, 
rapid advances in the engineering of viral vectors allows the manipulation of 
neuroprotective genes and identification of essential molecular targets in 
experimental models of ALS that can potentially be taken further to the clinic. 
 
6.2 Limitations of the study 
Purified motor neuron cultures provide an excellent tool for studying motor neuron 
biology and signalling pathways; nevertheless, they do not reflect the complex 
pathophysiological in vivo environment in disease models. In contrast to cell lines, 
the low number of cultured motor neurons makes it challenging to obtain high 
protein concentrations leading to detection issues using Western blotting. 
Alternatively, protein expression could be determined using immunocytochemistry, 
however, due to time constraints this was not possible to perform for some proteins 
that were not detected by western blotting 
 
The in vivo study was mainly limited by inefficient viral delivery to spinal motor 
neurons via retrograde delivery. The i.m route has the advantage of delivering genes 
directly to the muscles and takes the advantage of retrograde axonal transport. This 
approach is beneficial when investigating therapeutic strategies in neuromuscular 
diseases since it allows studying the effects on muscles and motor neurons. 
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Although lentiviral vectors pseudotyped with rabies-G glycoprotein have the 
capacity for retrograde transport, they do not transduce skeletal muscles as 
efficiently as AAV-based vectors. Alternative routes of delivery such as intrathecal 
or intracisternal administration of the vectors may provide more efficient CNS gene 
delivery for proof-of principle studies. 
 
The NMJ study in the transgenic SOD1 G93A mice was limited by the absence of 
significant denervation found on NMJ quantification at the time the mice were 
sacrificed (P100). With disease progression, adaptive mechanisms fail to re-
innervate the muscles, and thus later time points for NMJ analysis may be needed to 
observe potential therapeutic effects. 
 
6.3 Future work 
Although the in vitro work demonstrated a potential neuroprotective effect of PTEN 
silencing on transgenic SOD1 motor neurons, it is important to determine how long 
this effect will last. A time course experiment, where protein extracts from motor 
neurons are collected at different time points, will provide a better understanding of 
PTEN signalling as well as providing insight into negative feedback mechanisms 
that may counter act its neuroprotective effect. Since PTEN inhibition has been 
shown to increase neuronal size, detailed morphological analysis of motor neurons 
may demonstrate the effects of PTEN suppression on motor neuron morphology and 
potential oncogenic effects. Furthermore, examining the subcellular localisation of 
PTEN in transgenic SOD1 motor neurons and its relationship with SOD1 may 
provide clues on whether it plays a role in SOD1 toxicity. 
 
In this project, validation of the potential neuroprotective effect of PTEN inhibition 
in vivo was limited by inefficient vector delivery. Further studies are required to 
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determine whether different methods of vector preparation, purification and titration 
affect the retrograde axonal transport of AAV6 and AAV9 in WT and transgenic 
SOD1 mice. In addition,. alternative routes of administration such as intracisternal 
or intrathecal injections may prove to be more effective in spinal cord transduction 
and it would be interesting to identify whether effective PTEN silencing can be 
achieved in motor neurons via these routes. Furthermore, systemic administration of 
PTEN siRNA would provide essential information on the safety of systemic 
administration and any potential long-term side effects.  
 
Regarding the quantification of NMJs in the SOD1 model, compensatory 
mechanisms may mask pathological denervation and hence, a time course 
experiment where NMJs are quantified at different time points after PTEN silencing 
may provide a clear picture on the effect of PTEN silencing on NMJ degeneration. 
In addition, inconsistent effects of PTEN suppression were observed in the 
experimental mice, thus a dose response experiment may be required to determine 
the viral load needed to achieve a therapeutic effect of PTEN suppression. Finally, 
advances in the genetic engineering of viral-based vectors may generate more 
efficient AAV vectors for gene delivery to the CNS through muscular injections 
providing novel therapeutic strategies that can be taken further to the clinic. 
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